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Natural thiohistidines such as ergothioneine and ovothiols are biosynthesized by 
actinomycetes, fungi and many parasitic protozoa, respectively.  
Actinomycetes such as Mycobacterium tuberculosis produce mycothiol and ergothioneine as 
their principal low molecular mass thiols. It is only very recently that the link between 
ergothioneine and tuberculosis disease has started to emerge, these studies suggested that 
ergothioneine is essential for the survival of Mycobacterium tuberculosis, the causal agent of 
tuberculosis. The biosynthesis of ergothioneine involved five enzymes encoded by the genes 
egtA, egtB, egtC, egtD and egtE. Because of the essentiality of these enzymes, in particular 
EgtD, could be considered as a potential tuberculosis drug target. 
Ergothioneine is a newly discovered vitamin and is widely used in cosmetics as an antioxidant, 
whereas ovothiol biosynthesis has received interest for the synthetic design of potential 
trypanosomal drugs. However, the commercial availability of these thiohistidines is limited, 
mainly due to multiple challenges associated to their synthesis or isolation from natural 
sources.  
This study describes the improved total synthesis of the super-antioxidant, ergothioneine and 
all its biosynthetic pathway intermediates, including deuterated versions thereof. A simple, 
short and high yielding novel process of the synthesis of ergothioneine was developed. 
Additionally, enzymatic methods were also considered for the desulfurisation step. The C-S 
lyase experiments mediated by Mycobacterium smegmatis cell-free lysate provided small 






sulfoxide. Overoxidation of the latter substrate provided a sulfone that inhibited 
ergothioneine biosynthesis. While hercynylcysteine sulfoxide is known to be the substrate in 
Neurospora crassa, the EgtC enzyme in mycobacteria prefer γ-glutamyl 
hercynylcysteinesulfoxide as its precursor to ergothioneine. Hence, the need for sufficient 
quantity of this important metabolite has motivated the development of the first total 
synthesis of EgtC enzyme substrate, γ-glutamylhercynylcysteine sulfoxide. 
Finally, interesting synthetic challenges toward the synthesis of the most powerful natural 
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1.1. Naturally occurring Low Molecular Weight (LMW) thiols  
 
Naturally occurring low molecular weight thiols are essential for the maintenance of cellular 
redox potential in living organisms, hence they play a key role in the survival of the species. 
These natural thiols preserve the protein thiol-disulfide balance and protect the cells from 
various toxic reactive intermediates such as reactive oxygen (ROS) and nitrogen species 
(RNI).1,2  
Low molecular weight thiols including bacillithiol (BSH), mycothiol (MSH), glutathione (GSH) 
and trypanothione (TSH) are cysteine-based thiols. Coenzyme A (CoA) is a cysteamine-based 
thiol. It is noteworthy that cysteine is in fact the sulfur source in the biosynthesis of most 
naturally occurring thiols.3 (Figure 1.1)  




Figure 1.1. Chemical structures of Low Molecular Weight Thiols (LMW).  
 
Glutathione is present in many organisms including humans. Almost all eukaryotes contain 
GSH except some species such as Giardia duodenalis, Entamoeba histolytica, Tritrichomonas 
foetus and Trichomonas vaginalis. In these organisms GSH has been detected in millimolar 
levels making it the most common thiol in the cell.3 Trypanosoma and Leishmania produce 
ovothiols (OSHA, B & C) and trypanothione (TSH) which consist of two molecules of GSH linked 
together by a spermidine molecule or moiety.3 (Figure 1.1 & Figure 1.2)  




Figure 1.2. Chemical structures of Low Molecular Weight Thiols (LMW) (Thio-histidine-based thiol) 
 
However, most Gram positive bacteria lack GSH, but rely on alternate thiols for their 
protection against oxidative stress. Staphylococcus aureus, a Gram positive bacterium does 
not produce GSH; instead it produce millimolar quantities of the reduced coenzyme A 
(CoASH), acting as their principal protective thiol.2 Bacilithiol (BSH) is produced by several 
microorganisms including many Bacillus and Staphylococcus species such as Bacillus 
anthracis, Bacillus cereus, Staphylococcus agalactiae, and Streptococcus saprophyticus. The 
latter species do not produce GSH or MSH, they rely on BSH which is suggested to play an 
important role in the metabolic regulation process including detoxification of fosfomycin, an 
electrophilic xenobiotic.4   
 
Mycobacteria also lack GSH, however, they produce mycothiol (MSH) and ergothioneine 
(thio-histidine-based thiol) as their protective thiols. (Figure 1.1 & Figure 1.2) Extensive efforts 
have been conducted to shed more light on their essentiality toward the survival of Mtb. 
While quite substantial studies have been conducted on mycothiol, very little is known about 
the role played by ergothioneine as a protective thiol in mycobacteria. The next section will 
be dedicated to an extensive review of this valuable low molecular weight thiol, 
ergothioneine. 
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1.2. Ergothioneine  
 
Ergothioneine (ESH) was first isolated by a French pharmacist, Charles Tanret in 1909 from 
ergot (Claviceps purpurea), the fungal infection of rye grain.5 Since that discovery was made 
numerous studies has been conducted by the scientific community to understand its 
physiological role as protective thiol in humans and various organisms, mostly mycobacteria.  
Very recently, ESH has been advocated to be a new vitamin due to its beneficial role in human 
health as it acts as a very important physiological cytoprotectant.6  
 
1.2.1. Ergothioneine physical properties and distribution in living organisms  
 
Ergothioneine (ESH) is a natural thio-histidine betaine derivative (N,N,N-α-
trimethylammonium 2-mercaptohistidine) with a thiol group attached at the C-2 position of 
the imidazole ring. ESH is an unique natural C2-thio-imidazole containing amino acid.7 
 
1.2.1.1. Ergothioneine physical properties 
 
In aqueous solution and in solid state, the carboxyl group of ergothioneine is deprotonated. 
ESH exists in two tautomeric forms as thiol or and as a thione predominantly as illustrated in 
the Figure 1.3. The thione form is almost exclusively present under physiological conditions 
(pH 7.4).7,8  




Figure 1.3.  Tautomeric forms of ergothioneine.  
 
The fact that ESH is present in solution predominantly in the thione form explains its stability, 
therefore ESH is not easily auto-oxidized unlike alkylmercaptans, and this characteristic 
differentiates ESH from other biological LMW thiols.7   
Ergothioneine’s reduction potential (E0 = −60 mV) is significantly greater than glutathione 
(E0 = −0.240 mV), thus making ESH extremely difficult to oxidize.2,9 ESH is very stable even 
when aerated in aqueous solution. It has been proven that ergothioneine can be oxidized in 
very strong acidic solutions, but these forms (reduced/oxidized) happen to be present in 
solution simultaneously.10  
Furthermore, the X-ray structure of L-ESH-dihydrate confirmed the thione form of ESH, it 
revealed an uncommon S-C bond length of 1.69 Å, which is a value in-between the S-C single 
and double bond lengths of 1.82 and 1.56 Å, respectively. That unusual S-C bond length is due 
to the resonance thiol-thione form (thione form predominantly).11 
The pKa of ergothioneine was calculated according to Henderson-Hasselbalch equation from 
the data generated experimentally by 13C NMR chemical shift values and pH profiles and it 
was found to be 11.5.8 
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1.2.1.2. Ergothioneine distribution in living organisms  
 
Ergothioneine is synthesized by bacteria, specifically mycobacteria as revealed by exhaustive 
analyses of 101 mycobacterial strains from various sources. All these strains exhibited a high 
concentration of ergothioneine, about 1.4 µmol per gram on average.12 Similar ergothioneine 
concentrations were detected in many strains of Actinomycetes including Actinoplanes 
philippinensis, Nocardia asteroides strains and in three classes of Streptomycetes.13 
Ergothioneine is synthesized by cyanobacteria; both ergothioneine (up to 0.8 mg per gram of 
dry mass) and its biosynthetic precursor, hercynine were detected in Cyanobacterium 
phormidium, thus supporting that cyanobacteria produces high levels of ergothioneine.14  
Ergothioneine is synthesized by the fungus Neurospora crassa and higher comestible fungi 
like mushrooms.15,16 Very recently, it was discovered that the fission yeast, 
Schizosaccharomyces pombe synthesize ergothioneine as well.17 
 
ESH has been detected in millimolar concentrations in fungi, bacteria, plants and mammals. 
Plants, animals and humans do not synthesize ESH, but exclusively acquire it from their 
environment. Plants take up ESH from soil through their roots while animals as well as humans 
acquire it from their nutrition. Food such as mushrooms, red and black beans, corn, garlic, 
oats and meat (liver and kidney) are extremely rich in ergothioneine.18 (Figure 1.4) 





Figure 1.4.  ESH uptake chain  
 
In humans, ESH is present at millimolar level in specific cells and tissues believed to be 
exposed to oxidative stress including liver, kidney, heart, red bloods, semen and ocular lens 
tissues. ESH exists in the brain at slightly lower levels, thought to be in micromolar quantities. 
Studies showed that human red cells contain about 1.5-3.7 mg ESH/100 mL of blood, although 
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1.2.1.3. Ergothioneine specific transporter  
 
In 2005, Gründemann et al. discovered the ergothioneine specific transporter, OCTN1, which 
is responsible for the distribution and accumulation of ergothioneine across cells.19 
Previously, it was assumed that OCTN1 is involved in the transport of tetraethylammonium 
cation through the plasma membrane, though Gründemann et al. demonstrated that 
ergothioneine is in fact the key substrate transported, as ergothioneine was more than 100 
times more efficiently transported than tetraethylammonium and carnitine altogether.19 
Furthermore, OCTN1 transporter was expressed in over 293 human cells lines and its 
efficiency of transporting ergothioneine was established to be 195 µL per min per mg of 
protein.19 This discovery has motivated the scientific community to unveil ergothioneine’s 
role.  
Very recently, Frigeni et al. demonstrated that the OCTN1 transporter is in fact broadly 
tolerant to amino acid substitution whereas the OCTN2 transporter is exclusively carnitine 
specific.20 These results suggested that the SLC22A4 gene (OCTN1 encoding gene) could be 
derived from a duplication of SLC22A5 (OCTN2 encoding gene), hence OCTN1 transporter 
physiological role might not have been well-defined as yet.20  
 
1.2.2. Reconstitution of ergothioneine biosynthesis pathways 
 
The beneficial role of ergothioneine to human health has motivated biochemists to attempt 
the elucidation of its biosynthesis. The elucidation of ergothioneine biosynthesis started many 
decades ago, around the mid-20th century.15,21-25 
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In 1957, Wildy and Heath investigated the biosynthesis of ergothioneine in Claviceps 
purpurea. Their research revealed that when growing Claviceps purpurea cultures on media 
supplemented with either radio-labelled [α-14C] histidine or [2(ring-imidazole)-14C] histidine, 
radiolabelled, ergothioneine was isolated thus suggesting that the imidazole ring and the 
amino acid side chain of ergothioneine is biosynthetically derived from histidine. Therefore 
establishing that histidine or a closely related analogue could indeed be an ergothioneine 
biosynthetic precursor, and not histamine or 2-thiohistidine as initially believed.21,22 
The same year Melville et al. confirmed these findings by performing the study on a different 
organism, Neurospora crassa.25 This fungus was selected for the study because of its high 
concentration in ergothioneine (estimated to be in millimolar level). The authors used the 
classical radio isotopic labelling (14C and 35S) method and provided strong evidence that 
histidine is in fact the biosynthetic precursor of ergothioneine. The introduction of a sulfhydryl 
group at 2-position of the imidazole ring is provided by cysteine, and at least one of the three 
methyl groups of ergothioneine is derived from methionine.25 
In 1962, Askari et al. proposed the possible straightforward ergothioneine biosynthetic 
sequence in Neurospora crassa, which involved histidine, hercynine and thiol histidine as 
precursor intermediates, whereby cysteine is responsible for the introduction of sulfur at the 
2-position of the imidazole ring and three methyl groups of the betaine moiety derived from 
methionine.26 (Figure 1.5) 




Figure 1.5.  Proposed ergothioneine biosynthesis sequence by Askari et al.26 
 
Five years after Askari’s study, Genghof et al. confirmed that endogenous hercynine is the 
ESH biosynthetic precursor in Mycobacterium smegmatis.15,23 They also discovered that 
growing M. smegmatis cells supplemented with low concentration of cysteine and high 
concentration of histidine in the culture medium, resulted in the production of 100 to 200 µg 
of ESH per g of dry cells after only 2.5 to 3 hr of incubation, thus supporting that cysteine is 
the direct source of sulfur in ESH biosynthesis in M. smegmatis.23 
 
In 1974, Ishikawa et al. explored in depth the transfer of the sulfur atom from cysteine to the 
imidazole ring using cell-free extracts of Neurospora crassa. Sulfur was transferred onto 
histidine ring of hercynine by incubating cysteine and histidine in the presence of O2 and Fe2+. 
The sulfoxide intermediate, S-(β-amino-β-carboxyethyl)ergothioneine sulfoxide (Figure 1.6) 
was isolated and the latter was subsequently cleaved to ergothioneine and pyruvate by a PLP-
dependent enzyme.27 These authors attempted the chemical synthesis of the sulfoxide 
intermediate, without affording enough chemical structural evidence.27  





Figure 1.6.  Structure of S-(β-amino-β-carboxyethyl)ergothioneine sulfoxide 
 
Recently, two different ESH biosynthesis pathways have been discovered. Seebeck was the 
first to publish the gene cluster (egtABCDE) encoding for ESH biosynthesis in Mycobacterium 
smegmatis.28 In Mycobacterium smegmatis, ESH is synthesized by the sequential action of 
five enzymes encoded by the genes egtA, egtB, egtC, egtD and egtE.28  
The mycobacterial ESH pathway involves five steps, EgtD catalyses the N,N,N-α-
trimethylation of histidine to form hercynine; EgtA condenses glutamate and cysteine to form 
γ-glutamylcysteine (γ-Glu-Cys). Subsequently, EgtB, a FGE (Formylglycine Generating Enzyme) 
like enzyme catalyzes the oxidative S-C bond coupling between hercynine and γ-Glu-Cys to 
form γ-glutamyl cysteinyl hercynine sulfoxide, which become hydrolysed by the catalytic 
action of EgtC to form hercynylcysteine sulfoxide. The last step involves the C-S lyase of 
hercynylcysteine sulfoxide to yield ergothioneine. (Figure 1.7) 28-30  
 
In Mycobacterium smegmatis, γ-glutamylcysteine is the source of sulfur whereas in the 
fungus Neurospora crassa, cysteine is the source of sulfur. Neurospora crassa Egt1 enzyme 
catalyses the direct biotransformation of hercynine to hercynylcysteine sulfoxide. (Figure 
1.7)31,32  




Figure 1.7. ESH biosynthesis pathway structures in Mycobacterium smegmatis (EgtA- EgtE enzyme catalysis) 
and ESH biosynthesis pathway in the Fungal N. crassa (Egt1) 
 
In 2014, ergothioneine and selenoneine (a selenium-containing derivative of ergothioneine) 
biosynthesis was reconstituted in fission yeast, Schizosaccharomyces pombe, the genes 
encoding the pathway were also discovered. (Figure 1.8) 
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The selenoneine biosynthesis pathway in yeast is similar to the one found in Neurospora 
crassa and Mycobacterium smegmatis. It was furthermore demonstrated that ergothioneine 
pathways can produce selenoneine by simply supplementing culture medium with selenium 
during growth.17  
 
Actinobacteria including mycobacteria prefer γ-glutamylcysteine over cysteine as sulfur 
source as depicted in the Figure 1.7. Studies suggested that mycobacteria avoid the “cysteine 
problem”.33 Cysteine is readily auto-oxidized and its terminal 1,2-aminothiol group complexes 
with redox active transition metals such as iron and copper, that making free cysteine less 
available. Consequently, mycobacteria do not use cysteine but they turn to γ-
glutamylcysteine as their sufur source. γ-Glutamylcysteine possesses 1,2-amide thiol instead 
which is unable to complex with transition metals,  therefore γ-glutamylcysteine is more 
available than cysteine within the cell.34  
 
1.2.3. Enzymes of the ergothioneine biosynthesis pathway  
 
All the enzymes implicated in the ESH biosynthesis have recently been recombinantly 
expressed and purified.29,35-38 An overview of these enzymes will be provided.  
 
1.2.3.1. Methyltransferase EgtD  
 
EgtD is an S-adenosyl L-methionine (SAM)-dependent methyltransferase enzyme which 
catalyses the N,N,N-trimethylation of the α-amino group of histidine to form hercynine in the 
initial step of the mycobacterial ergothioneine biosynthesis process.28  
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The crystal structure coordinates of purified EgtD has been recently solved illustrating the 
binding pocket and supporting the catalytic mechanism.35,36 Intriguingly, the EgtD enzyme 
possesses an unique substrate binding domain dissimilar to any known methyltransferase.35 
EgtD contains a Rossman-like fold and belong to class I methyltransferases (MTases).39 It 
consists of two distinct domains: the catalytic MTase domain (a typical methyltransferase) 
which shares the highest sequence similarities with the histamine N-methyltransferase HNMT 
(PDB ID 1JQD; RMSD, 3.4 Å for 208 residues)40 and the substrate binding domain (unique to 
EgtD). (Figure 1.9)35  
 
Figure 1.9.  Crystal structure of methyltransferase EgtD (PDB 4PIM) isolated from Mycobacterium smegmatis. 
 
Moreover, EgtD shares 16% sequence identity with the human methyltransferase Ad-003 
(PDB 2EX4), which is believed to catalyze the N-terminal proline dimethylation.36   
 
1.2.3.2. Sulfoxide Synthetase EgtB  
 
The enzyme responsible for the second step in ESH biosynthesis is EgtB (EC 1.14.99.50) which 
is a non-heme iron enzyme sulfoxide synthetase that catalyses the central step in the 
ergothioneine biosynthesis pathway. EgtB is responsible for an O2-dependent oxidative C-S 
bond formation between γ-glutamylcysteine and hercynine.28  
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EgtB shares a common DUF323 domain with FGEs (formylglycine-generating enzymes), which 
catalytically mediates the generation of a formylglycine residue by posttranslational oxidation 
of the cysteine precursor.28,41 EgtB consists of residues 7–150 that folds to a DinB-like four-
helix bundle with long linkers between helices 1 and 2 (18 residues), 2 and 3 (34 residues), 
and 3 and 4 (7 residues). (Figure 1.10)  
 
Figure 1.10. Crystal structure of sulfoxide synthetase EgtB (PDB 4X8B) isolated from Mycobacterium 
thermoresistible. 
 
The EgtB crystal structure in the apo form as well as in complex with its natural substrate, 
along with its mechanistic and enzyme binding studies were also established.38 The same 
research group also demonstrates that a simple mutation of Tyr377 in the EgtB active site by 
Phe completely changes its catalytic activity.42 EgtB catalyses the oxidative C-S coupling 
between γ-glutamylcysteine  and hercynine to form γ-glutamylcysteine hercynine sulfoxide. 
Mutation of Tyr377 by Phe in the active site of EgtB results in the formation of EgtBY377F 
enzyme which instead catalyses the dioxygenation of γ-glutamylcysteine to form of γ-
glutamylcysteine sulfinic acid.42 The latter enzyme exhibited a strong similarity with the 
natural evolved cysteine dioxygenases (CDO, EC 1.13.11.20) which produces cysteine sulfinic 
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acid. CDOs and EgtB share no evolutionary relationship and their overall structure is quite 
different. 43 (Scheme 1.1) 
 
Scheme 1.1. Reactions catalysed by EgtBwild type, EgtBY377F and cysteine dioxygenase (CDO) enzymes. (Scheme 
adapted from Goncharenko et al. 42) 
 
1.2.3.3. Amidohydrolase EgtC  
 
EgtC is an amidotransamidase enzyme catalysing the hydrolysis of the glutamate from γ-
glutamylcysteinylhercynine sulfoxide to produce hercynylcysteine sulfoxide in the 
mycobacterial ergothioneine pathway.  
Crystal structure coordinates of EgtC enzyme in the apo form (Figure 1.12)37, in complex with 
glutamine/glutamate and in complex with its natural substrate, γ-glutamylcysteinyl hercynine 
γ-glutamylcysteine 
γ-glutamylcysteine 
γ-glutamylcysteine sulfinic acid  
γ-glutamylcysteinylhercynine 
sulfoxide 
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sulfoxide were solved, thus shedding light on the enzyme substrate binding pocket in support 
of the enzymatic catalytic mechanism. (Figure 1.11)37 Crystal structure of EgtC in complex with 
substrates (glutamine/glutamate and γ-glutamylcysteinyl hercynine) revealed an “open” 
conformation of the Ala90–Pro95 loop for hydrogen bonding and a large hydrophobic pocket 
with negative charge required for betaine recognition. The substrate-binding site is localised 
at the interface of the EgtC enzyme dimer.37  
 
           
 
 
1.2.3.4. PLP-dependent C-S lyase EgtE 
 
PLP-dependent EgtE catalyses the last step in the mycobacterial ergothioneine biosynthetic 
pathway. Thus, the cleavage of the C-S bond of hercynylcysteine sulfoxide produces 
ergothioneine, while releasing pyruvate and ammonia.   
Its catalytic activity was proposed by Seebeck but not demonstrated in vitro due to common 
difficulties in the overexpression of the PLP-dependent enzyme of Mycobacterium 
Figure 1.12.  Superposition of EgtC apo form 
(in red), EgtC in complex with 
glutamate/glutamine (in light blue) and 
EgtCC2A in complex with γ-glutamyl cysteine 
hercynine sulfoxide (in green).37 
Figure 1.11.  Apo enzyme crystal 
structure of EgtC (PDB 4ZFL).37    
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smegmatis. Due to that failure, Seebeck substituted EgtE enzyme by an unrelated β-lyase 
from Erwinia tasmaniensis, which successfully cleaved hercynylcysteine sulfoxide to yield 
ergothioneine.28  
Khonde et al. studied the EgtE C-S lyase activity of Mycobacterium smegmatis using cell lysate, 
which was later confirmed by Song et al.29,30 The latter authors successfully overexpressed 
and purified Mycobacterium smegmatis EgtE. However, to date the crystal structure 
coordinates of EgtE has still not been solved.  
 
Therefore, the elucidation of the crystal structure coordinates of these enzymes implicated in 
the mycobacterial ergothioneine biosynthesis pathway could help in designing ergothioneine 
biosynthesis inhibitors that could represent a novel class of anti-mycobacterial drugs 
candidates.  
 
1.2.4. Involvement of ergothioneine in the biosynthesis pathways of natural 
products 
 
It has emerged that ESH alongside cysteine, mycothiol (MSH) and glutathione (GSH) are 
involved in the biosynthesis pathways of natural products in many organisms illustrating an 
unique specificity.  
For example, MSH and ESH are involved in the biosynthesis of Lincomycin A, which has been 
widely used for half a century to treat Gram-positive bacterial infections.44 (Figure 1.13) 




Figure 1.13. The ESH (blue) and MSH (red) programmed biosynthetic pathway of lincomycin A. The recycling 
of ESH and the regeneration of MSH are shown as dashed lines. (Figure adapted from Zhao et al.44) 
 
Furthermore, two new bohemamine-type pyrrolizidine alkaloids (Spithioneines A and B) 
possessing an unusual ESH moiety, were isolated from a marine derived Streptomyces 
spinoverrucosus.45 (Figure 1.14) 




Figure 1.14.  Spithioneines A and B, two new bohemamine-type pyrrolizidine alkaloids possessing an 
ergothioneine moiety isolated from a marine-derived streptomyces spinoverrucosus.45 
 
Very recently, a Chinese group have isolated an unusual ergothioneine containing natural 
product, from an aqueous extract of ‘‘tian ma’’ (the Gastrodia elata rhizomes). This latter 
compound was named gastrolatathioneine and it is in fact an N-1',N-3', bis [4 –hydroxybenzyl] 
ergothioneine.46 (Figure 1.15)  
 
Figure 1.15.  Structure of Gastrolatathioneine isolated from ‘‘tian ma’’ (the Gastrodia elata rhizomes).46 
 
However, the genes encoding for ESH were absent in the plant that suggested that the 
gastrolatathioneine is co-produced by this higher eukaryote. Moreover, the plant enzyme 
that catalyses the transfer of the 4-hydroxybenzyl to ergothioneine is unknown to date.  
Recent knowledge suggests that ergothioneine could be vital for the survival of 
Mycobacterium tuberculosis, therefore link between ergothioneine and tuberculosis is worth 
an in-depth discussion.  
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1.3. Mycobacterium tuberculosis and anti-tuberculosis drugs 
 
1.3.1. Mycobacterium tuberculosis, a causative agent of tuberculosis 
 
Mycobacterium tuberculosis (Mtb) is the causative microbe of tuberculosis (TB), a worldwide 
infectious disease. Mycobacterium tuberculosis is capable of persisting in a dormant state in 
human host for many years before causing active disease in approximately 10% of people 
infected. The very long duration of TB treatment (up to 9 months) and the emergence of Mtb 
drug resistance strains are the main reason making the treatment of tuberculosis extremely 
challenging.47,48 As a result TB is the leading cause of mortality worldwide alongside the 
Human Immunodeficiency Virus (HIV) as it affects millions of people every year.49  
 
Mycobacterium tuberculosis typically affects lungs hence cause pulmonary TB, but can also 
affect other parts of the human body to cause extra pulmonary TB. TB infection spreads by 
inhalation of micro-droplets of 2.5 µm of diameter having 1-3 bacilli. The bacteria get 
phagocytosed by macrophages as soon as they reach the alveola of the pulmonary system. 
The host reacts by apoptosis of the infected macrophages, but virulent strains may escape 
apoptosis by subversion of the immune system, hence resulting in dormant bacteria in the 
macrophages.50 
 
The World Health Organization (WHO) declared TB a global public health emergency in 1993, 
since then impressive progress were made thus resulting in the decrease of TB mortality by 
45%.49 However, TB remains a global health problem despite the availability of various 
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antibiotics for many decades and the emergence of novel drugs. Almost one third of the 
world’s population asymptomatically still possess a dormant or latent form of Mycobacterium 
tuberculosis. Many factors such as poverty, malnutrition, immune system suppression, poor 
hygiene, tobacco smoking, excessive alcohol consumption, as well as co-infection with other 
diseases such as HIV, diabetes usually lead to the reactivation of the latent TB to active TB 
disease.50,51 About 95% of patients suffering from drug susceptible (DS) TB recovered after an 
adequate treatment, even though a minority of 5% may relapsed. However, if the TB patient 
does not get treated it will unavoidably lead to death. A simplified depiction of the phases of 


























Figure 1.16. Simplified depiction of phases of Mycobacterium tuberculosis infection. 
 
1.3.2. Global tuberculosis burden and tuberculosis drugs 
 
1.3.2.1. Tuberculosis burden 
 
Tuberculosis is spread through air and normally affects the lungs (pulmonary TB) but can also 
affect other sites as well (extrapulmonary TB). An overall of 5-15% of the estimated 3 billion 
people infected with Mtb will develop active TB during their lifetime, and this probability 
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In 2014, there were an estimated 9.6 million new TB cases worldwide, with approximately 1.5 
million deaths. The TB incidence rate has been dropping in the last decade, the cumulative 
decrease was 18% from 2000 to 2014.49 Asia (58%) and Africa (28%) recorded the most of the 
estimated number of TB cases occurred in 2014, whereas Eastern Mediterranean (8%), 
Europe (3%) and America (3%) registered a smaller proportion. India, Indonesia and China 
accounted for 48% of TB case globally, alongside Nigeria, Pakistan, South Africa, Bangladesh, 
Philippines, Democratic Republic of Congo, and Ethiopia making the top 10 countries with 








Figure 1.17.  Estimated tuberculosis incidence top-10 countries in 2014.49  
 
The countries with high-income such as USA, Canada, Australia, New Zealand, Western 
Europe exhibited a lower TB incidence rate of less than 10 cases per 100000 population per 
year, while Southern Africa, India, Russia and China displayed the highest TB incidence, 300 
or more cases per 100000 in 2014. (Figure 1.18) 
 
 













Figure 1.18.  Estimated tuberculosis rates, 2014.49 
 
1.3.2.2. HIV and Tuberculosis   
 
The Human Immunodeficiency Virus (HIV) weakens the human immune system, hence 
increases the chance of developing active TB especially when a patient is infected by 
Mycobacterium tuberculosis, the causative agent of TB disease. Amongst 9.6 million of TB 
cases reported in 2014, an estimated 1.2 million (12%) were living with HIV. The rate of TB-
HIV co-infection was higher in Africa which represents 74% of TB cases among people living 

















Figure 1.19.  Estimated HIV prevalence and relapse TB cases, 2014.49 
 
Despite, the number of deaths related to HIV associated to TB has drastically decreased by 
32% from 570000 deaths in 2004 to 390000 deaths in 2014, but TB infection amongst HIV 
patients remains a major concern as an estimated one-third of 1.2 million deaths among 
HIV/AIDS population were due to TB co-infection.49  
 
1.3.2.3. Current tuberculosis drugs  
 
The treatment of tuberculosis is difficult due to some major factors, such as persistence 
(survival of M. tuberculosis despite the use of TB drugs), complete drug resistance as well as 
relapse. Therefore, the management of TB disease requires lengthy drug treatment regiments 
of six to nine months. The treatment of drug-susceptible (DS)-TB involves a four-drug regimen 
of first-line anti TB drugs. An intensive phase includes the use of isoniazid, pyrazinamide, 
rifampicin, and ethambutol for a period of two months. The intensive phase is followed by a 
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continuation phase which includes the use of two drugs rifampicin and isoniazid for an 
additional 4 months period.50 (Figure 1.20) 
 
Figure 1.20.  Chemical structure of first line TB drugs. 
 
However, the second line TB drugs and third line TB drugs are either more expensive, or less 
effective (e.g. p-aminosalicylic acid), and have toxic side-effects (e.g cycloserine) than the first 
line drugs. (Figure 1.21 & Figure 1.22) 
 
Figure 1.21. Chemical structure of some second line TB drugs.  
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The second line TB drugs belong to several chemical classes including polypeptides (e.g. 
capreomycin), thioamides (e.g. ethionamide), aminoglycosides (e.g. kanamycin), 
fluoroquinolones (e.g. ciprofloxacin), and thioamides (e.g. ethionamide).  
It is noteworthy that the second line TB drugs are only mandatory in the extreme case, when 
the TB patient either does not tolerate the first line TB drugs or the treatment does not 
respond. 
 
Figure 1.22.  Chemical structure of some third line TB drugs.  
 
1.3.3. Drug-resistant tuberculosis  
 
Drug-resistant Mycobacterium tuberculosis strains were first reported in 1944 after the 
discovery of streptomycin. Later, resistance to others TB drugs were also established. TB drug 
resistance is due to genetic mutation which alter the affinity of either the target or the 
activator of the drug.48  
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Multidrug-resistant (MDR-TB) are strains resistant to at least one of the first list drugs, mostly 
isoniazid (INH) and rifampicin, the most effective anti-TB drugs. Extremely-drug resistant 
(XDR-TB) are Mtb strains resistant to isoniazid, rifampicin and to second line anti-TB drugs 
belonging to the fluoroquinolone family and resistant to at least one of aminoglycoside 
injectable drugs (kanamycin, capreomycin, or amikacin).48 MDR-TB is difficult to treat 
compared to susceptible TB, since less than 70% cure-rates are more often achieved.50 MDR-
TB has been surveyed worldwide, an estimated half a million cases was reported in 2011 and 
this rate remains almost unchanged to date. XDR-TB on the other hand has been reported in 
105 countries, in average 9.7% of people with MDR-TB possess XDR-TB.49,52 
 
More recently, totally-drug resistant (TDR) Mtb strains which exhibit resistance to all first-line 
and second anti-TB drugs have been reported, thus posing a huge threat for TB therapy. TDR-
TB is practically incurable and was reported in several countries such as India, South Africa, 
Italy and Iran.53,54 
 
Therefore, the development of new tools for prevention, diagnostics and new antitubercular 
drugs are urgently needed in order to bring TB disease under control. The development of 
novel chemotherapeutics which are effective against drug-resistant Mtb strains, less toxic and 
acting on new biological targets is of foremost importance.  
However, several drug candidates with novel modes of action are either in the late-stage 
clinical development or have been approved for TB chemotherapy. (Figure 1.23) Amongst 
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them bedaquiline (a diarylquinoline) and delamanid (a nitroimidazo-oxazole) have been 
















Figure 1.23.  Pipeline of new tuberculosis drugs. MDR-TB: multidrug-resistant tuberculosis OBR-optimised 
background regimen; DS-TB: drug-susceptible tuberculosis; LTBI: latent tuberculosis infection.55 
 
1.3.4. Tuberculosis biological drug targets.   
 
Existing TB drugs have diverse mechanisms of action. First line-TB drug targets the 
mycobacterial cell wall biosynthesis with Isoniazid as well as ethambutol blocking the 
synthesis of mycolic acid, an essential component of the mycobacterial cell wall.  































































Chemical classes: fluoroquinolone, rifamycin, oxazolidinone, nitroimidazole, diarylquinoline, benzothiazinone 
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Two newly approved TB drugs have quite dissimilar modes of action. Delamanid, inhibits the 
synthesis of mycolic acid, hence destroying the bacterial cell wall,56 while Bedaquinine targets 
the proton pump of ATP synthesis.57 Pyrazinamide, structurally similar to INH, is a prodrug 
readily transformed into pyrazinoic acid (its active form) by nicotinamidase/pyrazinamidase 
(PZase) enzyme.58 However, its mode of action has been debated, it is suggested that this 
drug inhibits the fatty acid synthase I (FAS),59 an enzyme implicating in the biosynthesis of 
mycobacterial fatty acid by depleting ATP reserves and by binding to the ribosomal protein 
S1.60-62 Rifampicin, acts on replicating and non-replicating mycobacteria by inhibiting the 
bacterial RNA-dependent polymerase.60 Cycloserine inhibits the mycobacterial cell wall by 
acting on the mycolylarabinogalactan-peptidoglycan complex.63 The aminoglycosides inhibit 
the protein synthesis by disturbing the translocation of peptidyl transfer RNA, while the 
thioamide TB drug inhibits the mycolid acid biosynthesis, even though the detailed 
mechanism remain unclear.64,65 Fluoroquinolone TB drugs are the first choice for the 
treatment of patient with multidrug-resistant (MDR-TB) and extensively drug resistant 
tuberculosis. Fluoroquinolone TB drugs act on Type II topoisomerase (DNA gyrase), which 
result on the inhibition of DNA replication and transcription.66-68  
 
Most existing drugs target the cell wall and is susceptible to the development of resistance. It 
is therefore important that future TB drugs also target essential metabolites, hence 
introducing novel mode of actions and reducing resistance or/and cross resistance with 
existing TB-drugs. Mycothiol and ergothioneine are the principal low molecular weight thiols 
produced by Mtb, and these metabolites play a key role in maintaining redox homeostasis 
which is essential for the in vitro and in vivo survival of Mtb. Therefore, enzymes of the 
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mycothiol and ergothioneine biosynthesis pathway appeared to be potential anti-TB drug 
targets.51,69,70  
1.4. Redox homeostasis in mycobacteria 
 
Homeostasis can be defined as a ‘relatively stable state of equilibrium or a tendency towards 
such a state between the different but interdependent elements or groups of elements of an 
organism, population, or group’ (Merriam-Webster). 
For many years, it has been known that Mtb is an obligate aerobe, although research has 
shown that Mtb can survive in vitro under anaerobic conditions for more than a decade. Mtb 
is exposed to various extreme and stressful environmental conditions during infection, which 
triggered an as yet uncharacterized response by the bacteria in order to maintain a normal 
redox state.51  
The bacterial host provides nutrients (carbon sources), gas and pathological conditions such 
as hypoxic granulomas, which allow the Mtb, through unknown mechanisms, to subvert the 
immune system and to cause TB proliferation. An intracellular redox imbalance state can 
affect the efficacy of TB drugs which require a bioreductive activation, these drugs include 
isoniazid (INH), ethionamide (ETA) and pretomanid (nitro-imidazole drug).51 Furthermore, it 
was established that INH resistance could be directly due to the increase in the ratio of 
NADH/NAD+, while mycobacteria with deletion mutations in the MSH biosynthesis pathway 
demonstrated resistance to INH and ETA.71 Nevertheless, the mechanism used by Mtb to 
maintain the in vivo redox homeostasis and their role in drug susceptibly and efficiency 
remain poorly understood. 
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The GSH redox couple (GSSG/2GSH) is lacking in Mtb, instead they possess millimolar 
quantities of the mycothiol redox couple (MSSM/2MSH) as major redox buffer. Recently, 
Bhaskar et al. developed a genetically encoded biosensor method to quantify the redox 
potential of mycothiol EMSH in real time for diverse Mycobacterium tuberculosis strains and 
mutants inside macrophages.72 Intriguingly, these studies revealed that the heterogeneity in 
the mycothiol redox potential EMSH of the Mtb population is induced by the intravacuoles and 
intramacrophage environment. Consequently, treatment with anti-TB drugs oxidatively 
affects this mycothiol redox potential EMSH which results in the disruption of the MSH 
homeostasis that contributes to the killing of Mtb.72  
Mycobacteria contain many other redox couples such as NADH/NAD+, NADPH/NADP+ and 
thioredoxin (TrxSS/Trs (SH) 2).51 The reduction of the mycothiol disulfide is catalysed by a 
special enzyme, the FAD-binding mycothiol reductase using NADPH as a cofactor as depicted 
in the equation below: 
 
It was reported that MSH deletion mutants are sensitive to oxidative stress caused by cumene 
hydroperoxide, H2O2, and superoxide radical (O2. –).73 While the redox potential of ESH ox/ESH 
red couple for mycobacteria is established (EO = −60 mV), its role as protective thiol is not well-
known. 
The understanding of the redox homeostasis in mycobacteria and how it influences drug 
efficacy remains the key to control tuberculosis disease. However, recent findings suggest 
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that ESH could be essential for the in vitro and in vivo survival of Mtb. Hence, enzymes 
implicated in its biosynthesis could be valuable TB drug targets.  
 
1.5. Unveiling the physiological role of ergothioneine in 
mycobacteria  
 
The role of mycothiol in Mycobacterium (smegmatis and tuberculosis) have been extensively 
studied in the last decade, whereas ESH’s natural function in Mycobacteria has recently been 
under the spot light. Various research groups have focused on the validation of ergothioneine 
biosynthesis as a potential tuberculosis drug target. Despite these recent efforts, the direct 
link between ESH and tuberculosis remains a topic for further investigation.  
 
Studies conducted by Ta et al. have revealed that a Mycobacterium smegmatis mutant 
(∆mshA) lacking mycothiol, overproduced ergothioneine and organic hydroperoxide 
resistance protein (Ohr), thus suggesting that ESH as well as Ohr act as an alternative 
antioxidant to compensate for any mycothiol loss.74 Sao Emani et al. confirmed these findings, 
moreover they attempted to quantify ESH in Mycobacterium smegmatis while comparing its 
intracellular versus extracellular concentration.70 The percentage of ergothioneine appeared 
to be higher extracellularly than intracellularly in either M. smegmatis wild type as well as M. 
smegmatis mutants (∆mshA, ∆egtDca), hence confirmed that M. smegmatis produce and 
secrete ESH.70 The presence of ESH extracellularly suggestes a possible existence of an ESH 
specific transporter in mycobacteria similar to the human ESH transporter OCTN1, which 
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could be responsible for the active diffusion of ESH outside the M. smegmatis cells, although 
these suggestions still have to be confirmed.70 
The same research group discovered that M. smegmatis egtD deletion mutants do not 
produce ergothioneine. More importantly it has been found that double M. smegmatis 
mutants (∆mshA ∆egtD), lacking mycothiol and ESH were significantly more sensitive to 
peroxide than either of the single mutants lacking ESH or MSH, thus suggesting that MSH as 
well as ESH play a crucial role in protecting M. smegmatis against oxidative stress while 
compensating each other. These findings suggested that the EgtD enzyme could be a potential 
mycobacterial drug target. Amongst all the other ESH enzymes evaluated in their study, only 
EgtD enzyme knockout results in M. smegmatis mutants sensitive to peroxide.70 
 
Richard-Greenblatt et al. have extended studies to better understand the role of ESH in 
Mycobacterium tuberculosis. They have identified a rv3701c gene from Mtb which encode for 
EgtD, the enzyme implicated in the first step of ESH biosynthesis.75 They have demonstrated 
that EgtD is essential for ESH biosynthesis but not required for the growth of Mycobacterium 
tuberculosis.75 In Mycobacterium tuberculosis, EgtD was discovered to be a substrate for 
either in vitro and cell base phosphorylation by a serine/threonine kinase enzyme, PknD. It 
was shown that this competitive reaction down-regulates ESH biosynthesis as 20% reduction 
in EgtD methyltransferase activity was observed.75  
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More importantly, this group showed that ESH is indeed required for the survival of Mtb 
during long starvation conditions as well as inside the murine macrophage as a rise in 
intracellular ESH was observed during late logarithmic growth.75 
 
Very recently Saini et al. have shown that specific Mtb WhiB3 redox sensor controls the 
production of ESH while maintaining bioenergetic homeostasis.47 Mtb ∆egtA, ∆egtD deletion 
mutants lacking ESH exhibited higher sensitivity to anti-TB drugs such as rifampin (RIF), 
isoniazid (INH), bedaquiline (BDQ), and clofazimine (CFZ) compared to Mtb wild type. 
Molecular biology studies suggested that ESH and MSH have distinct but overlapping 
physiological function in Mtb. Furthermore they showed that ESH is vital for Mtb survival in 
vivo in a mouse model of Mtb.47 
 
Unpublished research conducted at the University of Stellenbosch by Sao Emani (post doc 
fellow in Bienyameen Baker research group) have provided evidence of ESH being essential 
for the survival of Mtb cell cultures. This group claimed that the depletion of ESH in Mtb 
weakens the mycobacteria which eventually died. The same trend was still observed when 
Mtb ergothioneine deletion mutants (∆egt) were assayed in vitro either under mimicking 
human latent or active tuberculosis conditions. Nevertheless, still more research has to be 
conducted to establish that if the same feature can be replicated in vivo and inside the human 
host cells. 
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1.6. Aims and objectives of this study 
 
It is now emerging that ergothioneine is required for the survival of Mtb as demonstrated 
independently by two research groups (Baker B., University of Stellenbosch, Tygerberg, South 
Africa70 and Steyn, J.C., KwaZulu-Natal Research Institute for Tuberculosis and HIV, Durban, 
South Africa47,75).  
 
The reconstitution of ergothioneine biosynthesis pathway in mycobacteria will aid the 
understanding of the essentiality of ESH in mycobacteria. Designing potential mechanism 
based inhibitors targeting ergothioneine is mandatory for the development of future drugs 
against tuberculosis.  
 
Ergothioneine is commercially available but expensive due to the challenge associated with 
its synthesis. The biosynthetic pathway intermediates of ergothioneine are not commercially 
available. 
Ovothiol is structurally similar to ergothioneine and is the most powerful natural antioxidant. 
It has been suggested that ovothiols protect trypanosomatid parasites from oxidative stress.76 
Recent knowledge suggested that ovothiol A could be active against the proliferation of Hep-
G2, human liver cancer cells.77 Therefore developing a better process for the synthesis of this 
important thiol is of valuable interest.  
The research reported in this thesis aims to: 
(i) Develop improved synthetic methods to produce ergothioneine in a better yield. 
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(ii) Synthesize stable isotopically labelled substrates, essential tools for metabolomic 
studies and drug discovery.   
(iii) To perform the biotransformation of EgtE enzyme (PLP-dependent) substrates to ESH 
using cell-free lysate preparation from M. smegmatis monitored by LCMS technique, 
in order to shed light on the mechanism of C-S lyase as well as enzyme-substrate 
specificity.  
(iv) Design and develop a strategy for the first total synthesis of the EgtC enzyme substrate. 
Previously, this enzyme substrate was enzymatically synthesized in a very low amount. 
A viable synthesis protocol will provide the scientific community with valuable tools for 
further investigation of ESH and the TB link. 
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2.1. Background  
 
Ergothioneine is the newly discovered vitamin therefore huge interest worldwide in the 
molecule has been unveiled. Ergothioneine’s beneficial role has encouraged the scientific 
community to study this unique molecule in depth. Since its discovery in 1909, every year an 
average of 14 ergothioneine-related papers were per annum published. However, since 2006 
this number has increased drastically. In 2013 alone there were about 88 publications while 
in 2016 around 103 publications were published, thus demonstrating growing interest in 
ergothioneine over the last decade. (Figure 2.1) 
 
Figure 2.1. Ergothioneine-related publications over the last 55 years. Graph exported from 






























Ergothioneine is a powerful antioxidant thought to protect human skin, therefore it is 
extensively used as principal ingredient in the formulation of skin care products.2 The 
cosmetic industry uses the majority of the worldwide ergothioneine production. L’Oreal, a 
French cosmetic company, includes ergothioneine in its list of antioxidants in many of their 
patents for cosmetic and hair care application. Ergothioneine has also been administrated as 
a dietary supplement known to boost immunity.  
Ergothioneine can be isolated from organisms such as bacteria, though it is mostly isolated 
from mushrooms. Very recently, Wenxia et al. isolated L-ergothioneine from mushroom 
mycelium in a very low yield of 0.01-0.32% after hot water treatment, ultracentrifugation and 
chromatography using a mobile phase consisting of a mixture of acetonitrile-water (ratio 
80:20 to 88:12).3 This extremely low yielding effort is common for natural ergothioneine 
extracts. Hence, it is not economically viable to achieve a considerable scale of ergothioneine 
(Kg) production by isolating ergothioneine from natural sources.   
Commercial interest in ergothioneine has led chemists to embark on developing more 
efficient synthetic processes. Despite ergothioneine’s apparent simple structure, it’s 
synthesis is found to be very challenging. To date only few total chemical synthetic methods 
for L-(+)-ergothioneine have been published.4-6 Five major challenges can be considered when 
attempting the synthesis of L-(+)-ergothioneine (Figure 2.2): 
1. Orthogonal selective protection of the α-amino and carboxylic acid groups of histidine. 
2. Complete N-trimethylation of the N-α amino group. 
3. Regioselective thionation of the imidazole moiety. 




4. Preservation of the natural stereochemistry, avoiding or limiting any possible racemization 
throughout the process. 
5. Global deprotection.  
 
Figure 2.2. L-(+)-ergothioneine chemical structure highlighting chemical synthetic challenges. 
 
2.2. Ergothioneine chemical synthesis.  
 
2.2.1. Synthesis of L-ergothioneine using phenylchlorothionoformate (PCTF) as 
the sulfur source.4,7 
 
2.2.1.1. Synthesis of L-ergothioneine according to Yadan.  
 
In the latter part of the 20th century, French chemists Yadan et al. published a patent of L-
ergothioneine chemical synthesis starting from L-histidine, the natural precursor.4 This 
process involved multiple steps, starting by the protection of the carboxylic group followed 
by methylation of the N-α amino moiety.  
The key step was the thionation, via a Bamberger type imidazole cleavage. The sequential 
cleavage and reformation of imidazole ring 2.4 allow the introduction of a thiol functionality 












Figure 2.3. Bamberger-type cleavage: an AN-RORC process (addition of nucleophile, ring opening, ring 
closure).7 
 
The thiol group and the nitrogen at the C-3 position of the mercapto ring were protected as 
an ethyl carbamate. Quartenarization and deprotection yield L-ergothioneine 2.10 in an 
overall yield of 34%. (Scheme 2.1) 
 
Scheme 2.1. L-ergothioneine synthesis according to Yadan.4,7 Reagents and conditions. (a) MeOH, gaseous HCl; 
(b) 37% aqueous CH2O, H2, 10% Pd/C , rt; (c) (i). PCTF, NaHCO3, H2O/Et2O, (ii)  TEA, MeOH, rt (d) ClCO2Et, TEA, 









Despite the fact that this method was one of the earliest breakthroughs, it has many 
drawbacks. Beside numerous of steps, this approach uses toxic and hazardous 
phenylchlorothionoformate in the key step. Moreover, this method involved tedious 
chromatographic purifications. Hydrolysis under basic conditions (TEA) in the final step yields 
ergothioneine as a racemate (D,L- (±)). This process was difficult to reproduce in our 
laboratory.  
 
2.2.2. Synthesis of L-ergothioneine using potassium thiocyanate (KSCN) as the 
sulfur source.5 
 
2.2.2.1. Synthesis of L-ergothioneine according to Trampota.  
 
Fifteen years later (in 2010)  Trampota published a patent very similar to that of Yadan.5 This 
method successfully utilised the Bamberger cleavage reaction without any noticeable 
racemisation. The inorganic salt KSCN was used as the sulfur source and thionation was 
conducted prior to methylation, in contrast to the Yadan process. The mercaptohistidine 2.14 
was first S-protected by a readily removable t-butyl group.  
One of the critical steps was the methylation of the N-α amino group. The author utilised the 
mild reductive amination method using sodium triacetoxyborohydride as a reducing reagent. 




Quaternarization and deprotection afforded L-ergothioneine in an overall yield of 21%. 
(Scheme 2.2) 
 
Scheme 2.2. L-ergothioneine synthesis according to Trampota.5 Reagents and conditions. a) MeOH, gaseous 
HCl b) (i) H2O/THF, NaHCO3, BzCl (ii) Et2O/TEA c) MeOH, gaseous HCl d) concentrated  HCl, 90°C, 15hr e) H2O, 
KSCN, 90°C, 3hr f) (i) H2O, t-butanol, concentrated HCl, 90°C, 3hr (ii) Sodium Acetate, 2-propanol; g) THF, 37% 
aqueous CH2O, NaBH(OAc)3, 10°C h) MeOH, NH4OH, MeI, rt i) 40 mol equivalents concentrated HCl, 20 mol 
equivalents CH3CHSHCO2H, 110°C, 18hr. Overall yield  21%.5  




The author claimed to have developed a simple process as a limited amount of 
chromatographic purifications were performed, scalable, short and efficient to synthesize an 




Despite these improvements, the overall yield remains around 20 - 30 % similar to Yadan’s 
process probably due to multiple steps. Moreover, this process still uses a toxic sulfur source 
(KSCN) as well as a considerable amount of concentrated inorganic acid (e.g up to 40 mol 
equivalent of concentrated HCl in the last step) which drastically increases the waste stream. 
(Scheme 2.2) 
 
2.2.3. Biomimetic synthesis of L-ergothioneine using cysteine as the sulfur 
source.8 
 
In 2012, Erdelmeier et al. published a biomimetic synthesis of L-ergothioneine.6,8 The first two 
steps involved the N-quaternarization of histidine 2.4 to afford hercynine 2.18 in a good yield 
of 70-80% according to the published method by Reinhold et al.9 The key step was the 
synthesis of 2-cysteinylhercynine thioether intermediate 2.19 using cysteine, a natural and 
non-toxic sulfur donor in aqueous solvent. The last step was a pyrolytic C-S cleavage of the 
thioether 2.19 scavenged by 3-mercaptopropionic acid to yield L-ergothioneine 2.10. (Scheme 
2.3)  





Scheme 2.3. Biomimetic L-ergothioneine synthesis according to Erdelmeier et al.6,8 Reagents and conditions. 
a) 2 steps according to Reinhold et al. method,9 73% b) (i) HCl/Br2 (1.3 mol equivalents), (ii) cysteine (3-5 mol 
equivalents), H2O, 1 hr at 0°C, 58% optimum yield, c) 3-mercaptopropionic acid, 18 hr at 90-100°C, 80%, Overall 
yield 34%.  
 
2.2.3.1. Biomimetic synthesis of the key intermediate, 2-cysteinylhercynine thioether 
 
The biomimetic reaction was inspired by Ito who discovered the formation of an unusual 
thioether bond at the 2-position of imidazole ring after reacting bromine with histidine 2.4 to 
generate a bromo-activated histidine. This subsequently reacts with cysteine 2.20 to form 2-
S-cysteinyl histidine 2.21 in a very low yield of 19%. (Scheme 2.4)10  





Scheme 2.4. Synthesis of 2-S-cysteinyl histidine 2.21 according to Ito.10 
 
Histidine 2.4 is the biosynthetic precursor of hercynine 2.18,11 hence the same methodology 
as depicted in the Scheme 2.4 was optimized using hercynine 2.18 as a starting material. The 
large excess of cysteine (3-5 mol equivalents), bromination in an aqueous acidic medium (0.5 
M) in an ice bath 0-5 °C. These conditions were optimal to afford 2-cysteinylhercynine 
thioether 2.19 in a moderate yield of 46-58%.  
However, the excess cysteine can be removed by Dowex-H+ ionic exchange chromatography 
or by reacting the reaction mixture with benzaldehyde to yield the readily removable 
phenylthiazolidine-carboxylic acid.12 (Scheme 2.5) Alternatively the excess cysteine can be 
oxidised to cystine which is easy removed by filtration.13 





Scheme 2.5. Removal of the excess of cysteine.8 
 
Mechanistically, the reaction proceeds via a reactive bromolactone intermediate, produced 
by the reaction of bromine with hercynine, which is followed by cysteine introduction to 
afford the target sulfide compound, 2-cysteinylhercynine thioether 2.19. (Scheme 2.6) 
 
 
Scheme 2.6. Proposed mechanism of cysteine oxidative introduction. 8 
 




2.2.3.2. Pyrolytic cleavage of 2-cysteinylhercynine thioether yields L-ergothioneine  
 
The last step is the pyrolytic cleavage of thioether 2.19 in a presence of large excess of the 3-
mercaptopropionic acid scavenger. 3-Mercaptopropionic acid selectively reacts in situ with 
pyruvate 2.23 (by-product) to form the corresponding dithioketal 2.24, which is readily 
extracted alongside the unreacted 3-mercaptopropionic acid 2.22 in ethyl acetate. This 
facilitates the isolation of the desired product, L-ergothioneine 2.10 in 80% yield after 
crystallization without any chromatographic purification. (Scheme 2.7) 
 
Scheme 2.7. Pyrolytic cleavage of 2-cysteinylhercynine thioether 2.19 scavenged by 3- mercaptopropionic acid 
2.22. 
 
Although alternative C-S cleavage methods exist, such as heating at 100 °C for 18 h using a 
large excess of red phosphorus in hydroiodic acid medium, the latter was unacceptable due 
to the toxic waste that would be generated and tedious chromatographic purifications 
required.10  
Even though the mechanism of thermal cleavage of aryl-alkyl-sulfoxides are well known,14 the 
mechanism of pyrolysis of the thioether on the other hand remains unclear. Nevertheless, 




the reaction still progresses smoothly even under anaerobic conditions, thus suggesting that 
the reactive intermediate is not the sulfoxide (oxidation product of thioether).  
 
2.2.3.3. Drawbacks  
 
Despite the fact that this process has implemented many improvements, it is noteworthy to 
highlight some of the drawbacks such as the use of highly hazardous and toxic liquid bromine. 
Even though greener bromination methods are well documented,15 Erdelmeier et al. 
evaluated four alternative bromination methods which produced bromine in situ.8  
It is noteworthy that this process was hampered by huge amounts of inorganics salts (by 
product) which required ion exchange chromatography and reverse osmosis to allow isolation 
of the target product, L-ergothioneine.   
Finally, the reproducibility of this process was poor in our hands. This method required strict 
temperature control, stoichiometry of reactants and concentration of the reaction mixture, 
that provided much lower yields than the 46-58% reported.8  
 
In order to obtain a scalable, reproducible and high yielding ergothioneine chemical synthesis 
many drawbacks from previously reported process have to be addressed. The ideal process 
must also be shorter (fewer steps), allow simple purification, greener (using less or not toxic 
reagent or solvent) and more importantly affords an optically pure product for human 
consumption. 
 




2.3. Improved synthesis of L-ergothioneine  
 
During the course of this research, the strive toward developing a novel ergothioneine 
synthesis was attempted by addressing some of the drawbacks of past processes. 
 
2.3.1. Retrosynthetic analysis 
 
The retrosynthesis leads to a simple commercially available protected histidine 2.26, that 
affords hercynine derivative 2.15 through Nα-methylation as well as thionation using 
different approaches depending on the nature of the sulfur sources utilised. (Figure 2.4) 
According to this strategy, thionation requires the imidazole ring to be activated via 
bromination. 
 





Figure 2.4. Retrosynthesis strategy of L-ergothioneine 2.10. 
 
To date only few sulfur sources have been explored such as KSCN, PCTF 
(phenylchlorothionoformate), Na2S, as well as cysteine. The ideal sulfur source must be easy 
to introduce and any unwanted moiety (protecting group) must be facile to remove. 
 
2.3.2. Alternative sulfur sources to cysteine  
 
Even though cysteine was successfully introduced, many efforts were conducted to find an 
alternative sulfur source, that is simple to introduce and which allow for easy subsequent 
removal of the unwanted protecting group.  




Ito used Na2S as sulfur to synthesize 2-thiohistidine in 12%, while Erdelmeier et al. claimed 
they detected only traces of L-ergothioneine (2-4%) when they reacted Na2S as sulfur source 
on a bromine-activated hercynine (5 mmol-scale).8,10 For industrial production, Na2S is 
transformed to H2S (direct sulfur source) in acidic medium. H2S is toxic and hazardous gas thus 
the use of both Na2S and H2S reagents were found to be unattractive. Therefore, alternative 
sulfur sources were investigated.  
 
2.3.2.1. (2-nitrophenyl)methanethiol  
 
(2-Nitrophenyl)methanethiol 2.39 was the first alternative sulfur source investigated as the 
removal of the unwanted 2-nitrobenzyl moiety is facile and well documented.16 Using UV 
lamp irradiation, an inexpensive photo-technology would efficiently remove the 2-nitrobenzyl 
unwanted moiety.  
(2-Nitrophenyl)methanethiol 2.39 was synthesized in two consecutive steps in a good overall 
yield of 73% without the need of any chromatographic purification according to the 
literature.17 In a SN2 reaction 2-nitrobenzyl bromide 2.37 was transformed quantitatively into 
S-(2-nitrobenzyl) ethanethioate 2.38, followed by S-deacetylation to yield the target product, 
(2-nitrophenyl)methanethiol 2.39. (Scheme 2.8) 





Scheme 2.8. Synthesis of (2-nitrophenyl)methanethiol 2.39. Reagents and conditions. (i) KSAc (potassium 
thioacetate) (5.3 mol equivalents), THF, overnight at rt, quantitative; (ii) MeOH/HCl, overnight at 60 °C, 73%.17 
 
A key diagnostic in the 1H NMR spectrum of S-(2-nitrobenzyl) ethanethioate 2.38 was the 
slightly deshielded proton signal resonated as a singlet at δH 2.31 ppm integrating for 3 
protons thus confirming the presence of acetate group. While the 1H NMR spectrum of 2.39 
showed disappearance of acetate group present in 2.38 at δH 2.31 ppm and the appearance 
of a characteristic SH proton resonating as a triplet at δH 2.13 ppm (J = 8.4 Hz) suggesting a 
coupling with the methylene proton resonating as a doublet at δH 4.02 ppm (J = 8.4 Hz) 
(expended in the spectrum) in its neighbourhood. This confirmed the successful synthesis of 












Figure 2.5.  1H NMR spectrum of 2.38 vs 2.39 showing successful deacetylation. 
 
Having (2-nitrophenyl)methanethiol 2.39 in our possession, it was utilised as a sulfur source. 
N-benzyl hercynine 2.30 was brominated by NBS followed by thiol addition using 1.5 mol 
equivalents of (2-nitrophenyl)methanethiol 2.39. (Scheme 2.9) 
 
 





Scheme 2.9. Attempted synthesis of L-ergothioniene 2.10 using (2-nitrophenyl)methanethiol 2.39 as a sulfur 
source. 
 
This reaction did not afford the desired product 2.40, instead, the disulfide, 1,2-bis(2-
nitrobenzyl)disulfane 2.41 was isolated in high yield of 81%. The evidence of this disulfide 
2.41 was provided by the 1H NMR spectrum which revealed the disappearance of the 
characteristic SH protons resonated at δH 2.13 ppm in proton NMR of 2.39. (Figure 2.6) 





Figure 2.6. 1H NMR spectrum confirming the oxidation of (2-nitrophenyl)methanethiol 2.39 to the disulfide 
2.41. 
 
Furthermore, EI+ mass spectrum of 2.41 showed the molecular ion at m/z 336.0 [M]+ 
calculated for C14H12N2O4S2 336.0, hence confirming the structure of the disulfide 2.41.  
These results suggested that (2-nitrophenyl)methanethiol 2.39 was easily oxidized to its 
disulfide form 2.41 under the reaction conditions (side reaction). That high isolated yield of 
81% of disulfide recovery does not mean that the adduct 2.40 was not formed; it might have 
been produced at very low (< 5%) could not have been detected. It is noteworthy that this 
thiol (2-nitrophenyl)methanethiol 2.40 appeared to be malodorous with a very bad smell 
even at lower concentration, this does not make it a favoured sulfur source especially for 
SH 




industrial scale. Therefore the investigation of (2-nitrophenyl)methanethiol 2.39 as a sulfur 
source for the synthesis of L-ergothioneine 2.10 was not pursued any further. 
 
2.3.2.2. Thioacetic acid  
 
Thioacetic acid 2.42 was also investigated as sulfur donor due to its facile deacetylation under 
basic conditions. We suggested to use an excess of thoacetic acid to compensate for potential 
side reactions hence 4 mol equivalents were utilized. One possible side reaction is the 
hydrolyse of thioacetic acid to acetic acid that could possibly occurred under the reaction 
conditions, therefore more than one mol equivalents are required to accomplish the 
sulfurization reaction.  
N-benzyl hercynine 2.30 was brominated using NBS (2.0-2.5 mol equivalents) in DMF solvent, 
subsequently followed by the sulfurization using 4 mol equivalents of thioacetic acid 2.42. 
Several attempts to isolate the pure (S)-3-(2-(acetylthio)-1H-imidazol-4-yl)-2-
(trimethylammonio)propanoate 2.43 were unsuccessful due to its degradation, thus 
suggesting that this intermediate was unstable upon purification. Therefore, the crude 
residue 2.43 obtained after removal of solvent to dryness was immediately deacetylated 
under basic conditions (NaOMe) in methanol without any prior purification. Reverse phase 
chromatography afforded the target compound L-ergothioneine 2.10 which was 
contaminated by traces of desulfurized and acetylated products (Scheme 2.10).  





Scheme 2.10. L-ergothioneine 2.10 synthesis using thioacetic acid 2.42 as a sulfur donor. 
 
The proton NMR analysis of the aromatic region (9.1-6.4 ppm) was consistent with the 
successful synthesis of the target compound, L-ergothioneine 2.10 as the major product of 
the reaction. (Scheme 2.10)  
A key diagnostic signal was the disappearance of the imidazole proton H-2' which resonated 
as a singlet around δH 8.2 ppm in the 1H NMR spectrum of (S)-3-(1-benzyl-1H-imidazol-4-yl)-
2-(trimethylammonio)propanoate 2.30, thus clearly confirmed the regioselective thionation 
at the 2-position of the imidazole ring. (Figure 2.7) 





Figure 2.7.  1H NMR spectrum in D2O at 300 MHz (aromatic region from 9.1 to 6.4 ppm) comparison between 
2.30 & 2.10 obtained after sulfurization using thioacetic acid as the sulfur source. 
 
The reaction yield was calculated by integration of the aromatic region between 9.4 and 6.5 
ppm assuming that the desired product formed are characterized by one aromatic H-5' 
proton. The desired product, L-ergothioneine 2.10 was obtained in a crude estimate yield of 
64% based on 1H NMR after two steps. Close 1H NMR spectrum inspection revealed the 
presence of impurities as by-products of the reaction, including the desulfurized product, 
hercynine (14%) as depicted in the Figure 2.8.  
The presence of the desulfurized product, hercynine was further confirmed by LCMS analysis 
which displayed the molecular ion at m/z 199.1239 as [M+2H]+ (positive mode) calculated 
C9H17N3O2+ (199.1315) at the retention time of 9.62 min. (Figure 2.9) 





Figure 2.8. Reaction yield based upon 1H NMR integration of the isolated L-ergothioneine 2.10 (aromatic 
region from 9.4 to 6.5 ppm) from the reaction using thioacetic acid as a sulfur source.  
 
Figure 2.9. HRMS spectrum of the desulfurized product, hercynine. Retention time of 9.62 min. (Positive 


















It is suggested that the L-ergothioneine 2.10 major product of the reaction could get oxidized 
under these strong oxidative and alkaline conditions (NBS/DMF, NaOMe) to form an highly 
unstable sulfinic acid derivative which degraded during the isolation process to form 
hercynine after elimination of sulfur dioxide. (Figure 2.10)18,19 That could explain the presence 
of hercynine revealed in the 1H NMR spectrum and confirmed by LCMS studies. (Figure 2.8 & 
Figure 2.9) 
 














Furthermore, the EI+ mass spectrum (direct injection) analysis revealed the molecular ion of 
L-ergothioneine sodium adduct at m/z 253.7 calculated for C9H16N3NaO2S+ (253.1) and the 
characteristic fragment at m/z 127.8 calculated for C5H7N2S+ 127.0 corresponding to a loss of 
N(CH3)3 and carbonyl groups, a similar fragmentation pattern with the one reported by Wang 














Figure 2.11. EI+ mass spectrum of purified L-ergothioneine 2.10.  
 




 2.3.3. Improved synthesis of L-ergothioneine using cysteine as the sulfur 
source. 
 
Early research conducted by Erdelmeier et al. have demonstrated the instability of hercynine 
upon bromination.6,8 It was suggested that liquid bromine was consumed rapidly by 
hercynine, leading to the formation of a bromolactone hercynine intermediate (very 
unstable) which reacts with cysteine to form the desired sulfide.  
Therefore, if the reaction mixture is not maintained at a low temperature (below 2 °C), it will 
lead to multiple decomposition products. Controlling the temperature and time of this 
reaction appeared to be very crucial. However, to date, attempts to isolate this bromolactone 
intermediate has been unsuccessful.  
Ito has already proven the existence of bromolactone intermediate as the reaction only 
proceeded with the histidine derivative having a free carboxylate moiety. In other words, 
histidine esters did not provide the lactone intermediate, hence no sulfurization reaction had 
occurred.10  
The first challenge was to select a starting material which will give rise to a more stable 
bromolactone derivative. The N-benzyl protected histidine seemed more attractive as a 
starting material. The benzyl group would also impart greater lipophilicity useful for C18 or 
silica purification. The presence of benzyl group attached to the imidazole group possibly 
exert a mesomeric effect which stabilises the heterocyclic ring.  
 




2.3.3.1. Synthesis and characterisation of (S)-3-(1-benzyl-1H-imidazol-4-yl)-2-
(trimethylammonio) propanoate (N-benzyl hercynine) 
 
Nꞇ-benzyl hercynine 2.30 was synthesized in three consecutive steps starting from the 
commercially available Nꞇ-benzyl-Nα-(tert-butoxycarbonyl)-L-histidine 2.27. Standard acid 
deprotection yielded Nꞇ-benzyl-L-histidine 2.28 in an excellent yield of 90%. Direct reductive 
amination of Nꞇ-benzyl-L-histidine using formaldehyde and sodium triacetoxyborohydride 
afforded the dimethyl product, Nꞇ-benzyl-Nα,Nα-dimethyl-L-histidine 2.29 quantitatively. The 
last step entailed the quartenarization using iodomethane as an alkylating reagent to yield 
the protected hercynine, (S)-3-(1-benzyl-1H-imidazol-4-yl)-2-(trimethylammonio) 
propanoate 2.30 in an excellent yield of 93% (Scheme 2.11).  
 
Scheme 2.11. Synthesis of (S)-3-(1-benzyl-1H-imidazol-4-yl)-2-(trimethylammonio) propanoate (Nꞇ-benzyl 
hercynine 2.30).   
 




The 1H NMR spectrum of N-benzyl histidine 2.28 revealed the disappearance of Boc resonance 
around 1.5 ppm confirming the successful Boc removal. The successful synthesis of Nꞇ-benzyl-
Nα,Nα-dimethyl-L-histidine 2.29 was confirmed by the 1H NMR spectrum which displayed a 
characteristic deshielded singlet resonating at δH 2.69 ppm integrating for six protons 
confirming the successful introduction of two equivalent methyl groups. (Figure 2.12) 
 
Figure 2.12.  1H NMR spectrum of Nꞇ-benzyl-Nα,Nα-dimethyl-L-histidine 2.29 in D2O at 300 MHz.  
 
The 13C NMR spectrum of Nꞇ-benzyl-Nα,Nα-dimethyl-L-histidine 2.29 displayed a carbonyl 
signal at δC 168.7 ppm, seven aromatic carbon signals resonated at δC 135.2, 135.1, 133.6, 
129.4, 128.5, 127.6, 121.0 ppm, and four aliphatic carbon resonances at δC 66.0, 65.9, 52.9, 




21.9 ppm, thus confirming the carbon skeleton identity of Nꞇ-benzyl-Nα,Nα-dimethyl-L-
histidine 2.29.  
Furthermore, the EI+ mass spectrum displayed the molecular ion [M]+ at m/z 273.1 calculated 
for C15H19N3O2 (273.1) as well as the molecular ion of a fragment corresponding to a loss of 
carbonyl group [M-CO2]+ at 229.1 calculated C14H19N3 (229.2) [M-CO2]+ thus confirming the 
assigned structure of Nꞇ-benzyl-Nα,Nα-dimethyl-L-histidine 2.29.  
The last step entailed the quaternarization of Nꞇ-benzyl-Nα,Nα-dimethyl-L-histidine 2.29. It is 
noteworthy, that the quaternarization reaction is usually a very difficult step as it often 
required the longest reaction time, suffered from low yield as the reaction barely reach 
completion and gave rise to certain degree of racemization.21 In our case the racemization 
was not investigated but it was feared that prolonged treatment under basic conditions may 
lead to racemization.  
The reaction was conducted in a dry tetrahydrofuran with iodomethane as an alkylating 
reagent for 1-2 days at room temperature, crystallization in absolute ethanol afforded (S)-3-
(1-benzyl-1H-imidazol-4-yl)-2-(trimethylammonio) propanoate 2.30 as a yellow solid isolated 
in the iodide salt in a very high yield of 93%.  
The 1H NMR spectrum of (S)-3-(1-benzyl-1H-imidazol-4-yl)-2-(trimethylammonio) propanoate 
2.30 revealed the disappearance of singlet resonance at δH 2.69 ppm belonging to dimethyl 
group and the appearance of a characteristic deshielded singlet at δH 3.33 ppm integrating for 
9 protons which was attributed to N,N,N-trimethyl (betaine) group, thus confirming the 
successful quaternarization.  




The 13C NMR spectrum, corroborated by a mass spectrum confirmed the structure of the 
target compound, (S)-3-(1-benzyl-1H-imidazol-4-yl)-2-(trimethylammonio) propanoate 2.30. 
The ESI+ mass spectrum revealed the molecular ion [MH]+ at m/z 288.2 calculated for 
C16H22N3O2+ (288.2) [MH]+, two characteristic fragments at m/z 244.2 calculated for C15H22N3+ 
(244.2) [M-CO2 ]+ corresponding to a loss of carbonyl and at m/z 199.2 calculated for C12H13N3 
(199.1) [M-CO2–CH3)3]+ corresponding to a loss of carbonyl and trimethyl group, hence 
supporting the structure of (S)-3-(1-benzyl-1H-imidazol-4-yl)-2-(trimethylammonio) 
propanoate 2.30. 
 
2.3.3.2. Synthesis and characterisation of (S)-3-(2-(((R)-2-amino-2-carboxyethyl)thio)-1H-
imidazol-4-yl)-2-(trimethylammonio) propanoate (2-cysteinylhercynine thioether)  
 
Having successfully synthesized N-benzyl hercynine 2.30, the next challenge was to attempt 
the synthesis of 2-cysteinylhercynine thioether 2.19. The synthesis of (S)-3-(2-(((R)-2-amino-
2-carboxyethyl)thio)-1H-imidazol-4-yl)-2-(trimethylammonio) propanoate 2.19 was 
conducted in 2 consecutive steps. First N-benzyl hercynine 2.30 was brominated with 2.5 mol 
equivalents of N-bromosuccinimide (NBS) in DMF in the dark. Subsequent thionation using 
excess of L-cysteine (2-2.5 mol equivalents) as a sulfur donor afforded the 2-
cysteinylhercynine thioether acetate salt 2.19 in a good yield of 76% after C18 reverse phase 
chromatography. (Scheme 2.12) 





Scheme 2.12. NBS/DMF mediated synthesis of 2-cysteinylhercynine thioether 2.19. 
 
2.3.3.2.1. Selective and mild bromination of the imidazole ring  
 
Previously bromination utilised liquid bromine,8 therefore developing milder bromination 
conditions were of interest especially on industrial scale.  
NBS was the preferred milder bromine source as it easy to handle than dense fuming liquid 
bromine.  It is noteworthy that NBS was already successfully used as a brominating reagent 
by Jain et al. to synthesize ring-bromohistidines and histamines.22 (Figure 2.13) 
 
Figure 2.13. Structures of ring-bromohistidine/histamine. 
 




These authors demonstrated that using one mol equivalent of NBS in the absence of light 
afforded readily separable mixtures of 2,5-dibromohistidines/histamines derivatives (10-
25%) and 5-bromohistidines derivatives (70-75%), while 2 mol equivalents afforded 2,5-
dibromohistidines/histamines in a rather higher yield (65-75%). Electrophilic halogenation 
performed on N-Boc protected histidine/histamine methyl ester as a starting material led to 
better yield, whereas the unprotected histidine/histamine resulted to over consumption of 
NBS. Incomplete reactions thus gave rise to a multitude of inseparable products.22   
The early reports by Jain et al. encouraged the use of NBS to halogenate the imidazole ring of 
Nꞇ-benzyl hercynine 2.30 prior to cysteine 2.20 introduction.22 Firstly, only one mol equivalent 
of NBS in acetonitrile gave multiple products on TLC suggesting incomplete reaction and 
probably multiply brominated and/or decomposition products.  
Schmir et al. have shown that the reaction of bromine or NBS with imidazole in aqueous 
media might also lead to oxidative degradation of the heterocycle ring, thus causing the 
imidazole ring to decompose into ammonia, glyoxal and formamide. However the authors did 
not provide any evidence of the labile lactone intermediate.23  
Secondly, using 2 to 2.5 mol equivalents of NBS in dry DMF as a solvent gave a much cleaner 
reaction on TLC, hence these conditions were found to be optimal. Regina et al. previously 
utilised NBS-DMF to selectively monobrominate electron rich aromatic compounds.24  
Isolation of the brominated intermediates were attempted to shed light on the reaction 
mechanism. Delightfully, two N-debenzylated bromohistidines were found, stable enough to 
be isolated by reverse phase C18 column chromatography. The monobrominated 




intermediate, 5-bromohercynine 2.31 was isolated in very high yield (90%), while 2,5 
dibromohercynine intermediate 2.32 was isolated in a low yield of 10%. Bearing in mind that 
bromination of histidine derivatives having a free carboxylic acid results in the formation of 
the labile bromolactone derivative, it is believed that brominated products (2.32 and 2.33) 
isolated from this reaction could be derived from their related bromolactones. (Scheme 2.13) 
 
Scheme 2.13. Selective and mild bromination of the imidazole ring.25,26 
 
A key diagnostic resonance in the proton NMR spectrum of 2.31 was the presence of one 
aromatic proton resonating at δH 7.4 ppm assigned for the H-2' in the imidazole ring, thus 
supporting the structure of mono 5-brominated product 2.31. There was no proton signal in 
the aromatic region of the proton NMR spectrum of 2.32, hence supporting the presence of 
the 2,5-dibrominated product 2.32.  
Moreover, NBS-mediated N-debenzylation is not novel as it was extensively studied in N-
benzylamide substrates by Wang et al., where the authors proposed a plausible mechanism.27 
Baker et al. on the other hand proposed a free radical mechanism. However, NBS-mediated 
N-debenzylation of N-benzyl imidazole is not well known.28  
 
 




2.3.3.2.2. Mechanism of NBS-mediated synthesis of 2-cysteinylhercynine thioether.  
 
Based on the reaction outcome, it can be envisaged that the 2-cysteinylhercynine thioether 
2.19 formation proceeds via a stepwise mechanism. Hence, bromination followed by 
lactonisation and subsequent debenzylation and finally cysteine introduction gave the target 
product as depicted in the Figure 2.14.  
 
 
Figure 2.14.  Proposed mechanism of the formation of 2-cysteinylhercynine thioether 2.19 NBS-mediated 
using N-benzyl hercynine 2.30 as substrate.  
 
Mechanistically, it is suggested that the first mol equivalent of NBS produces the brominium 
cation which results in a SNAr to form the bromolactone hercynine N-benzyl derivative 2.33. 
The second mol equivalent reacts with the lactone intermediate 2.33 to form the 




debenzylated bromolactone hercynine 2.35 and benzaldehyde as a by-product. This putative 
mechanism suggested the need for an excess of NBS (2.0-2.5 mol equivalents) to 
subsequently brominate and debenzylate the substrate. The last step is the cysteine 
introduction through sulfurization to afford the desired product, 2-cysteinylhercynine 
thioether 2.19 after rearomatisation. (Figure 2.14) 
The evidence of the bromolactone being the reactive intermediate was provided by Ito in his 
earlier research.10 However, 5-bromohercynine and 2,5-dibromohercynine were the only 
isolated intermediates prior to the oxidative cysteine introduction. It is likely that these 
isolated intermediates are derived from their related bromolactones, which are highly 
unstable intermediates that may have been decomposed during the isolation process. (Figure 
2.14) 
 
2.3.3.2.3. Cysteine oxidative introduction and characterization of the 2-cysteinylhercynine 
thioether  
 
Thionation was accomplished by oxidative addition of excess (2-2.5 mol equivalents) of 
cysteine to yield 2-cysteinylhercynine thioether 2.19 in a yield of 76%. It is noteworthy that 
this yield is better than any previously reported synthesis while using a relatively moderate 
amount of cysteine (2-2.5 mol equivalents). Erdelmeier et al achieved 46-58% yield using 3-5 
mol equivalents of cysteine.8  
The 1H NMR spectrum of 2-cysteinylhercynine thioether 2.19 revealed one aromatic 
resonance at δH 7.41 ppm assigned to be proton at H-5' of the imidazole, thus confirming a 
successful thionation at 2-position of the imidazole ring. Two deshielded protons resonated 




at δH 4.54 ppm (doublet of doublets, J = 7.7, 4.4 Hz) and 4.42 ppm (triplet, J = 5.0 Hz) 
respectively, characteristic of α-amino protons confirming the presence of the two amino acid 






































































Figure 2.15.  1H NMR spectrum of 2-cysteinylhercynine 2.19 in D2O at 400 MHz. 
 
The 13C NMR spectrum 2-cysteinylhercynine thioether 2.19 displayed ten carbon signals 
resonating at δC 170.3, 170.0, 129.4, 128.9, 120.9, 61.0, 54.4, 51.7 (for N,N,N-trimethyl 
group), 36.3 and 23.9 ppm; thus confirming the carbon skeleton identity of 2-
cysteinylhercynine thioether 2.19. 
Furthermore, high-resolution mass spectrum (ESI+) displayed the molecular ion at m/z 
317.1277 [M]+ calculated for C12H21N4O4S+ 317.1284 [M]+ supporting the structure of 2-
cysteinylhercynine thioether 2.19 as shown in the Figure 2.16. 




   
Figure 2.16.  ESI/QTOF mass spectra of 2-cysteinylhercynine thioether 2.19 in positive ion mode 
 
2.3.3.3. C-S bond cleavage of 2-cysteinylhercynine thioether affords L-ergothioneine  
 
After successfully synthesizing 2-cysteinylhercynine thioether 2.19, the last challenge was to 
cleave C-S bond to yield the target compound, L-ergothioneine 2.10.  
Thermal cleavage of 2-cysteinylhercynine thioether scavenged by an excess of 3-
mercaptopropionic acid (10 mol equivalents) was utilised by Erdelmeier et al to yield L-
ergothioneine in good yield of 80%.6 Therefore in the course of this research, we investigated 
alternative cleavage methods that are milder.  
In an earlier publication, it was demonstrated that hercynylcysteine sulfoxide can be cleaved 
by either a β-lyase from Erwinia tasmaniensia (PLP-enzyme) or PLP itself to produce L-
ergothioneine.11 Most C-S lyase enzymes in the literature utilise thioether as substrates, but 
only fewer catalyse sulfoxides C-S bond lysis.18 Thus inspired the investigation of the 
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2.3.3.3.1. Enzymatic C-S bond cleavage of 2-cysteinylhercynine thioether: Biomimetic 
synthesis of L-ergothioneine 
 
Due to lack of pure EgtE enzyme, 50 mM of 2-cysteinylhercynine thioether 2.19 was incubated 
at 37°C with M. smegmatis cell-free lysate enzymatic preparation for 24 hr. LCMS analysis 
indicated conversion of 2-cysteinylhercynine thioether 2.19 to L-ergothioneine 2.10, about 
19.2 (±0.2) ng/mL of L-ergothioneine was detected.   
 
2.3.3.3.2. Enzyme-free, PLP mediated C-S lyase of 2-cysteinylhercynine thioether 
 
The same assay was performed using 50 mM of PLP alone, and 50 mM of 2-cysteinylhercynine 
thioether 2.19 was cleaved to L-ergothioneine 2.10, about 96 ±2 ng/mL was detected by 
LCMS. (Figure 2.17) 
 
Figure 2.17.  Non-enzymatic production of ESH catalysed by PLP. TIC extracted for ESH and PLP using 2-
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2.3.3.3.3. Enzyme-free, PLP mediated C-S lyase of 2-cysteinylhercynine thioether: NMR 
experiment and attempted ergothioneine isolation 
 
LCMS technique showed successful C-S lyase of 2-cysteinylhercynine thioether 2.19 as L-
ergothioneine was detected and quantified at retention time of 15 min. Therefore, the 
enzyme-free PLP experiment were conducted on mg scale. 2-Cysteinylhercynine thioether 
2.19 was cleaved by pyridoxal-5-phosphate at 37-40 °C. Dowex-H+ ion exchange and C18 
reverse phase column chromatography were utilised to isolate L-ergothioneine 2.10 in a good 
yield of 76%. (Scheme 2.14) 
 
Scheme 2.14. Enzymatic-free cleavage of C-S bond in 2-cysteinylhercynine thioether 2.19 catalysed by PLP. 
 
Key diagnostics in the 1H NMR spectrum of the isolated L-ergothioneine 2.10 was the 
characteristic aromatic proton resonating at δH 6.85 ppm shifted from δH 7.41 ppm in 2-
cysteinylhercynine thioether in 2.19 as well as the disappearance of one α-amino proton 
belonging to the cysteine moiety, which resonated as a doublet of doublets (J = 7.7, 4.4 Hz) 
at δH 4.54 ppm in 2-cysteinylhercynine thioether 2.19 thus confirming the successful C-S 
cleavage of 2-cysteinylhercynine thioether 2.31. (Figure 2.18) 





Figure 2.18. Portion of 1H NMR spectrum in D20 at 300 MHz (7.9-6.0 ppm) of PLP, 2-cysteinylhercynine 
thioether 2.19 and ESH 2.10.    
 
This result was encouraging, however for industrial scale preparations it would be better to 
design a process that allows an easy purification method. Supporting PLP (cheap and 
recyclable) on a solid support would be a viable option for large scale synthesis of ESH 
compared to the expensive enzymatic process. PLP solid supported would afford the desired 
product of the reaction, L-ESH 2.10 in greater yield by simple filtration and easier purification 










2.3.3.4. Summary of the improved synthesis of L-ergothioneine using cysteine as the sulfur 
source. 
 
L-ergothioneine 2.10 was successfully synthesized in fewer steps, two steps starting from NꞆ-
benzyl hercynine 2.30 or four steps starting from N-benzyl histidine 2.28 as starting material. 
(Scheme 2.15) 
 
Scheme 2.15. Improved biomimetic L-ergothioneine synthesis. Reagents and conditions. a) (i) CHO, 
NaBH(OAc)3, acetonitrile, 24 hr at rt, quantitative, (ii) CH3I, dry THF, 1-2 days dark at rt, 93%; (b) (i) NBS (2.5 mol 
equivalents)/DMF, (ii) cysteine, rt, 76%; c) PLP, 37-40°C, 76%; d) M.smegmatis. cell free lysate extract. Overall 
yield of sequential steps a, b and c is 54%. Overall yield of sequential steps a, b and d is at least 70% 
 




Many improvements were implemented to efficiently introduce cysteine in a one pot 
synthesis, N-benzyl hercynine 2.30 was first brominated and subsequently coupled with 
cysteine to afford 2-cysteinylhercynine thioether 2.19 in a very good yield of 76%.  
The last step was achieved by a C-S lyase of 2-cysteinylhercynine thioether 2.19 which could 
be performed either quantitatively by M. smegmatis cell-free lysate enzymatic preparation 
or by PLP to yield L-ergothioneine 2.10 in a good yield of 76%.  
This method allows the synthesis of L-ergothioneine 2.10 in fewer steps. This process is 
relatively simplified, shortened, all reactions were performed at ambient temperatures of 25-
40 °C (energy saving) and in good overall yield of 54-70%. Thus, a greater overall yield has 
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EgtE, a PLP-dependent enzyme catalyzes the C-S cleavage of 2-cysteinylhercynine sulfoxide to 
yield L-ergothioneine, ammonia and pyruvate. The chemistry and the biotransformation of 
the substrates involved in this step will be discussed in depth. 
 
In order to study this last step, the synthesis of the 2-cysteinylhercynine sulfoxide (natural 
EgtE substrate) was required. Consequently, the sulfide precursor, 2-cysteinylhercynine 
thioether and the over oxidized sulfone, 2-cysteinylhercynine sulfone would also be obtained. 
The stable isotopically labelled hercynine-d3 and ergothioneine-d3 would be accessed to shed 
light on the mechanism of C-S lyase by the EgtE enzyme as well as enzyme-substrate 
specificity.   
 
3.1. Synthesis of hercynine and its stable isotope labelled versions, 
hercynine-d3 as well as ESH-d3  
 
Genghof et al. have demonstrated that in mycobacteria, endogenous hercynine is in fact the 
biosynthetic precursor of ergothioneine.1 Early ergothioneine biosynthetic pathway 
elucidation studies in various organisms (such as bacteria and fungi) utilized radiolabeled 
intermediates.2 Due to the huge safety risk associated with the use of radiological techniques 




and the non-availability of these techniques in our laboratory, it was decided to utilize stable 
isotopic, deuterated intermediates instead. It is noteworthy that these labelled intermediates 
are valuable internal standards for the quantitation of pathway metabolites during external 
stimuli, drug treatment or metabolomics studies. 
 
3.1.1. Synthesis of hercynine and hercynine-d3 
 
Hercynine 3.3 and hercynine-d3 3.4 were synthesized following multiple strategies, starting 
with L-histidine 3.1, dimethylation via reductive amination was followed by quaternarization 
to yield the target compounds. (Scheme 3.1) 
 
Scheme 3.1.  Two steps synthesis strategy of hercynine 3.3 and hercynine-d3 3.4. Reagents and conditions. 
Dimethylation: First approach: 37% solution CH2O, NaBH4, H2O, ice water bath (0-5 °C), 3 hrs, quantitatively; 
Second approach: 37% solution of CH2O, NaBH(OAc)3 /CH3CN, 18-24 hrs at rt; Quaternarization: NH4OH, MeOH, 
24 hr at rt, using CD3I (61%) or using CH3I 3.3, (42%); Direct route: Dimethyl sulphate, NaOH (10%), 0°C to rt.  
 




3.1.1.1. One-pot synthesis of hercynine using dimethyl sulphate mediated N-alkylation. 
 
Hercynine 3.3 can be synthesized in one pot by reacting histidine 3.1 under aqueous basic 
conditions (NaOH 10%) with dimethyl sulphate as an alkylating reagent. This one pot N-α 
trimethylation method was previously reported by Fattori et al.3 (Scheme 3.2)  
 
Scheme 3.2. One-pot synthesis of hercynine 3.3.  
 
Hercynine 3.3 synthesized according to this method required C18 reverse phase 
chromatography to remove sulphate salts (by-products). Hercynine was synthesized in a 
crude yield of 92%. However, the NMR analysis of hercynine synthesized accordingly revealed 
small contamination with N-monomethyl-histidine and N,N-dimethyl histidine intermediate 
products, which can be removed with difficulty by ionic exchange chromatography. 
Therefore, alternative approach for the synthesis of hercynine was considered.  
 
3.1.1.2. Dimethylation using in situ reduction.  
 
Histidine 3.1 was dimethylated using 37% formaldehyde in H2O in the presence of an excess 
of NaBH4 (2-3 mol equivalents) under cooling in an ice water bath to yield Nα,Nα-dimethyl-L-
histidine 3.2 quantitatively. (Scheme 3.3) 





Scheme 3.3. Synthesis of hercynine 3.3 and hercynine-d3 3.4 via improved synthesis of Nα,Nα-dimethyl 
histidine 3.2. 
 
An exothermic reaction between NaBH4 and water produced hydrogen gas in situ and 
NaBO3.n H2O salts as side products. This highly exothermic reaction is controlled by cooling 
the reaction vessel in an ice bath at 0-5 °C to slow down the side reaction. The imine 
intermediate resulting from the reaction between histidine 3.1 and formaldehyde is reduced 
by NaBH4 to form Nα,Nα-dimethyl-L-histidine 3.2 quantitatively, after C18 reverse phase flash 
chromatography to remove NaBO3.n H2O salts. 
 
The 1H NMR spectrum of Nα,Nα-dimethyl-L-histidine 3.2 revealed two aromatic signals 
resonating both as a singlet at δH 7.70 and 6.95 ppm confirming the presence of the imidazole 
ring. A key feature was a slightly deshielded proton signal resonating as a singlet at δH 2.51 
ppm, integrating for 6 protons. This confirmed the successful introduction of two equivalents 
of N-methyl groups to the amine. (Figure 3.1.) 
 





Figure 3.1. 1H NMR of Nα,Nα-dimethyl-L-histidine 3.2 at 300 MHz. 
 
The 13C NMR spectrum of Nα,Nα-dimethyl-L-histidine 3.2 revealed seven carbon signals 
resonating at δC 176.6, 135.8, 133.4, 117.4, 70.9, 41.4 and 27.1 ppm respectively, hence 
confirming the identity of Nα,Nα-dimethyl histidine 3.2. (Figure 3.2) 





Figure 3.2. 13C NMR of Nα,Nα-dimethyl-L-histidine 3.2 at 101 MHz. 
 
Furthermore, the EI+ mass spectrum displayed a molecular ion at m/z 184.0 [MH]+ calculated 
for C8H14N3O2 (184.1) [MH]+ and a fragment corresponding to a loss of carbonyl at m/z 139.0 
calculated for C7H12N3 (139.0) [M-CO2]+, thus supporting the structure of Nα,Nα-dimethyl-L-
histidine 3.2. 
 
3.1.1.3. Dimethylation using sodium triacetoxyborohydride.  
 
L-histidine 3.1 was dimethylated via reductive amination by reacting 37% formaldehyde 
solution with sodium triacetoxyborohydride used as a reducing reagent with acetonitrile as 
solvent in the presence of a catalytic amount of glacial acetic acid.  
Nα,Nα-dimethyl-L-histidine 3.2 synthesized as described above was found to be very difficult 
to purify. Hence, the crude product 3.2 was obtained after filtration through celite (to remove 
inorganic salts) and drying under high vacuum. Quaternarization was conducted using 




iodomethane to afford hercynine 3.3 in a yield of 42% after two steps. Alternatively, 
iodomethane d3 afforded the hercynine-d3 3.4 product in a moderate yield of 61% (in two 
steps) after C18 reverse phase chromatography and crystallization. The difference in yield 
between hercynine 3.3 and hercynine-d3 3.4 could be attributed to the quality of the starting 
material, as CD3I was better quality than CH3I which decomposed faster over time. (Scheme 
3.4) 
 
Scheme 3.4. Synthesis of hercynine 3.3 or hercynine-d3 3.4. Reagents and conditions. (i) a) 37% solution of 
CH2O, NaBH(OAc)3 /CH3CN, 18-24 hrs at rt; b) NH4OH, MeOH, 24 hr at rt, using CD3I (61% after 2 steps) or using 
CH3I (42% after 2 steps).  
 
The 1H NMR spectrum of hercynine-d3 3.4 revealed two aromatic protons resonating at δH 
7.84 and 7.12 ppm, respectively. Three aliphatic protons resonating as a doublet of doublets 
(J = 10.6, 4.7 Hz) at δH 4.01 ppm was characteristic of the α-amino acid proton and the 
methylene protons, which were deshielded and resonated as a multiplet from δH 3.39 to 3.36 
ppm. A singlet signal integrating for 6 protons was attributed to the Nα,Nα-dimethyl protons 
in deuterated (d3) form supporting the structure of hercynine-d3 3.4. 
The 13C NMR spectrum corroborated by ESI/QTOF analysis confirmed the structure of 
hercynine-d3 3.4. A high-resolution mass spectrum revealed the molecular ion at m/z 
201.1414 [M]+calculated for C9H13D3N3O2+ (201.1431) [M]+. (Figure 3.3) 
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Figure 3.3. Top. Theoretical HRMS isotopic pattern calculated for C9H13D3N3O2+ [M]+. Bottom. Experimental 
ESI/QTOF mass spectra of hercynine-d3 3.4 in positive ion mode. 
 
The 1H NMR spectrum of hercynine 3.3 displayed two aromatic signals resonating at δH 7.89 
ppm and 7.11 ppm respectively, suggesting the presence of the imidazole ring. A key 
characteristic signal was a singlet resonance at δH 3.35 ppm integrating for 9 protons proving 
successful quaternarization.  
The 13C NMR spectrum of hercynine 3.3 revealed seven carbon signals resonating at δC 170.9, 
136.1, 131.2, 116.7, 78.4, 52.2 and 25.0 ppm respectively confirming the identity of hercynine 
3.3.  
Furthermore, the EI+ mass spectrum displayed molecular ion at m/z 197.1 [M]+ calculated for 
C9H15N3O2+ (197.1) [M]+ and a characteristic base peak corresponding to a loss of three 




methyls at m/z 152.0 calculated for C6H6N3O2 (152.0) [M-(CH3)3]+, thus supporting the 
structure of hercynine 3.3.   
 
It is noteworthy that Reinhold et al. have synthesized hercynine via Pd/C catalytic 
hydrogenation of the histidine imine produced in a presence of 37% solution of formaldehyde 
in water. Subsequent quaternarization with iodomethane under basic conditions gave 
hercynine 3.3 in an overall yield of 73%.4 However this approach was not attempted, because 
it requires a tedious ionic chromatographic purification as well as the use of a huge amount 
of resin that makes it unattractive especially in Kg scale synthesis.  
 
3.1.1.4. Synthesis of stable isotopically labelled ergothioneine-d3 
 
The synthesis of L-ergothioneine-d3 3.7 was performed in three steps starting from a 
commercially available mercaptohistidine 3.5 (or synthesized according to the literature5). 
The thiol group of mercaptohistidine 3.5 was protected by a t-butyl group in order to 
selectively dimethylate the α-amino group, (S)-3-(2-(tert-butylthio)-1H-imidazol-4-yl)-2-
(dimethylamino) propanoic acid 3.6 was isolated in a low yield of 33.7%. Quaternarization 
using iodomethane-d3 and the subsequent removal of the S-t-butyl protecting group afforded 
the target compound, ESH-d3 3.7 quantitatively. This method was adapted from the Trampota 
patent.5 (Scheme 3.5) 





Scheme 3.5. Synthesis of ESH-d3 (3.7). Reagents and conditions: i) a) t-butanol/HCl, refluxed for 3-4 hrs; b) 37% 
solution CH2O, NaBH(OAc)3 /THF, 6-8 hrs at 10 °C, 33.7%; ii) a) NH4OH, CD3I/MeOH, 24 hr, rt; b) HCl, 2-
mercaptopropionic acid  refluxed for 21 h (quantitative).  
 
The 1H NMR spectrum of ESH-d3 3.7 displayed the characteristic aromatic proton resonating 
as a singlet at δH 6.95 ppm suggesting the presence of a mercapto heterocyclic ring. A 
deshielded proton resonating as a multiplet from δH 4.34 – 4.13 ppm and two protons 
resonated as doublet of doublets (J = 11.3, 8.5 Hz) at δH 3.41 ppm suggesting the presence of 
an α-amino acid. Key features in the 1 H NMR spectrum were the down field resonance of a 
singlet integrating for 6 protons (deuterated protons are blank in 1 H NMR) from δH 3.01 ppm 
in 3.6 to δH 3.39 ppm indicative of the presence of a Nα,Nα,-dimethyl CD3 group; and the 
disappearance of the singlet resonated at δH 1.50 ppm in 3.6 supporting the successful t-butyl 
deprotection.  
 
The 13C NMR spectrum of ESH-d3 3.7 revealed seven carbon resonances at δC 180.3, 134.9, 
119.1, 115.8, 75.5, 52.5 and 22.7 ppm respectively, thus confirming the identity of ESH-d3 3.7.  
Moreover, a high-resolution mass spectrum (ESI+) displayed the molecular ion at m/z 
233.1160 [M]+ calculated for C9H13D3N3O2S+ (233.1152) [M]+ and a characteristic 
fragmentation pattern as shown in the Figure 3.4, thus supporting the structure of ESH-d3 3.7. 
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Figure 3.4. Top. Theoretical HRMS isotopic pattern calculated for C9H13D3N3O2S+ [M]+. Bottom. Experimental 
ESI/QTOF mass spectra of ergothioneine-d3 (3.7) in positive ion mode. 
 
3.2. Total synthesis of 2-cysteinylhercynine sulfoxide and 2-
cysteinylhercynine sulfone 
 
3.2.1. Synthesis of 2-cysteinylhercynine sulfoxide (EgtE enzyme substrate)  
 
The natural EgtE substrate, 2-cysteinylhercynine sulfoxide 3.8 was first isolated from cell-free 
extracts of Neurospora crassa by Ishikawa et al.6 Later on, it was synthesized by enzymatic 




action of EgtB and EgtC on hercynine and γ-glutamylcysteine.7 Song et al. isolated and 
characterized 2-cysteinylhercynine sulfoxide (EgtE natural substrate) produced 
biosynthetically by the enzymatic action of OvoA enzyme on hercynine and cysteine.8  
Synthesized 2-cysteinylhercynine thioether 2.19 was oxidized using 2.4 mol equivalents of 
30% H2O2 in a presence of a catalytic amount of para toluene sulfonic acid (0.07 mmol) at 
room temperature to afford 2-cysteinylhercynine sulfoxide 3.8 as a yellow solid in good yield 
of 71% according to a published method by Rostami et al.9 (Scheme 3.6)  
 
 
Scheme 3.6. Synthesis of 2-cysteinylhercynine sulfoxide 3.8. 
 
A previously reported mechanism of selective oxidation of sulfides to sulfoxides in H2O2 using 
catalytic sulfuric acid was published by Shaabani et al.10 and Rostami et al.9 They proposed 
two plausible mechanisms, the first hypothesis is that the catalyst, para-toluene sulfonic acid 
3.9 might act as a proton source which transfer a proton to peroxide to generate a reactive 
oxygen species 3.11. The latter reacts with the sulfide 3.12 to form the target sulfoxide 3.14, 
after deprotonation of the hydrosulfonium cation 3.13 by para-toluene sulfonate 3.10, thus 
regenerating the catalyst. (Scheme 3.7) 






Scheme 3.7. Proposed mechanism of sulfoxidation using H2O2 and p-TsOH acting as a proton source.  
 
An alternative hypothesis is that the selective sulfoxidation could proceed through oxygen 
transfer on the sulfide 3.12 by pertolylsulfonic acid 3.15 (reactive intermediate) which is 




Scheme 3.8. Proposed mechanism of sulfoxidation proceeding through pertolylsulfonic acid 3.9 (reactive 
intermediate) 
 
The 1H NMR spectrum of 2-cysteinylhercynine sulfoxide 3.8 displayed one aromatic signal that 
resonated at δH 8.01 ppm attributed to proton H-5' of the imidazole ring. A key diagnostic 




signal was the downfield shift of the methylene proton adjacent to the sulfoxide which 
resonated as doublet of doublets in the 1H NMR spectrum of thioether 2.19 from 3.50-3.36 
ppm to 3.65 ppm (J = 15.0, 3.3 Hz), thus suggesting the successful introduction of sulfoxide 
(electron withdrawing group).   
The 13C NMR spectrum of 2-cysteinylhercynine sulfoxide 3.8 revealed two carbonyl signals 
resonating at δC 171.8 and 170.1 ppm, respectively. Three aromatic signals resonating at δC 
156.6, 129.5 and 125.5 ppm suggesting the presence of an imidazole heterocyclic. Five 
aliphatic carbon signals resonating at δC 72.5, 49.5, 49.1, 43.5 and 20.8 ppm, thus confirming 
the identity of 2-cysteinylhercynine sulfoxide 3.8. 
Furthermore, a high-resolution mass spectrum (ESI+) displayed the molecular ion at m/z 
334.1321 [MH]+ calculated for C12H22N4O5S+ (334.1311) [MH]+, and a characteristic base peak 
corresponding to a loss of three methyls and carbonyl at m/z 241.0321 calculated for 
C8H9N4O3S (241.0395) [M-(CH3)3-CO2-2H]+, hence supporting the structure of 2-
cysteinylhercynine sulfoxide 3.8. (Figure 3.5) 
 






Figure 3.5. Top. Theoretical HRMS isotopic pattern calculated for C12H22N4O5S+ 334.1311 [MH]+. Bottom. 
Experimental ESI/QTOF mass spectra of 2-cysteinylhercynine sulfoxide 3.8 in positive ion mode. 
 
3.2.2. Synthesis of 2-cysteinylhercynine sulfone  
 
It is well known that 2-cysteinylhercynine sulfoxide 3.8 is the EgtE enzyme substrate.7  
However, it was proposed to synthesize the sulfone derivative, which will be assayed in order 
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activity of the EgtE enzyme. This will shed light on the mechanism of the C-S lyase of EgtE as 
well as enzyme-substrate specificity.  
2-Cysteinylhercynine thioether 2.19 was oxidized all the way to the 2-cysteinylhercynine 
sulfone 3.16 at room temperature (65%) by using a large excess of 30% solution of H2O2, 4.8 
mol equivalents, in a presence of catalytic amount of boric acid (0.08 mmol) according to a 
method published by Rostami et al.11 (Scheme 3.9) 
 
Scheme 3.9. Synthesis of 2-cysteinylhercynine sulfone 3.16. 
 
A key characteristic signal in the 1H NMR spectrum of 2-cysteinylhercynine sulfone 3.16 was 
one aromatic proton resonating as a singlet at δH 8.01 ppm. Two deshielded protons 
resonating both as doublet of doublets at δH 4.52 ppm and 3.89 ppm respectively, 
characteristic of α-amino protons and one singlet δH 2.89 ppm integrating for 9 protons, thus 
supporting the structure of 2-cysteinylhercynine sulfone 3.16.  
Another key diagnostic feature was the downfield shift of methylene protons resonating as 
doublet of doublets in the 1H NMR spectrum of thioether 2.19 from 3.50-3.36 ppm to δH 3.67 
ppm, thus supporting a successful oxidation of the sulfur atom adjacent to the methylene.  




The 13C NMR spectrum corroborated by mass spectrum (ESI+) confirmed the structure of 2-
cysteinylhercynine sulfone 3.16. An high-resolution mass spectrum (ESI+) revealed the 
molecular ion at m/z 349.1177 [M]+, calculated for C12H21N4O6S+ (349.1182) [M]+. (Figure 3.6) 
 
 
Figure 3.6.  Top. Theoretical HRMS isotopic pattern calculated for C12H21N4O6S+ [M]+. Bottom. Experimental 
ESI/QTOF mass spectra of 2-cysteinylhercynine sulfone 3.16 in positive ion mode. 
3.3. In vitro reconstitution of ergothioneine biosynthesis in 
Mycobacterium smegmatis.  
 
Having successfully synthesized the ergothioneine biosynthetic precursors, hercynine-d3 3.4, 
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ergothioneine in mycobacteria was attempted as illustrated in the simplified flow chart 














Figure 3.7. Simplified flow chart of the biotransformation mediated by EgtE crude enzyme preparations.  
 
The last step of mycobacterial ergothioneine biosynthesis is catalyzed by EgtE (a PLP-
dependent enzyme) which involves the lysis of the C-S bond of 2-cysteinylhercynine sulfoxide 
M. smegmatis 
cultures harvested 
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3.8 to form ergothioneine.7 The study of this transformation will help to understand the 
mechanism of the C-S bond lysis. 
Seebeck published the reconstitution of the mycobacterial ergothioneine biosynthesis 
pathway. He managed to isolate all enzymes implicated in the pathway but failed to 
overexpress the EgtE enzyme.7 The aim was to isolate EgtE via classic protein purification, but 
due to the lack of access to a pure M. smegmatis EgtE enzyme at the time of this research, 
Mycobacterium smegmatis cell-free lysate enzymatic preparations were utilized in the study. 
However, very recently mycobacterial EgtE enzyme was successfully isolated and 
characterized by Song et al.12  
 
3.3.1. Total protein quantitation  
 
Mycobacterium smegmatis cell-free extracts were isolated from cultures grown and 
harvested at the late exponential phase according to a published method by El-Sayed.13 The 
total protein concentration was evaluated for reproducibility purposes and was calculated 
from a calibration curve established by the Bradford method. The total protein concentration 
was found to be 10 µg/µL.  
3.3.2. Ergothioneine quantitation 
 
A LCMS method was utilised to monitor the biotransformation of 2-cysteinylhercynine 
thioether 2.19, 2-cysteinylhercynine sulfoxide 3.8, 2-cysteinylhercynine sulfone 3.16 as well 




as hercynine-d3 3.4 synthesized. This technique was chosen due to its sensitivity therefore 
requiring a very small amount of sample.  
The production of ESH was monitored at retention time of 1.5 min. (Figure 3.8) The high-
resolution mass spectrum (ESI+) of the natural ESH displayed peaks at m/z 230.0958 [M]+ and 
at m/z 231.0980 corresponding to [M]+ and [M + H]+ respectively. (Figure 3.9) 
 
Figure 3.8.  Overlaid TIC of ergothioneine (Top 25 ng mL-1, bottom 12.5 ng mL-1 concentrations). Retention time 
of 1.5 min. (Positive ionization mode) (ESI+) and column (Eclipse + C18 RRHD 1.8 µm.2.1 X 50, Agilent 1290 
infinity, Germany) 
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The calibration curve was established from eight different concentrations (0.78, 1.56, 3.125, 
6.25, 12.5, 25, 50, 100 ng mL-1) of ESH prepared in triplicate. (Figure 3.10) The limit of 
quantitation (LOQ) for ESH was 0.78 ng mL-1 (lowest concentration of ESH standard used to 
construct the calibration curve) similar to the one reported by Wang et al.14 while the limit of 
detection (LOD) for ESH was 9 pg mL-1 (LOD is the lowest concentration of ESH standard 
required to display a LCMS response and determined experimentally). The expected range of 
quantitation was 0.78-100 ng mL-1. (0.78 ng mL-1 (lowest concentration) and 100 ng mL-1 
(highest concentration) used to construct the calibration curve in the experiment, therefore 
any value outside this range is considered not accurate for the experiments) 
 
Figure 3.10. Calibration curve of ESH. 
 
3.3.3. Biotransformation of EgtE substrates to ergothioneine using crude M. 
smegmatis enzyme preparations. 
 
Biotransformation of synthesized substrates using cell-free Mycobacterium smegmatis crude 
enzyme preparations were assayed in triplicate, repeated several times (more than three 
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times) and these results were reproducible. Reactions (100 µL) were allowed to incubate at 
37°C for 1 day at pH = 7.4 (20 mM Tris-HCl buffer) and the production of ergothioneine was 
quantified using LCMS. (experimental section).15  
The negative control reaction containing only the crude M. smegmatis cell-free extract was 
also treated under the same conditions as the ergothioneine precursors. The concentration 
of ESH thus obtained was 5.70 (±0.30) ng mL−1, which equate to that of endogenous ESH. This 
concentration was above the limit of detection (0.78 ng mL−1), thus any increase in the 
concentration of ESH in the experiment above 1 ng mL−1 is considered enough to be ascribed 
to basal levels or biotransformation of the respective substrates by the crude endogenous 
enzymes of the ESH pathway.  
 
3.3.3.1. Enzymatic synthesis of ergothioneine-d3 (3.7) using hercynine-d3 (3.4) as a 
substrate.  
 
As anticipated, when hercynine-d3 (3.4) was used as the substrate in the enzymatic reaction, 
the endogenous concentration (baseline) of ESH remained unchanged. However, as expected, 
the LCMS analysis of the enzymatic reaction mixture revealed the production of ESH-d3 (3.7) 
at the same retention with the natural ESH (1.5 min). (Scheme 3.10) 





Scheme 3.10. Enzymatic biotransformation of hercynine-d3 (3.4).  
 
The high-resolution mass spectrum (ESI+) displayed a peak at m/z 233.1161 corresponding to 
[M + D3]+. Peak values at m/z 230.0958 [M]+ or at m/z 231.0980 [M + H]+ belonging to the 
natural ESH were not detected in the chromatogram. This clearly shows that the crude M. 
smegmatis enzymes (dialyzed extract) transformed the hercynine-d3 (3.4) into ESH-d3 (3.7). 
This proved that the isolated crude enzyme extract was fully functional in the reconstitution 
of ESH synthesis. (Figure 3.11) 
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3.3.3.2. Biotransformation of EgtE substrates to ergothioneine using crude M. smegmatis 
enzyme preparations 
Three cysteinyl hercynine derivatives were assayed in the presence of the crude M. 
smegmatis enzymatic preparations. EgtE substrate, 2-cysteinylhercynine sulfoxide 3.8 
biosynthetically produced the highest concentration of ESH (22.6 ±0.3 ng mL−1). The 2-
cysteinylhercynine thioether 2.19 appeared to be almost as good a substrate as the 2-
cysteinylhercynine sulfoxide 3.8 producing 19.2 (±0.2) ng mL−1 ESH. However, 2-
cysteinylhercynine sulfone 3.16 did not produce any noticeable amount of ESH as the 4.3 
(±0.1) ng mL−1 detected was attributed to endogenous ESH. (Figure 3.12 & Figure 3.13) 
Thus, the EgtE enzyme recognized both, 2-cysteinylhercynine thioether 2.19 and 2-
cysteinylhercynine sulfoxide 3.8 as substrates, while the sulfone 3.16 could not be cleaved in 
the active site of the EgtE enzyme. 
 
Figure 3.12.  In vitro reconstitution of ESH; 100 µL reactions containing 20 mM Tris HCl pH= 7.4, 20 mM NaCl, 
0.2 mM FeSO4.7 H2O, 0.5 mM mercaptoethanol, 83 µL of crude M. smegmatis enzymes and 50 mM of either (a) 
2-cysteinylhercynine thioether (2.19); (b) 2-cysteinylhercynine sulfoxide (3.8); (c) 2-cysteinylhercynine sulfone 




(3.16) and (d) control. The crude enzyme reactions were incubated for 1 day at 37° C followed by analysis by 
LC/MS. 
 
Figure 3.13. TIC extracted for ESH in-vitro reconstititued experiment using substrate: (a) 2-cysteinylhercynine 
thioether (2.19) as substrate, (b) 2-cysteinylhercynine sulfoxide (3.8) as substrate.  
 
3.3.4. Non-enzymatic cleavage of the C-S bond catalyzed by PLP 
 
It is well known that PLP-dependent transformations can also undergo enzyme-free 
conversion albeit with a much slower rate and specificity.16 Thus, the non-enzymatic 
treatment of the sulfide (2.19) with 50 mM PLP at 37 °C resulted in an efficient formation of 
ESH (96 ±2 ng mL−1) (green line). However, under the same conditions, the sulfoxide (3.8) 
(blue line) and sulfone (3.16) (orange line) produced no ESH at all. (Figure 3.14) Thus the 
oxidation state of the sulfur atom is crucial for the C-S bond lysis as only the sulfur 2.19 
displayed an efficient cleavage.  
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Figure 3.14. Non enzymatic production of ESH catalysed by PLP. TIC extracted for ESH and PLP using 2-
cysteinylhercynine thioether (2.19) (green line), 2-cysteinylhercynine sulfoxide (3.8) (blue line) and 2-
cysteinylhercynine sulfone (3.16) (orange line).  
 
3.3.5. Mycobacterium smegmatis EgtE inhibition by 2-cysteinylhercynine 
sulfone  
 
2-Cysteinylhercynine sulfone 3.16 did not produce any ESH either when assayed using cell-
free crude M. smegmatis enzyme preparation or under enzyme-free PLP-mediated 
conditions. 
When 100 µL reactions containing 50 mM 2-cysteinylhercynine sulfone 3.16 and either 50 
mM 2-cysteinylhercynine thioether 2.19 or 50 mM 2-cysteinylhercynine sulfoxide 3.8 were 
incubated with cell-free M. smegmatis enzymatic preparation at pH = 7.4 (20 mM Tri-HCl 
buffer) at 37 °C for 1 day, insignificant amounts of ESH produced, 8 and 4.3 (±0.1) ng mL−1 of 
ESH were detected respectively. That were within the range of the endogenous ESH 
concentration (5.7 (±0.3) ng mL−1). (Figure 3.15 & Figure 3.16)  





Figure 3.15. LCMS spectrum of M. smegmatis. ESH enzymes inhibition. (a) TIC extracted for ESH in enzymatic 
reaction using sulfoxide (3.8) as a substrate. (b) TIC extracted for ESH in the enzymatic reaction using sulfoxide 
(3.8) and sulfone (3.16) as an inhibitor.   
 
Figure 3.16.  LCMS spectrum of M. smegmatis. ESH enzymes inhibition. (a) TIC extracted for ESH in enzymatic 
reaction using sulfide (2.19) as a substrate (b) TIC extracted for ESH in the enzymatic reaction using sulfide (2.19) 
and sulfone (3.16) as an inhibitor.   
 
When sulfone 3.16 was added to the 2-cysteinylhercynine thioether 2.19 enzymatic reaction, 
ESH biosynthesis was inhibited by 60%. Inhibition of ESH biosynthesis was over 80% when 
ESH 
ESH 




sulfone 3.16 was added to the 2-cysteinylhercynine sulfoxide 3.8 enzymatic reaction. (Figure 
3.17).  
Percentage ESH inhibition was determined using this formula: % ESH inhibition = (ESHsubstrate-ESH 
after inhibition by sulfone)/ESH substrate; eg. % ESH thioether = (19.23-7.60)/19.23 = 60% and % ESH sulfoxide = 
(22.93-4.26)/22.93 = 81%.  
 
Figure 3.17. Ergothioneine biosynthesis inhibition studies contain; 100 µL reactions containing 20 mM Tris HCl 
pH= 7.4, 20 mM NaCl, 0.2 mM FeSO4.7 H2O, 0.5 mM mercaptoethanol, 83 µL of crude M. smegmatis enzymes 
and 50 mM of either substrate sulfide (2.19), sulfoxide (3.8) alone or in the presence of sulfone (3.16) 
respectively (c) control no substrates.  
 
These findings have suggested that adding 2-cysteinylhercynine sulfone 3.16 to the enzymatic 
reaction mixtures significantly inhibits the in vitro biosynthesis of ESH in M. smegmatis, hence 










3.3.6. Minimum Inhibitory Concentration (MIC) of 2-cysteinylhercynine 
sulfone, ESH-inhibitor.  
 
The minimum inhibitory concentration inhibition of 2-cysteinylhercynine sulfone 3.16 was 
assayed against Mycobacterium smegmatis strain mc2 155 using a broth dilution method with 
the Alamar blue stain used for visualization as shown in the Figure 3.18.17  
 
Figure 3.18.  Broth dilution method. 
 
Even though 2-cysteinylhercynine sulfone 3.16 did not exhibit better MIC’s than existent TB-
drugs such as Isoniazid (INH) and Rifampin (RIF) used as positive control in this study; 2-
cysteinylhercynine sulfone 3.16 still inhibited M. smegmatis growth at concentrations of 
1600–1700 µg/mL (experiment performed in triplicate). Due to the fact that sulfone 3.16 
(ESH-inhibitor) inhibits Mycobacterium smegmatis growth, may suggest that the sulfone 
inhibitor could be toxic to the cell. 2-Cysteinylhercynine sulfone 3.16 in combination with 




either Isoniazid (INH) or Rifampin (RIF) did not show synergy in the inhibition of 
Mycobacterium smegmatis.  
 
3.3.7. Proposed mechanism of C-S lyase of sulfide (2.19), sulfoxide (3.8) and 
sulfone (3.16) catalysed by PLP.15  
 
C-S lyases are a subclass of enzymes that catalyse the cleavage of C-S bond by other processes 
than by hydrolysis or oxidation. Most C-S lyase enzymes cleave sulfur substrates through 
elimination, hence generating either a double bond or a new ring. In the literature, only few 
sulfoxides have been reported as substrates of C-S lyase enzymes.  
However, many PLP-dependent C-S lyases have been previously reported in primary 
metabolism or xenobiotic detoxification,18 such examples include cysteine S-conjugate β-
lyases.19 Recently, they are reported in secondary metabolism7,12,15, that GliI, a PLP dependent 
C-S lyase involved in the key step of the biosynthetic pathway of gliotoxin (secondary 
metabolite) was extensively studied by Scharf et al.20  
This section will be dedicated to discussing the proposed mechanism of the PLP-dependent 
C-S lyase, EgtE.  
The pKa value of the amino acid α-hydrogen usually is in the range 20–30 and many enzymes 
effectively increase the α-hydrogen acidity with the aid of a coenzyme, PLP. PLP-dependent 
enzymes exist in their native state as an internal aldimine (Schiff base) with the ε-amino group 
of a lysine residue present in the catalytic site. The amino acid substrate displaces the lysine 




from the internal aldimine to form a new aldimine, termed external aldimine. The formation 
of such an external aldimine can reduce the pKa value of the α-proton of the substrate from 
30 to as low as 6.16  
PLP-dependent enzymes have been differentiated on the basis of their tertiary structures, 
more specifically according to fold types I–V. EgtE is classified as a fold type V which is found 
mainly in enzymes that catalyze β-replacement and β-elimination reactions. In the absence 
of a crystal structure of EgtE, structure homology analysis amongst mycobacteria is not 
possible. However, a putative β-lyase from E. tasmaniensis appeared to catalyse this step but 
has a sequence similarity to EgtE of M. smegmatis and M.tb of only 14%.  
Thus, the proposed mechanism of this C–S β-lyase utilising 2-cysteinylhercynine thioether  
(2.19) as a substrate was based on that of the well characterized cystalysin from Treponema 
denticola which shares 31% sequence identity to the β-lyase from E. tasmaniensis.21 It may 
well be that actinomycetes have similar β-lyases at work.22 It has also been observed to be a 
rather facile non-enzymatic (PLP only) β-elimination with the 2-cysteinylhercynine thioether 
(2.19). (Figure 3.19) 





Figure 3.19.  β-Elimination of the sulfide (2.19).15 
 
However, the conversion of the natural substrate, 2-cysteinylhercynine sulfoxide (3.8), to ESH 
is not consistent with the literature.7 Elimination of an unstable (β-amino-β-
carboxyethyl)ergothioneine sulfinate (3.17) is envisaged, whereby self-condensation leads to 
the thiosulfinate, which in turn decomposes to ESH and an equivalent amount of relatively 
stable (β-amino-β-carboxyethyl)ergothioneine sulfenic acid (3.18). (Figure 3.20) 





Figure 3.20.  β-Elimination of the sulfoxide (3.8).15 
 
Subsequently, the latter sulfenic acid 3.18 can be reduced to the thiol, ESH, with the aid of 
excess mercaptoethanol, but this may be difficult under the current experimental 
conditions.23 The 2-cysteinylhercynine sulfoxide (3.8) does not lead to the production of ESH 
in the absence of a reductant, such as mercaptoethanol. This mechanism was further 
confirmed by Song et al., who demonstrated that ESH could only be detected when incubating 




2-cysteinylhercynine sulfoxide 3.8 with pure EgtE enzyme in a presence of DTT as reductant. 
However, in vivo it is suspected that natural thiols such as mycothiol, cysteine, glutathione 
might act as reductant to accomplish this role.12 (Figure 3.21)  
 
 
Figure 3.21.  Sulfenic acid 3.18 conversion to ESH. 
 
It is noteworthy that the involvement of sulfenic acid 3.18 as a key intermediate during the 
catalysis of EgtE enzyme was provided very recently by Song et al.12 These authors managed 
to trap this unstable intermediate in a presence of cyclohexane-1,3-dione 3.19 and 




characterized the sulfenic acid-cyclohexane dione adduct 3.20 isolated following cellulose 
chromatography. Moreover, they proposed that the highly unstable sulfenic acid 3.18 
disproportionates to produce the thiol ester of thiosulfinic acid 3.21, the latter will hydrolyse 
to form either ESH 2.10 or ergothioneine-2-sulfinic acid 3.22 depending on the assay 
conditions. However, the highly unstable sulfinic acid 3.22 degrades to hercynine 3.3 during 
the isolation process via elimination of sulfur dioxide under acidic conditions.24 (Figure 3.22) 
 
Figure 3.22. Proposed model explaining EgtE reaction using sulfoxide (3.8) as a substrate. (Adapted from song 
et al.12) 
ESH inhibition by 2-cysteinylhercynine sulfone 3.16 could proceed through system 
stabilisation resulting to the formation of very stable quinonoid conjugated intermediates (4 




possible intermediates) which cannot be C-S cleaved, hence no ESH cannot be detected. 
(Figure 3.23) 
 
Figure 3.23.  Stabilisation of the sulfone (3.16).  
 
3.3.8. Summary of major findings  
 
In summary, 2-cysteinylhercynine thioether 2.19 was synthesized in 5 sequential steps in a 
good overall yield of 64-70%. Catalytic oxidation of the thioether 2.19 yielded 2-
cysteinylhercynine sulfoxide 3.8 in a good yield of 71%, or if further oxidised, 2-
cysteinylhercynine sulfone 3.16 in a moderate yield of 65%. (Scheme 3.11)  





Scheme 3.11. Synthesis of cysteinylhercynine thioether 2.19, sulfoxide 3.8 and sulfone 3.16.15 
 
It has been found that 2-cysteinylhercynine thioether 2.19 and 2-cysteinylhercynine sulfoxide 
3.8 biosynthetically produced ESH, with 2-cysteinylhercynine sulfoxide 3.8 producing the 
highest amount of ESH (22.6 ng mL−1) thus suggesting that the sulfoxide intermediate 3.8 is 
the preferred biological EgtE substrate. This finding was later on confirmed by Song et al. 
based on kinetic parameters determined using purified M. smegmatis EgtE enzyme.12  
When performing the non-enzymatic PLP-mediated reactions, only 2-cysteinylhercynine 
thioether 2.19 produced ESH (96 ±2 ng mL−1), while either 2-cysteinylhercynine sulfoxide 3.8 
or 2-cysteinylhercynine sulfone 3.16 produce no ESH at all. (Scheme 3.12) 





Scheme 3.12. Biotransformation and non enzymatic PLP-mediated reactions of cysteinylhercynine thioether 



















It was proposed to develop a method for detection of thiols particularly L-ergothioneine. This 
method has to be cheaper, almost instantaneous, less interference and allowing ESH 
detection even at very low level.  
Recently, Sotgia et al. developed a simple, fast, accurate method for routine quantification of 
ESH in whole blood using ultra-performance liquid chromatography and UV-vis detection 
while achieving a limit of detection (LOD) and limit of quantification (LOQ) of 3.85 and 11.67 
µmol/L, respectively.25 Although, this method appeared to be attractive, it remains very 
expensive as it uses costly chromatographic columns and equipment, therefore it was advised 
to develop a different approach which would involve relatively cheaper reagents and 
equipment such as UV-vis spectrophotometer.   
A well known UV-vis spectrophotometric method is well documented.26,27 This method 
involves the monitoring of the formation of a specific adduct which exerted a strong 
absorbance at about λmax 420 nm resulting from the reaction of Ellman’s reagent (5,5′-dithio-
bis(2-nitrobenzoic acid) and free thiols like coumpounds as well as enzymes having SH- 
groups. However, it was reported incomplete reactions of certain substrates mostly hindered 
protein sulfhydryls with Ellman’s reagent even after a prolonged reaction time. Therefore, 
Riener et al substitute Ellman’s reagent by 4,4′-dithiodipyridine (DTDP), which reacts 
efficiently with hindered protein sulfhydryls even without the use of cystamine as a catalyst.27 




Furthermore the same autors optimised the sensitivity, the limit of detection and the assay 
time of DTDP and traditional Ellman/cystamine methods.27  
 
It is well known that simple as well as complex thiols react easily, rapidly and selectively with 
propiolic ester (methyl and ethyl propiolic ester) to yield thioacrylates which exhibited 
characteristic UV-vis absortion at λmax 280-290 nm. This procedure utilised inexpensive 
reagents and allows the detection and quantitation of thiols even at nanomolar level using 
NMR as well as UV-vis spectrophotometric techniques.28 
Zacharis et al. systematically studied ethyl propiolate (EP) as a novel derivating reagent for 
thiols and this derivatization reaction was also investigated under flow conditions and UV 
detection at λmax 285 nm.29 Moreover the same group optimized this method to detect and 
quantify glutathione (GSH) in vegetables.30 
 
3.4.2. Propiolic acid, a reagent for thiol detection, tagging and derivatization 
 
During the course of this investigation, propiolic acid was utilized rather than their ester 
derivatives (novel approach) as a reagent for thiol detection, tagging and derivatization. 
Propiolic acid is very cheap, stable and less volatile than their ester derivatives.  
 
Several thiols were assayed such as L-cysteine, N-acetyl cysteine, thiophenol, before assaying 
the non-enzymatic cleavage of 2-cysteinylhercynine thioether 2.19 by PLP, in order to 








3.4.2.1. L- cysteine  
 
The Owen method28 was followed using propiolic acid as thiol derivatizing instead of methyl 
or ethyl propiolates. (Scheme 3.13) 
 
Scheme 3.13. Synthesis of thioacrylates 3.20 and 3.21 obtained from the reaction of propiolic acid 3.23 and L-
cysteine 2.20 
UV-vis spectrophotometric analysis of this reaction at µM (micromolar) level revealed a 
characteristic absorption at λmax 275 nm suggesting successful formation of thioacrylates. 
(Figure 3.24)  
 
Figure 3.24.  UV-vis spectrum monitoring the formation of thioacrylate formed from the reaction between L-




















UV-vis spectrum of derivatization of L-cysteine by propiolic acid
Cysteine 1 microM
Propiolic acid 1.5 microM
Reaction product
λmax 275 nm 




The 1H NMR spectrum of L-cysteine is blank at region above 5.5 ppm, while thioacrylates 
displayed a characteristic NMR patterns at this region, hence the reaction was assayed at 
NMR scale.  
It is noteworthy that Owen managed to isolate the cis isomer 3.25 at good yield of 65% after 
recrystallisation in water. The isolation of thioacrylates 3.24 and or 3.25 were not attempted 
during our investigation, however proton NMR spectrum analysis of the crude reaction 
mixture revealed the presence of two isomers both resonating as doublet, cis (J = 10.1 Hz) 
and trans (J = 15.3 Hz) at the ratio of 2.5:1 or 70:30 around 7.8 to 5.6 ppm, thus supporting 
Owen’s finding that the cis isomer is predominant even when propiolic acid 3.23 is utilized as 
thiol derivatization reagent instead of methyl or ethyl propiolate.(Figure 3.25) 
 
Figure 3.25. 1 H NMR spectrum of crude reaction of cysteine (2.20) and propiolic acid (3.23) in D2O  at 300 MHz 













































Cis J 10.1 Hz
























3.4.2.2. N-Acetyl cysteine and thiophenol  
 
N-Acetyl cysteine and thiophenol were also assayed. Surprisingly the reaction of N-acetyl 
cysteine with propiolic acid did not reveal any characteristic thioacrylate absorptions.(Figure 
3.26) Though, the reaction of thiophenol with propiolic acid displayed even stronger 
absorption around 270-280 nm, unfortunately this maxima absorption cannot entirely be 
attributed to thioacrylates as it coincides with the thiophenol (aromatic compound) 
spectrum, which itself displayed a strong absorbance at the same region. (Figure 3.27) 
However, these results were not investigated further to evaluate the scope and limitations of 
this method.  
 




























Figure 3.27.  UV-vis spectrum of the reaction of propiolic acid 3.23 with thiophenol (at 25°C). 
 
3.4.2.3. In situ L-ergothioneine detection and derivatization during non-enzymatic 
cleavage of C-S bond of 2-cysteinylhercynine thioether 2.19  
 
The discovery of non-enzymatic cleavage of the C-S bond of 2-cysteinylhercynine thioether 
2.19 catalysed by PLP was one of the breakthroughs during the course of this research. 
Therefore, the direct in situ derivatization of L-ergothionine 2.10, product of this reaction was 
















UV-vis spectrum of Thiophenol detection using propiolic acid
Thiophenol 1 mM
Propiolic acid 1 mM
Propiolic acid 1 mM+ Thiophenol 1
mM





Scheme 3.14. In situ derivatization of L-ergothioneine (2.10) by using propiolic acid (3.23) during the 
enzymatic-free cleavage of 2-cysteinylhercynine thioether (2.19).  
 
The formation of thioacrylate derivative (ESH-propiolic acid adduct) 3.26 was monitored by 
UV-vis spectrophotometry. Even at the low level of 5 mM, the UV-vis spectrum revealed a 
strong absorption at λmax 300 nm attributed to be characteristic of thioacrylate 3.26. Thus, 
confirming that L-ergothioneine 2.10 can be detected in situ after successfully being 
derivatized by propiolic acid 3.24, while no interferences were observed. (Figure 3.28)  
The calibration curve can aid to quantify L-ergothioneine, nevertheless the limit of 
quantitation and limitation or scope of this method were not evaluated.  
Is it noteworthy that this method can also be utilized to monitor the rate of the thiol oxidation 
in the sulfurization reaction. (Chapter 2, section 2.3.2.2) 





Figure 3.28.  UV-vis spectrum of the reaction of propiolic acid (3.23) with L-ESH (2.10) produced in situ during 





























UV-vis spectrum of monitoring of ergothioneine during the non 
enzymatic cleavage of 2-cysteinylhercynine mediated by PLP 
PLP
Sulfide 5 mM
Time 0, Non enzymatic cleavage of
substrate mediated by PLP 15 mM"
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Mycobacterium tuberculosis and the saprophyte Mycobacterium smegmatis contain a five-
gene cluster (egtABCDE) that enables the cells to produce ESH from the primary metabolites 
cysteine, glutamate, histidine, and S-adenosylmethionine.1  
Actinobacteria including mycobacteria prefer γ-glutamylcysteine over cysteine as sulfur 
source to produce ESH.2 Although the reason remains unclear, a plausible explanation could 
be that these microorganisms avoid the “cysteine problem”. Accordingly, cysteine is readily 
auto-oxidized and the terminal 1,2-aminothiol group of cysteine complexes with redox active 
transition metals such as iron and copper. Consequently reducing the availability of cysteine 
intracellularly.2 
Mycobacteria which grows under a high O2 partial pressure environment, would have less 
available intracellular cysteine, therefore γ-glutamylcysteine is utilised as a safer sulfur 
source. In γ-glutamylcysteine, the α-amino group of the cysteine moiety is coupled to the γ-
CO2H of glutamic acid, hence it cannot bind to transition metals. Moreover, γ-
glutamylcysteine biosynthesis being ATP driven is not affected by a very low cysteine 
concentration, thus actinobacteria having egtA and egtC genes would still produce 
ergothioneine even under cysteine poor and /or O2-rich environments.3 
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Amongst all enzymes implicated in mycobacterial ergothioneine biosynthesis, only EgtB, a 
formylglycine-generating like enzyme (FGE), uses γ-glutamylcysteine. EgtB catalyzes the 
oxidative coupling between hercynine and γ-glutamylcysteine to produce γ-glutamyl cysteinyl 
hercynine sulfoxide (EgtC enzyme substrate). The knock out/ knock down studies of this 
particular EgtC enzyme substrate is important from a drug discovery point of view. EgtC 
catalyses the removal of γ-glutamyl from γ-glutamyl cysteinyl hercynine sulfoxide (EgtC 
enzyme substrate), therefore knocking down of this enzyme would help understanding the 
mechanism of γ-glutamyl cysteinyl dependence by mycobacteria. Knowledge that could allow 
the design of potential EgtC inhibitors. The EgtC substrate can aid in the screening of potential 
prodrugs targeting mycobacterial EgtC enzyme. 
Intensive efforts have been conducted in our laboratory to synthesize all the ergothioneine’s 
biosynthetic pathway metabolites. The latter would be considered as valuable tools for 
studies to better characterise the enzymes of the ergothioneine pathway in Mycobacterium 
tuberculosis.4,5 At the time of this research, the EgtC substrate was the only ergothioneine 
biosynthetic pathway intermediate that was not yet chemically synthesized. However, it was 
enzymatically produced by Seebeck in a very small quantity (250 ug).6  
In this chapter the design and the total synthesis of γ-glutamylcysteinylhercynine sulfoxide or 
(2S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-2-carboxyethyl)sulfinyl)-1H-imidazol-4-
yl)-2-(trimethylammonio)propanoate (the EgtC enzyme substrate) is described.  
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4.2. Retrosynthetic strategies of EgtC enzyme substrate  
 
Strategies toward the total synthesis of the EgtC enzyme substrate, (2S)-3-(2-(((R)-2-((S)-4-
amino-4-carboxybutanamido)-2-carboxyethyl)sulfinyl)-1H-imidazol-4-yl)-2-
(trimethylammonio) propanoate (4.1) was explored in depth. Three methods were 
investigated following the retrosynthesis strategy utilized as shown in the Figure 4.1 
 
Figure 4.1.  EgtC substrate retrosynthetic strategies. 
 
The proposed retrosynthetic strategies consider cleavage on the distal side of the hercynine 
moiety, cleavage on the left side of the sulfur atom (method 1) or on the right side of the 
sulfur atom (method 2). In method 3 there is a disconnection between the carbonyl carbon 
of the γ-glutamic acid moiety and the N-amino moiety of 2-cysteinylhercynine thioether 2.19.  
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The major difference amongst these strategies are based on the choice of the thiol fragment 
used as a synthon. Ergothioneine 2.10 (discussed in chapter 2) was the synthon used in 
method 1, while γ-glutamylcysteine 4.18 and 2-cysteinylhercynine thioether 2.19 (discussed 
in chapter 2) were the synthons for the method 2 and 3, respectively. 
4.3. Synthesis of EgtC enzyme substrate through S-alkylation of 
ergothioneine. (Method 1) 
 
4.3.1. Retrosynthetic analysis  
 
The envisioned strategy was based on using a starting material that already include a 
mercapto histidine moiety. S-alkylation of L-ergothioneine 2.10 by the protected N5-((S)-1-
carboxy-2-chloroethyl)-L-glutamine intermediate 4.3 to form γ-glutamylcysteinylhercynine 
thioether 4.2, subsequently the sulfide can be oxidized to its sulfoxide derivative 4.1, the 
target compound. The N5-((R)-1-carboxy-2-chloroethyl)-L-glutamine intermediate 4.3 can be 
derived from the protected γ-glutamylserine 4.4, a dipeptide formed by amide coupling 
between the protected glutamic acid 4.6 and the protected serine 4.5. (Scheme 4.1) 
Chapter 4 Synthesis of γ-glutamylcysteinylhercynine sulfoxide, the glutamine 





Scheme 4.1. Retrosynthetic strategy of EgtC substrate 4.1 involving S-alkykation of ergothioneine 2.10 
 
4.3.2. Synthesis of benzyl N5-((S)-1-(benzyloxy)-3-chloro-1-oxopropan-2-yl)-N2-
(tert-butoxycarbonyl)-L-glutaminate 
 
The synthesis of the key intermediate, benzyl N5-((S)-1-(benzyloxy)-3-chloro-1-oxopropan-2-
yl)-N2-(tert-butoxycarbonyl)-L-glutaminate 4.13 involved four sequential steps, protection of 
simple amino acids, amide coupling, selective deprotection and substitution of the hydroxyl 
group by a chloro group. (Scheme 4.2)  
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Scheme 4.2. Synthesis of benzyl N5-((S)-1-(benzyloxy)-3-chloro-1-oxopropan-2-yl)-N2-(tert-butoxycarbonyl)-L-
glutaminate 4.13. Reagents and conditions. (i) TBDMSCl, DBU/CH3CN, 0 °C to rt, overnight, quantitative; (ii) 
(Boc)2O, Et3N/H2O/dioxane, overnight at rt (quantitative); (iii) EDC. HCl, DIPEA, HOBt, DCM, 24 hr at rt, 86%; (iv) 
TBAF (1M in THF)/ dry THF, 5-10 h at rt, 59%; (v) 2,4,6-trichloro[1,3,5]triazine/DMF, DCM, 21 h at rt, 83%. 
 
The hydroxyl group of a commercially available benzyl L-serinate 4.7 was protected as the 
TBDMS according to literature procedures.7 Benzyl O-(tert-butyldimethylsilyl)-L-serinate 4.8 
was isolated quantitatively after aqueous work up and organic extraction. The NMR data were 
fully in accordance fully with the one reported by Gagnepain et al.7  
Commercially available (S)-4-amino-5-(benzyloxy)-5-oxopentanoic acid 4.9, was 
quantitatively converted into the Boc protected product. The presence of an up-field singlet 
at δH 1.49 ppm in the 1H NMR spectrum of 4.10 was consistent with the successful Boc 
introduction.  
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The next step involved the amide coupling of benzyl O-(tert-butyldimethylsilyl)-L-serinate 4.8 
with (S)-5-(benzyloxy)-4-((tert-butoxycarbonyl)amino)-5-oxopentanoic acid 4.10 in the 
presence of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) hydrochloride, N,N-
diisopropylethylamine (DIPEA) and hydroxy-benzotriazole (HOBt) to give the dipeptide 4.11, 
in an excellent yield of 86%. Key signals in the 1H NMR spectrum of 4.11 were three up-field 
signals resonating as a singlet at δH 0.85 ppm (for t-butyl), a multiplet from δH 0.09 to -0.04 
ppm (for 2 X CH3) and a singlet at δH 1.43 ppm (for Boc). A downfield signal resonating as a 
multiplet from δH 7.31 to 7.27 ppm integrating for 10 protons and two methylene proton 
signals resonating as a multiplet from δH  5.27 to 5.06 ppm intergrating for 4 protons, thus 
confirming the presence of two benzyl groups. Additionaly, 13C NMR and EI+ mass spectrum 
revealed the sodium adduct assigned to m/z 651.2 and calculated for C33H48N2NaO8Si (651.3) 
with a mass fragmentation corresponding to a loss of a Boc group [MH–Boc]+ to give m/z 
529.2, thus confirming the structure of 4.11.  
Step 3 entailed selective silyl (TBDMS) deprotection which was achieved by reaction 
compound 4.11 with tetra n-butylammonium fluoride (TBAF) in anhydrous THF. The 
desilylated product 4.12 was isolated in a moderate yield of 59%. A key diagnostic in the 1H 
NMR spectrum of 4.12 was the disappearance of tert-butyl dimethyl silyl signals (δH 0.85 ppm 
(9 protons) and multiplet from δH 0.09 to -0.04 ppm (6 protons)) providing evidence for the 
complete desilylation of compound 4.11. The proton NMR of the desilylated product 4.12 α 
aromatic protons resonating as a multiplet from δH 7.39 to 7.30 ppm integrating for 10 
protons, and methylene protons resonating as a multiplet from δH 5.24 to 5.04 ppm 
integrating for 4 protons, thus supporting the presence of two benzyl groups. Two α carbon 
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protons were also shown in the proton NMR of 4.12, both signals resonating as triplets at δH 
3.44 and 3.61 ppm, hence confirming the presence of two amino acid moieties. The 13C NMR 
spectra corroborated by mass spectra confirmed the structure of benzyl N5-((S)-1-(benzyloxy)-
3-hydroxy-1-oxopropan-2-yl)-N2-(tert-butoxycarbonyl)-L-glutaminate 4.12.  
 
The final step (step 4) entailed the substitution of the hydroxyl group of 4.12 by a chloro 
group. This was achieved according to the methodology described by Lidia et al.8 by reacting 
the alcohol compound 4.12 with the 2,4,6-trichloro[1,3,5]triazine (TCT)/DMF complex known 
as Vilsmeier-Haack type complex to yield the crude target compound, benzyl N5-((S)-1-
(benzyloxy)-3-chloro-1-oxopropan-2-yl)-N2-(tert-butoxycarbonyl)-L-glutaminate 4.13 in a 
83% yield (crude yield). Attempts to purify the synthesized product 4.13 by SiO2 gel 
chromatography resulted in its degradation as revealed by NMR, therefore the product was 
used in the next step without any further purification. The lability of compound 4.13 is not 
unexpected due to the reactive nature of the methylene chloride side chain.  
As expected the 1H NMR spectrum of benzyl N5-((S)-1-(benzyloxy)-3-chloro-1-oxopropan-2-
yl)-N2-(tert-butoxycarbonyl)-L-glutaminate 4.13 was similar to the 1H NMR spectrum of 
starting material 4.12. Strong evidence was provided by the EI+ mass spectrum which 
displayed a molecular ion at m/z 532.1 for [35M, 14.5%]+ and 534.0 for [37M, 4.8%]+ calculated 
for C27H3335ClN2O7 (m/z) 532.2 [35M]+ and C27H3337ClN2O7 (m/z) 534.2 [37M]+, with an intensity 
ratio of peaks of 3:1 characteristic isotopic patterns of chlorinated molecule; moreover, 
fragments corresponding to a loss of Boc group were observed at m/z 431.1 ([35M-Boc]+, 
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61.9%) and 433.1 ([37M-Boc]+, 20.2%]+ calculated for C22H2435ClN2O5 (431.1) and for 
C22H2437ClN2O5 (433.1), thus supporting the structure of 4.13. 
 
With both retrosynthons, the benzyl N5-((S)-1-(benzyloxy)-3-chloro-1-oxopropan-2-yl)-N2-
(tert-butoxycarbonyl)-L-glutaminate 4.14 and ergothioneine 2.10 (synthesized and discussed 
in the chapter 2) in our possession, the next challenge was to attempt an S-alkylation reaction, 
similar to that which was described by Ishikawa et al.9 This method involves treatment of a 
protected chloro methyl peptide 4.13 with ergothioneine 2.10 in a presence of Et3N. (Scheme 
4.3)  
 
Scheme 4.3. Attempted S-alkylation of ergothioneine 2.10 by benzyl N5-((S)-1-(benzyloxy)-3-chloro-1-
oxopropan-2-yl)-N2-(tert-butoxycarbonyl)-L-glutaminate 4.13. Reagents and conditions. Et3N, CH3CN, rt to 
60°C. 
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The mechanistic detail of this reaction was suggested by Ishikawa et al.9 it was proposed that 
the reaction could possibly proceed through a cyclo ethylenimine-2 carboxylic acid derivative 
4.16 (reactive intermediate) formed via the intramolecular substitution of the chloro 
intermediate 4.13. Subsequent nucleophilic attack of the sulfur atom of ergothioneine 2.10 
via SN2 on the reactive cyclo ethylenimine intermediate results in the formation of two 
possible thioether products. (Scheme 4.4) 
 
Scheme 4.4. Proposed mechanism of formation of thioether 4.15 similarly to the one suggested by Ishikawa 
et al.9 
 
Many conditions were investigated for the S-alkylation of ergothioneine 2.10 by benzyl N5-
((S)-1-(benzyloxy)-3-chloro-1-oxopropan-2-yl)-N2-(tert-butoxycarbonyl)-L-glutaminate 4.13, 
such as reaction time, temperature and concentration, but none has proven successful. When 
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the reaction was performed at room temperature, no product was formed as we believed 
that the formation of the reactive intermediate, the cyclo enimine 4.16, is highly hindered 
and is not straightforward. However, when the reaction was allowed to reflux at 60 °C for a 
prolonged time (up to 1 day), TLC analysis of the reaction mixture revealed multiple 
overlapping spots, inseparable by silica gel chromatography, hence no purification was 
attempted. NMR analysis of the crude reaction mixture, did not reveal any characteristic 
signal of the desired product 4.15 and was inconclusive.  
One plausible explanation could be the instability of the alkyl chloride substrate of this 
reaction, the benzyl N5-((S)-1-(benzyloxy)-3-chloro-1-oxopropan-2-yl)-N2-(tert-
butoxycarbonyl)-L-glutaminate 4.13, as established earlier. Due to the failure of this S-
alkylation reaction, this synthetic approach was abandoned and an alternative route was then 
investigated.  
 
4.3.2. Synthesis of γ-glutamylserine (N5-((S)-1-carboxy-2-hydroxyethyl)-L-
glutamine) 
 
With the protected γ-glutamylserine 4.12 in our hand, global deprotection gave γ-
glutamylserine 4.14. The latter peptide was not commercially available and thought to be 
useful as a γ-glutamylcysteine isostere. This alcohol is a valuable intermediate towards the 
synthesis of activated (halogenated) derivatives γ-glutamylserine which could be 
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investigated as alternative to the instable alkyl chlorinatined version 4.13. Especially when 
the need of alternative esters is required.  
The deprotection of γ-glutamylserine 4.12 was accomplished in a one pot synthesis by 
catalytic hydrogenation on Pd/C under acidic conditions (TFA) in a protic solvent (methanol) 
to afford γ-glutamylserine 4.14 in excellent yield of 95%. (Scheme 4.5)  
 
Scheme 4.5. Synthesis of N5-((S)-1-carboxy-2-hydroxyethyl)-L-glutamine 4.14. Reagents and conditions. 
H2/Pd/C (10%), TFA, MeOH, 24 hr at rt, 95%. 
 
The disappearance of aromatic proton signals resonating at δH 7.3 ppm, methylene proton 
signals around δH 5.2 ppm and Boc signal resonating at 1.44 ppm present in the 1H NMR 
spectrum of 4.12, was a confirmation of successful deprotection of 4.12. The proton NMR of 
γ-glutamyl serine 4.14 revealed two α carbon protons resonating at δH 4.27 ppm and 4.03 
ppm suggesting the presence of two amino acids. The proton NMR spectrum of 4.14 also 
revealed three methylene protons resonating as multiplets from δH 3.94 to 3.62 ppm, 2.81 to 
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4.4. Biomimetic synthesis of (2S)-3-(2-(((R)-2-((S)-4-amino-4-
carboxybutanamido)-2-carboxyethyl)sulfinyl)-1H-imidazol-4-yl)-2-
(trimethylammonio) propanoate. (Method 2) 
 
In this approach, the action of EgtB is mimicked. The non-heme iron sulfoxide synthetase 
enzyme (EgtB) of the mycobacterial ergothioneine biosynthetic pathway, catalyzes the O2-
dependent C-S bond formation between γ-glutamylcysteine and hercynine.6,10 
The retrosynthetic strategy entailed the construction of sulfur-carbon (S-C) bond by coupling 
a dipeptide, γ-glutamylcysteine 4.18 as a sulfur source with an activated hercynine 4.19. The 
resulting thioether can be oxidized by either mCPBA in the presence of protecting groups or 
H2O2 after deprotection. It is noteworthy that this strategy was successfully utilized in the 
literature in the synthesis of the 2-cysteinylhercynine thioether, the only difference being the 
use of cysteine as a sulfur source rather than γ-glutamylcysteine 4.18.5,11,12 Bromolactone 
hercynine 4.19 is generated in situ via the bromination of the protected hercynine 4.22, 
whereas the dipeptide γ-glutamylcysteine 4.18 was derived from an amide coupling between 
protected glutamic acid 4.21 and protected cysteine 4.20. (Figure 4.2) 
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Figure 4.2.  Biomimetic retrosynthetic strategy of EgtC enzyme substrate 
 
4.4.1. Synthesis of O, S-dibenzyl-L-cysteinate 
 
The benzyl protecting group was preferred for the protection of the sulfur and carboxylic acid 
groups of cysteine 2.20, leaving the Boc group available for selective deprotection and 
subsequent amide coupling. The benzyl protecting group introduces some hydrophobicity to 
the molecule which proved to be useful for SiO2 gel chromatographic purification, especially 
when working with a polar amino acid, even more the benzyl protecting group can easily be 
removed under neutral conditions such as Pd/C catalytic hydrogenation.   
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Firstly, the synthesis of O,S-dibenzyl-L-cysteinate 4.23 was attempted in two steps, starting 
with a selective S-benzylation performed as described in the literature,13,14 using benzyl 
bromide in ethanol under basic conditions (NaOH) to yield S-benzyl-L-cysteine 4.26 in good 
yield of 86%. Boc protection of the amino group of S-benzyl-L-cysteine 4.26 prior to the 
benzylation yield O,S-dibenzyl-N-(tert-butoxycarbonyl)-L-cysteinate 4.28 in an excellent yield 
of 95% after two steps. Finally, standard Boc deprotection (TFA) yield the desired protected 
cysteine, O,S-dibenzyl-L-cysteinate 4.23, in an excellent overall yield of 86%. (Scheme 4.6)  
Noteworthy is that O,S-dibenzyl-L-cysteinate 4.23 was synthesized according to this approach 
in multi-gram scale quantities (10.8 g) from cysteine (7.5 g) in a good overall yield of 84%, 
after four sequential steps without the need of any SiO2 column purifications. 
 
Scheme 4.6. Synthesis of O,S-dibenzyl-L-cysteinate 4.23. Reagents and conditions. (i) NaOH/EtOH, BnBr (1 eq), 
rt 1-2 hrs, 80%; (ii) a) (Boc)2O, NaOH, THF/H2O, 24 hr at rt; b) BnBr/DMF, 24 hr at rt, 95% after two steps (iii) TFA, 
16 hr at rt, 91%. Overall yield of 86%. 
 
The 1H NMR spectrum of O,S-dibenzyl-L-cysteinate 4.23 displayed two downfield signals both 
resonating as a multiplet from δH 7.39 – 7.30 integrating for 5 protons (assigned for O-CH2-
Ph) and from δH 7.28 – 7.21 (assigned to S-CH2-Ph), thus supporting the structure of 4.23. 
(Figure 4.3)  
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Figure 4.3. 1H NMR spectrum of O,S-dibenzyl-L-cysteinate 4.23 in CDCl3 at 300 MHz. 
 
Furthermore, the 13C NMR spectrum (Figure 4.4) corroborated by EI+ MS analysis confirmed 
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Figure 4.4. 13C NMR spectrum of O,S-dibenzyl-L-cysteinate 4.23 in CDCl3 at 101 MHz. 
 
4.4.2. Synthesis of γ-glutamylcysteine (N5-((R)-1-carboxy-2-mercaptoethyl)-L-
glutamine) 
 
γ-Glutamylcysteine 4.18 is usually synthesized enzymatically by action of an immobilized γ-
glutamyltranspeptidase which catalyzed the α,γ amide bond linkage between cysteine and 
glutamic acid.15 γ-Glutamylcysteine 4.18 can also be isolated from a culture medium 
fermented by a specific over expressing γ-glutamylcysteine yeast strain (saccharomyces 
cerevisiae strain).16,17  The need for gram quantities of the commercially available γ-
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The synthesis of γ-glutamylcysteine 4.18 involved DIC amide coupling between two suitably 
protected amino acids, 4.10 and 4.23 synthesized earlier. Followed by the one-pot removal 
of the benzyl and Boc protecting group as outlined in the Scheme 4.7 below. The target 
product, γ-glutamylcysteine 4.18 was isolated in mg quantities an excellent yield of 85% upon 
filtration and followed by C18 reverse phase chromatography.  
 
Scheme 4.7. Synthesis of γ-glutamylcysteine 4.18. Reagents and conditions. (i) DIC, HOBt, DIPEA, DCM, 24 hr at 
rt, 92%; (ii) H2, Pd/C (10%), TFA, MeOH, 24 hr at rt, 85%.  
 
The proton NMR spectrum of γ-glutamylcysteine 4.18 revealed three sets of methylene 
protons, one resonating as doublet at δH 3.87 ppm assigned to the cysteine β-carbon protons, 
multiplets from δH 2.82 to 2.47 ppm and from δH 2.38 to 2.20 ppm belonging to glutamic acid 
β and γ protons, respectively. 1H NMR data was consistent with those reported in the 
literature.18  
The 13C NMR spectrum of γ-glutamylcysteine 4.18 displayed three carbonyl signals resonating 
at δC 173.2, 170.5 and 156.9 ppm as well as five aliphatic carbon signals resonating at δC 51.2, 
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47.8, 29.3, 25.3 and 23.3 ppm, respectively, thus confirming the carbon skeleton identity of 
the synthesized γ-glutamylcysteine 4.18. (Figure 4.5) 
 
Figure 4.5. 13C NMR spectrum of γ-glutamylcysteine (4.18) in DMSO-d6  at 101 MHz. 
 
Futhermore, the ESI+ mass spectrum displayed the molecular ion [MH]+ at m/z 251.2 
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With γ-glutamylcysteine 4.18 in our possession, the next target was to synthesize the γ-
glutamylcysteinylhercynine thioether 4.2. The sulfurization reaction was carried out 
according to our improved procedure5 (discussed in the chapter 2). N-benzyl hercynine 2.30 
was brominated with an excess of N-bromosuccinimide (NBS) (2.0 mol equivalents) in DMF 
solvent. Subsequently the sulfur source, γ-glutamylcysteine 4.18 was added in one portion. 
Reverse phase C18 column chromatography yielded the desired product 4.2 in a very low yield 
of 7% as outlined in the Scheme 4.8.  
 
 
Scheme 4.8. Synthesis of (S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-2-carboxyethyl)thio)-1H-
imidazol-4-yl)-2-(trimethylammonio) propanoate 4.2. Reagents and conditions. NBS (2.0 eq), N-Bn hercynine 
2.30, DMF, 1-3 hrs at rt, 7%. (method adapted from Khonde et al.5)  
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The 1H NMR spectrum of (S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-2-
carboxyethyl)thio)-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate 4.2 displayed one 
aromatic deshielded signal resonating as a singlet at δH 8.52 ppm, and three α amino acid 
signals resonating as a multiplet in the region from δH 4.31 to 4.17 integrating for two protons 
assigned to the amino acid protons (γ-glutamylcysteine moiety), and from δH 3.97 to 3.83 ppm 
integrating for one proton assigned to α amino acid proton (hercynine moiety). It also 
displayed one singlet signal resonating at δH 3.78 ppm integrating for 9 protons assigned to 
the N,N,N-trimethyl group, and three sets of methylene signals resonated as two doublet of 
doublets at δH 3.61, 3.50 ppm (J = 12.2, 6.5 Hz) and two multiplet signals from δH 2.70 to 2.56 
ppm and δH 2.27 to 2.08 ppm was also observed in the proton NMR of 4.2, thus supporting 
the structure of (S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-2-carboxyethyl)thio)-1H-
imidazol-4-yl)-2-(trimethylammonio)propanoate 4.2.  
Only 2 mg of the extremely hygroscopic thioether 4.2 was recovered after C18 reverse 
column chromatography.  
Mechanistically, it has been proposed that the reaction could proceed through the formation 
of the 5-bromohercynine lactone derivative 4.29 (reactive intermediate).11,12 The latter reacts 
with γ-glutamylcysteine 4.18, the sulfur source, to yield the target thioether 4.1 after 
rearomatization as outlined in the Scheme 4.9. (Mechanism discussed in depth in the chapter 
2). 
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Scheme 4.9. Putative mechanism of the sulfurization of the protected hercynine derivative 2.30 by γ-
glutamylcysteine 4.18. 
 
Before investigating an alternative strategy, a study was conducted to shed light on the 
potential reason for the low yielding synthesis (7%) of the thioether 4.2 via the sulfurization 
reaction as descrived above. NBS/DMF is a strong oxidative medium, therefore it was 
suspected that the oxidation of the γ-glutamylcysteine 4.18, a side reaction competing with 
the sulfurization could be the reason for the low yielding observed.  
 
4.4.4. UV-vis spectroscopic study of the oxidation of γ-GluCys as a competing 
side reaction during sulfurization.  
 
The proposed mechanism as illustrated in the scheme 4.10 above suggests that the reactive 
intermediate is the highly unstable 5-bromolactone 4.29.11,12 During the course of the 
investigation, the bromination step was improved, thus minimising the formation of a 
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multitude of decomposition by-products as a result of the degradation of the lactone 4.29. 
(Improved method described in the chapter 2 and published earlier)5.  
The NBS-mediated bromination was followed by the sulfurization reaction using γ-
glutamylcysteine 4.18 as a sulfur source. It is well known that free thiols can readily oxidize 
to their disulfides. NBS/DMF is an oxidative medium, a possible side reaction is the oxidation 
of γ-glutamylcysteine 4.18 to form its disulfide derivative 4.30. (Scheme 4.10) 
 
Scheme 4.10. Oxidation of γ-GluCys 4.18 in NBS/DMF to form its disulfide derivative 4.30 which can be 
reduced by DTT.  
 
UV-vis spectroscopy was used to monitor the oxidation of the sulfur in the reaction mixture. 
Disulfides do not react with the thiol derivatizing reagent, DTNB (5,5'-Dithio-bis-(2-
nitrobenzoic acid)) while the free thiol 4.35 reacts rapidly with DTNB 4.32 to form the thiol-
TNBA (thio-2-nitrobenzoic acid) adduct 4.38 and TNBA 4.37 by-product which absorbs in the 
characteristic UV-vis region between 412-420 nm.19 Disulfide 4.31 does not react with DTNB 
but it can be reduced to its free thiol derivative 4.35 by DTT.20 (Scheme 4.11 & Scheme 4.12)  
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Scheme 4.11. Disulfide does not react with 5,5'-Dithio-bis-(2-nitrobenzoic acid) (DTNB) [Ellman’s reagent] 
 
Scheme 4.12. Reduction of disulfide to free thiol by DTT (1,4-Dithiothreitol, Cleland’s reagent) and 
derivatization of free thiol compounds (RSH) by 5,5'-Dithio-bis-(2-nitrobenzoic acid) (DTNB) generating TNBA 
adduct detected at λ max 412 – 420 nm.  
 
The oxidation of the sulfur source, γ-GluCys 4.18, led to the formation of γ-GluCys disulphide 
4.30 in NBS/DMF very rapidly, hence less γ-GluCys 4.18 (free thiol) was available for the 
sulfurization, which explains the low yield observed using this approach.  
DTNB was added to a mixture of γ-glutamylcysteine 1 mM/NBS/DMF which were allowed to 
react for 5 min. UV-vis analysis revealed no absorption above 400 nm (yellow line), supporting 
the absence of a detectable free thiol (γ-GluCys 4.18), this suggests that γ-GluCys 4.18 (free 
thiol) is rapidly oxidized to γ-GluCys disulfide 4.30 under these conditions. The characteristic 
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UV-vis band absorption (λmax 412- 420 nm) was revealed only after the reaction mixture was 
reduced by DTT prior to DNTB reaction (blue line), thus further suggested the presence of γ-
GluCys disufide 4.30. (Figure 4.6)  
 
Figure 4.6.  UV-vis spectroscopy monitoring of the oxidation of γ-GluCys 4.18 (1 mM) in presence of NBS/DMF 
(at 25°C).  
 
A comparative study was undertaken using cysteine under the same conditions. The study 
showed that γ-GluCys 4.18 oxidized very rapidly within the first minute while the formation 
of cystine (cysteine disulphide) was complete after 1 h of the reaction (dash blue line). (Figure 
4.7)  
The very rapid oxidation of γ-GluCys 4.18 in NBS/DMF could explain the low yield of 7% of the 
sulfurization as there was almost no free thiol available to react. Noteworthy, Birtic et al. 
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-238 mV.21 This supports the facile oxidation of γ-GluCys 4.30 under reaction conditions thus 
supporting our findings.  
 
Figure 4.7. UV-vis spectroscopy monitoring of the oxidation of cysteine (1 mM) in a presence of NBS/DMF (at 
25°C).  
 
In the other hand, the sulfurization using cysteine as a sulfur source affords a better yield 
(76%) as published earlier,5 (detailed in the chapter 2). This experiment illustrates the fact 
that the formation of cystine (cysteine disulphide)  in a presence of NBS/DMF proceeds 
somewhat slower within 1 hr. 
This route yield the thioether 4.2 in a very low yield, hence this synthetic strategy is not easily 
scalable. Due to the oxidation side reaction, the optimization of the yield was not attempted 
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4.5. Synthesis of (2S)-3-(2-(((R)-2-((S)-4-amino-4-
carboxybutanamido)-2-carboxyethyl)sulfinyl)-1H-imidazol-4-yl)-2-
(trimethylammonio) propanoate. (Method 3) 
 
Due to successful optimisation of the 2-cysteinylhercynine thioether synthesis,5 the 
envisioned strategy to synthesize γ-glutamylcysteinylhercynine sulfoxide 4.1 (EgtC enzyme 
substrate) was based on using a synthon that already has the required thioether moiety. The 
target compound 4.1 can thus be formed by sulfoxidation of the thioether precursor 4.2, 
which in turn is constructed via the amide coupling between the protected γ-glutamate 4.5 
and the protected hercynylcysteine thioether 4.39. (Figure 4.8) 
 
Figure 4.8. Retrosynthetic analysis of (2S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-2-
carboxyethyl)sulfinyl)-1H-imidazol-4-yl)-2-(trimethylammonio) propanoate proceeding through amide 
coupling of the protected hercynylcysteine thioether 4.39 (EgtE enzyme substrate). 
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4.5.1. Synthesis of (2S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-2-
carboxyethyl)sulfinyl)-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate 
 
The synthesis of (2S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-2-carboxyethyl) 
sulfinyl)-1H-imidazol-4-yl)-2-(trimethylammonio) propanoate 4.1 using the described 
retrosynthesis strategy above consisted of four consecutive steps, including protection of the 
staring material, 2-cysteinylhercynine thioether 2.19 (described in the chapter 2), followed by 
amide coupling as well as a sulfoxidation. (Scheme 4.13)  
 
Scheme 4.13.Total synthesis of (2S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-2 carboxyethyl)sulfinyl)-
1H-imidazol-4-yl)-2-(trimethylammonio) propanoate 4.1. Reagents and conditions. (i) a. (Boc)2O, CH3CN/H2O, 
overnight at rt; b. BnBr, DMF, 24 hr at rt, 33%; (ii) a. TFA, DCM, overnight at rt; b. DIC, DIPEA, HOBt, N-Boc α-
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glutamate benzyl ester 4.10, DCM, 24 hr at rt, 88%; (iii) mCPBA, DCM, 6 hr at rt, 72%; (iv) TFA, Pd/C, H2, MeOH, 
2 days at rt, 65%. Overal yield of 14%.  
 
4.5.1.1. Protection of 2-cysteinylhercynine thioether 2.19. (Step 1) 
 
2-Cysteinylhercynine thioether 2.19 was double protected in an one-pot synthesis by Boc and 
benzyl groups under basic conditions (NaOH) according to a method published by Arnaud et 
al.22  
The compound, (S)-1-(benzyloxy)-3-(2-(((R)-3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-3-
oxopropyl)thio)-1H-imidazol-4-yl)-N,N,N-trimethyl-1-oxopropan-2-aminium 4.41 was 
isolated in a low yield of 33% after SiO2 column chromatography without any prior aqueous 
work up. Attempted aqueous work up to remove salts prior to SiO2 gel column 
chromatography purification led to an even lower yield of 18%, suggesting that a considerable 
amount of material was lost during the purification process, as the protected product 4.41 is 
amphiphilic thus making it extremely difficult to efficiently perform organic solvent extraction 
from the aqueous medium.  
The proton NMR spectrum of 4.41 displayed an up-field signal resonating as a singlet at δH 
1.41 ppm integrated for 9 protons suggesting the presence of Boc protecting group. A 
downfield signal resonating as a multiplet from δH 5.36 to 5.03 ppm integrated for 4 protons 
and a further downfield signal resonating as a multiplet from δH 7.27 to 7.42 ppm integrating 
for 10 protons suggesting the presence of two benzyl ester groups, thus confirming the 
successful double protection of 2-cysteinylhercynine thioether 2.19 to form (S)-1-(benzyloxy)-
3-(2-(((R)-3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)thio)-1H-imidazol-4-yl)-
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N,N,N-trimethyl-1-oxopropan-2-aminium 4.41. The 13C NMR spectrum of 4.41 provided 
further evidence of the successful protection as it displayed the correct amount of carbon 
signals supporting the carbon skeleton of 4.41. 
 
4.5.1.2. Synthesis of (S)-1-(benzyloxy)-3-(2-(((R)-3-(benzyloxy)-2-((S)-5-(benzyloxy)-4-((tert-
butoxycarbonyl)amino)-5-oxopentanamido)-3-oxopropyl)thio)-1H-imidazol-4-yl)-N,N,N-
trimethyl-1-oxopropan-2-aminium. (Step 2) 
 
Step 2 entailed the Boc removal followed by the amide coupling in a presence of DIC,23 HOBt 
and DIPEA to yield the amide 4.42 in a yield of 88%.  
Key diagnostic signals in the proton NMR spectrum of 4.42 was the appearance of a 
characteristic Boc signal resonating at δH 1.42 ppm; two methylene signals resonating at δH 
2.19 ppm as a doublet of doublets and as a multiplet from δH 2.08 ppm to 1.89 ppm 
respectively. One α-amino acid proton resonating at δH 3.99 ppm as doublet of doublets of 
doublets belonging to the γ-glutamate moiety. In addition, the proton NMR spectrum 
displayed a multiplet and an overlapped singlet signal resonating from δH 7.46 ppm to 7.25 
ppm integrating for 16 protons assigned for three phenyls and one aromatic imidazole proton 
confirming the structure of 4.42. 13C NMR spectrum provided further evidence as it revealed 
five carbonyl signals resonating at δC 173.1 (2C), 172.0, 171.2, 155.3 and 149.3 ppm, 
consistent with the structure of 4.42.  
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4.5.1.3. Sulfoxidation of the protected γ-glutamyl cysteinyl hercynine thioether. (Step 3) 
 
Catalytic methods to efficiently oxidize sulfur to the sulfoxide using H2O2 is well 
documented.24,25 
It was practical to utilize the relatively non-polar protected 4.42 as a substrate for the 
sulfoxidation, thus allowing the sulfoxidation with a milder oxidant (1.1 mol equivalent of 
mCPBA) in DCM solvent. This approach provides better control thus preventing any over 




Step 3 involved the sulfoxidation of the thioether 4.42 by mCPBA in DCM to yield the sulfoxide 
4.43 in a good yield of 72%. (Scheme 4.14) 
 
Scheme 4.14. Synthesis of (2S)-1-(benzyloxy)-3-(2-(((R)-3-(benzyloxy)-2-((S)-5-(benzyloxy)-4-((tert-
butoxycarbonyl)amino)-5-oxopentanamido)-3-oxopropyl)sulfinyl)-1H-imidazol-4-yl)-N,N,N-trimethyl-1-
oxopropan-2-aminium 4.43. Reagents and conditions. mCPBA, DCM, 6 hr at rt, 72%. 
 
A key diagnostic signal in the proton NMR spectrum of 4.43 was the methylene proton directly 
bonded to the sulfur atom resonating as a multiplet shifted further downfield from the region 
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of δH 2.67 – 2.44 ppm in 4.42 to the region of δH 4.45 – 4.20 ppm as observed in the NMR 
spectrum of 4.43. The strong downfield shift suggests the successful oxidation of sulfur to the 
sulfoxide, which exerts an electron withdrawing strong deshielding effect to its adjacent 
methylene proton. The diastereotopicity introduced by the sulfoxidation was clearly revealed 
as a ratio of 3.5:1 whereby methylene proton adjacent to sulfoxide group resonated as 
multiplets from δH 4.31 to 4.25 ppm for the major diastereoisomer and from δH 4.24 to 4.20 
ppm for the minor diastereoisomer. (Figure 4.9) 
 
Figure 4.9. Portion of 1H NMR spectrum of the sulfoxide 4.43 (between δH 4.7-3.8 ppm) illustrating the 
diastereotopicity.  
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Furthermore, the FTIR spectrum revealed a characteristic strong absorption band at 1048 cm-
1 and 1026 cm-1 corresponding to the sulfoxide functional group, thus supporting the 
successful oxidation of the thioether 4.42 to the sulfoxide 4.43.  
The last step (step 4) entailed the complete removal of protecting groups in a one-pot 
synthesis. The latter was achieved by Pd/C hydrogenation of the protected sulfoxide 4.43 in 
20% TFA/MeOH. The target compound, (2S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-
2-carboxyethyl)sulfinyl)-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate 4.1 was 
obtained in a moderate yield of 65%. The target compound 4.1 was synthesized in an overall 
yield of 14%.  
The evidence of structure of (2S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-2-
carboxyethyl)sulfinyl)-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate 4.1 was furnished 
by spectroscopic techniques. Two dimensional NMR; HSQC and COSY (Figure 4.10) were 
utilized to support a full structural assignment.  
The proton NMR spectrum of 4.1 revealed the disappearance of all three phenyl protons in 
the region of δH 7.40 – 7.25 ppm and Boc signal at δH 1.42 ppm thus confirming the successful 
deprotection of 4.43 to yield the target compound 4.1. The NMR data of 4.1 were consistent 
with those reported by Seebeck.6 However, amino acid residues of a peptide are ionisable 
and the net charge of a peptide is therefore dependent on the pH of the medium. Studies 
revealed that the chemical shifts of a peptide observed in the NMR is strongly pH-dependent, 
which could explain the slightly downfield shift in some chemical shifts of the synthesized 
substrate compared to the natural one.26  
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4.5.1.4. Table 4.1. NMR comparison of synthetic and biosynthetic γ-
glutamylcysteinylhercynine sulfoxide (EgtC enzyme substrate) 4.1. 
 
Positions Synthetica 
1H NMR 400 MHz 
Biosyntheticb 
1H NMR 600 MHz 
Syntheticb 
13C NMR 101 MHz 
Biosynthetica 
13C NMR 
1   174.9   
2 4.01 (m, 1H) 3.97 (1H, m) 85.6 79 
3 3.63 (dd, J = 11.6, 4.1 
Hz, 1H, H-3a) 
3.53 (dd, J = 11.6, 8.6 
Hz, 1H, H-3b) 
3.18-3.38 (m, 2H, 
pro-R and pro-S) 
27.7  27 
2'   133.9    
4'                      129.7  
5' 7.65 (s, 1H) 7.29 (s, 1H) 128.8 124 
1'' 4.28 (dt, J = 13.2, 6.7 
Hz, 2H, major 
diastereoisomer), 4.24 
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2'' 4.48 (m, 1H) 3.97 (1H, m) 56.1 56 
3''   182.0  
1'''   177.1   
2''' 2.83 – 2.58 (m, 2H) 2.48 (t, J = 7.6 Hz, 2 
H) 
36.7  33 
3''' 2.41 – 2.21 (m, 2H) 2.16 (m, 2 H) 29.4  28 
4''' Overlapped 4.48 (m, 
1H) 
3.92 (t, J = 6.33 Hz, 2 
H) 
53.7  55 
5'''   182.0   
N-methyl 3.94 (s, 9H) 3.15 (s, 9 H) 52.1  54 
a Recorded in D2O (pD non determined)     b Taken from Seebeck6 (recorded in D2O, 20°C, pD = 5.0) 
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Figure 4.10. COSY 1H - 1H NMR spectrum of (2S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-2-
carboxyethyl)sulfinyl)-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate or γ-glutamylcysteinylhercynine 




Three possible synthetic routes were explored and discussed in depth in this chapter, 
resulting in the successful first synthesis of the target compound, (2S)-3-(2-(((R)-2-((S)-4-
amino-4-carboxybutanamido)-2-carboxyethyl)sulfinyl)-1H-imidazol-4-yl)-2-
(trimethylammonio)propanoate 4.1.  
Despite the fact that the method 2 utilizing γ-glutamylcysteine 4.18 as a sulfur source for the 
sulfurization, led to the synthesis of the thioether intermediate 4.1 in a low yield of 7%, this 
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approach can still be improved. Several improvements can be conducted such as the 
optimization of the reaction conditions, including slow addition of γ-glutamylcysteine (sulfur 
source), lower temperature to reduce the rate of the oxidation side reaction or the addition 
of a easy removable or recyclable reducing reagent in situ thus allowing the availability of the 
free sulfur 4.18 required for the sulfurization reaction.   
The availability of this metabolite (EgtC enzyme substrate) will provide a tool for future 
tuberculosis drugs discovery research, thus paving the way for further research to shed light 
on the role played by ergothioneine in the survival of Mycobacterium tuberculosis.  
Very recently, Seebeck et al. solved the co-crystal complex of EgtCC2A (1.8 A°) complexed with 
the natural sulfoxide 4.1, thus establishing the chirality of the natural sulfoxide 4.1 (EgtC 
enzyme substrate) to be of S-configuration for the sulfur atom.3 Even though asymmetric 
sulfoxidation of thioether is well documented, it was not attempted in this synthetic 
route.27,28 It is noteworthy that further studies can be conducted including the asymmetric 
sulfoxidation of the protected thioether intermediate 4.42 in order to yield an enriched 
diastereoisomer of the EgtC enzyme substrate 4.1, which will shed more light on the sulfoxide 
substrate-EgtC enzyme interactions and specificity.  
Amongst all the three synthetic routes, it appeared that the total synthesis of the 
mycobacterial EgtC enzyme substrate (glutamine amidohydrolase enzyme substrate) 
proceeding through amide coupling of EgtE enzyme substrate (method 3), is the best as it is 
scalable while utilizing overall less expensive materials, one drawback would be that this 
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route involves multiple steps (including the synthesis of the key intermediate, 2-
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In this chapter, the main focus will be to address interesting advances conducted in the field 
of histidine like compounds. After successfully developed interesting synthetic strategies for 
the synthesis of ergothioneine and its biosynthetic pathway metabolites as discussed in 
previous chapters. It was therefore decided to apply that knowledge gained in the synthesis 
of ovothiols, structurally similar to ergothioneine, with a N-methyl at the more hindered 
position of the imidazole ring (N-3 position) and a thiol group at the 5-position. 
 
5.1. Introduction  
 
Ovothiols are 3-methyl-5-mercaptohistidines derivatives first isolated from marine 
invertebrates. It exists as three types of ovothiols, denoted A, B and C, they differ amongst 
them by their degree of methylation at the α-amino group. Ovothiol A has a free α-amino 
group, while ovothiol B and C are α-mono and α,α-dimethylated, respectively. (Figure 5.1) 
 
 
Figure 5.1. Structure of ovothiols (A, B & C). 
 
The thiolate group of ovothiol exhibits the lowest basicity amongst all natural thiols, with a 
pKSH of 1.42 that makes it readily oxidizable, hence ovothiol is a potent natural antioxidant.1  
                       R1             R2 
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Ovothiols were first isolated from eggs and ovarian tissues of marine invertebrates by Turner 
et al.2 Ovothiol A isolated from starfish Evasterias troschelii, whereas ovothiol B and C were 
isolated from the scallop Chlamys hastate and sea urchin Strongylocentrotus purpuratus, 
respectively.2  
It has been suggested that ovothiols protect trypanosomatid parasites, such as Leishmania 
donovani and Crithidia fasciculata from oxidative stress produced by their macrophages 
during infection.3 It is reported that ovothiol C is present in millimolar concentration in sea 
urchin eggs and are responsible for the protection of eggs during oxidative envelope 
maturation.2 Ovothiols display interesting physical properties that have encouraged the 
scientific community to study its nutritional benefits for humans.  
Ovothiol analogues were synthesized and their in vitro antioxidant properties evaluated, 
interestingly, 1-methyl-2-(3-trifluoromethylphenyl)-4-mercaptoimidazole has been shown to 
be a potent agent in mammalian cerebral protection.4 
Moreover, recent research demonstrated that ovothiol A could be active against the 
proliferation of Hep-G2, human liver cancer cells.5 
 
5. 2. Biosynthesis of Ovothiols 
 
The biosynthesis of ovothiol involves three sequential steps. The enzyme OvoA, a sulfoxide 
synthase (characterized from the bacterium Erwinia tasmaniensis and the pathogenic protist 
Trypanosoma cruzi) catalyzes the first step of the biosynthesis. That initial step involves the 
oxidative coupling between cysteine and histidine to generate S-(5’-L-histidyl)-L-cysteine 




sulfoxide.1 It is argued that OvoA is similar to EgtB; the latter is a mononuclear non-heme iron 
enzyme which catalyzes the oxidative sulfurization of hercynine by γ-glutamylcysteine in the 
biosynthesis of ergothioneine.6,7 OvoA and EgtB are both iron-dependent enzymes and they 
share a homologue domain with formylglycine-generating enzymes.8  
OvoB catalyzes the second step, the C-S bond lysis of S-(5’-L-histidyl)-L-cysteine sulfoxide to 
produce 5-mercaptohistidine. The latter is believed to be methylated by a C-terminal 
methyltransferase domain. (Scheme 5.1)  
However, the first enzyme implicated in the biosynthesis of ovothiols, OvoA, has been 
proposed to be a potential drug target for anti-infective therapy.8  
 
Scheme 5.1. Ovothiols biosynthesis pathway. 
 




5.3. Ovothiol synthesis 
 
Unfortunately, the availability of ovothiol A is limited, its isolation from natural marine 
sources such as sea urchin and algae is labour intensive and not cost effective.2,9 
However, ovothiol A total synthesis methods are well documented, but these procedures are 
not simple and require multiple steps.10,11 This is mainly due to the fact that the 4-
mercaptohistidine core is constructed from simple starting materials such as N-methyl-prop-
2-yn-1-amine or 1H-imidazole rather than L-histidine, which is more closely related. (Figure 
5.2)  





Figure 5.2. Previous ovothiols total synthesis routes proposed by Ohba et al.11 (right) and Holler et al.10 (left) 
Reactant a is (R)-2,5-dihydro-3,6-diethoxy-2-isopropylpyrazine, n-butyllithium. (Scheme adapted from 
Mirzahosseini et al.12) 




However, recently Mirzahosseini et al. claimed to have developed a cost effective synthesis 
of ovothiol A starting with L-histidine as a starting material. That strategy is attractive as it 
reduces drastically the number of steps, including many synthetic challenges.12  
 
5.4. Design and synthesis of ovothiol A using L-histidine as a starting 
material 
 
Due to the synthesis interest in ergothioneine, knowledge and skills gained is applicable to 
the synthesis of ovothiols. To this end, two main reactions, regioselective N-methylation and 
bromination, were investigated and will be thoroughly discussed.  
 
5.4.1. Retrosynthetic analysis  
 
The ovothiol A retrosynthetic strategy involves the regioselective thionation at the 5-position 
of the imidazole heterocyclic ring using two synthons, (S)-2-amino-3-(4-bromo-1-methyl-1H-
imidazol-5-yl) propanoic acid 5.2 and a sulfur source 5.3. The Intermediate 5.2 is constructed 
by regioselective bromination at 5-position of the imidazole heterocyclic ring of N∏-methyl-L-
histidine 5.4 which is derived from L-histidine 5.5 a simple starting material and biosynthetic 
precursor of the target compound, ovothiol 5.1 (Figure 5.3). 





Figure 5.3. Ovothiol A retrosynthetic analysis. 
  
5.4.2. Regioselective methylation at N-3 position of the imidazole heterocyclic 
ring 
 
Histidine possesses three ionizable functions, acidic carboxylic group (pKa1 1.82), basic amino 
acid group (pKa2 9.17) and imidazole side chain (pKa3 6.00), with an isoelectronic point pI of 
7.59 whereby histidine exists predominantly as a zwitterion.  
The imidazole heterocyclic ring exists in three exchangeable tautomeric conformations in 
aqueous buffer solutions. Two tautomers (denoted ε and δ) are neutral predominantly at high 
pH and act as hydrogen bond acceptors or donors, whereas the cationic tautomer is dominant 
at low pH.13 (Figure 5.4) 
 
 





Figure 5.4. pKa of histidine ionisable functions (left), imidazole tautomeric conformations (right).  
 
The first challenge was to achieve a selective methylation at the hindered N-3 position of the 
imidazole ring. In order to achieve that task, it was imperative to first and foremost protect 
any competing functional groups, the amino and carboxylic acid, respectively groups, thus 
directing the methylation at the desired position.  
Van Den Berge et al. developed an attractive method for the regioselective N-methylation of 
substituted imidazole derivatives to furnish the less stable, most sterically hindered isomer.14 
These authors developed a mild sequence strategy which involved a protection, methylation 
and deprotection to yield the more hindered N-methylated imidazole isomer, the 1,5 isomer 
as the major product. (Scheme 5.2) 
 
Scheme 5.2. Van Den Berge et al.14 N-methylation strategy. Reagents and conditions. (i) PhSO2Cl, Et3N, CH3CN, 
8h; (ii) MeOTf, 24 hr; (ii) MeBuNH, heated at 80 °C.  
 
  




The protecting group strategy is crucial for the success of this methodology. The proton in the 
imidazole heterocyclic ring is delocalised and a rapid tautomerism equilibrium of (NH)-
derivatives is established between the two nitrogen atoms.14 Due to the fact that the N-
alkylation of the less hindered nitrogen is relatively faster, the N-alkylation by a relatively 
smaller group leads to a mixture of the N-1 methylated (major) and the N-3 methylated 
(minor) product. But using a bulky N-alkylating group leads to almost exclusively one isomer 
at less hindered N-1 position, thus will direct the next alkylation to the more hindered N-3 
position of the imidazole ring.14 It is noteworthy that the regioselective N-alkylation is only 
governed by steric factors as electronic properties of substituents have no significant effect 
(Scheme 5.3.  14  
 
Scheme 5.3.  Steric hindrance directs N-alkylation on the imidazole ring.  
 
The first step entailed the complete protection of L-histidine (starting material) by a bulky 
protecting group. Subsequently N-3 regioselective methylation of the protected histidine. 




However, several protecting groups as well as methylating reagents were investigated and 
will be discussed thoroughly. 
 
5.4.2.1. Synthesis of tert-butyl (S)-4-(3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-3-
oxopropyl)-1H-imidazole-1-carboxylate 
 
Bulky tert-butyl carbonate (Boc) and benzyl groups were chosen to protect the amino and 
carboxylic acid groups respectively prior to attempted regioselective N-methylation, due to 
their relatively well documented easy introduction and removal.  
The synthesis of tert-butyl (S)-4-(3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-
1H-imidazole-1-carboxylate was conducted in two consecutive steps, double Boc protection 
of L-histidine 5.5 to yield Nα,NꞆ-bis(tert-butoxycarbonyl)-L-histidine 5.6 in a yield of 63%. 
Subsequent benzyl esterification of Nα,NꞆ-bis(tert-butoxycarbonyl)-L-histidine 5.6 in DMF in 
the presence of Cs2CO3 afforded the target compound, tert-butyl (S)-4-(3-(benzyloxy)-2-((tert-
butoxycarbonyl)amino)-3-oxopropyl)-1H-imidazole-1-carboxylate 5.7 in an excellent yield of 
91%. (Scheme 5.4) 
  
Scheme 5.4.  Synthesis of tert-butyl (S)-4-(3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-1H-
imidazole-1-carboxylate. Reagents and conditions. (i) (Boc)2O (2 eq), NaHCO3, H2O/THF (2:1), 24 hr at rt, 63%;15 
(ii) Cs2CO3 (1.5 eq), BnBr (1.02 eq)/DMF, 22 hr at rt, 91%.  
 




Evidence of successful double Boc protection was provided by a proton NMR spectrum of 5.6 
which revealed the presence of two singlets, one resonated at δH 1.61 ppm integrating for 9 
protons slightly deshielded and attributed to the Boc group of the imidazole ring, while the 
second resonated at δH 1.46 ppm integrating for 9 protons assigned to the Boc on the α-amino 
group. The 13C NMR spectrum of 5.6 revealed twelve carbon signals resonating at δC 173.1, 
155.2, 146.2, 137.0, 136.5, 115.6, 86.4, 79.7, 52.8, 29.7, 28.4 and 27.8 ppm respectively, thus 
supporting the carbon skeleton of Nα,NꞆ-bis(tert-butoxycarbonyl)-L-histidine 5.6.  
A key diagnostic signal in the 1H NMR spectrum of tert-butyl (S)-4-(3-(benzyloxy)-2-((tert-
butoxycarbonyl)amino)-3-oxopropyl)-1H-imidazole-1-carboxylate 5.7 was the appearance of 
a multiplet that resonated from δH 7.38 ppm to 7.27 ppm integrating for 5 protons and a 
methylene proton that resonated as a quartet (J = 12.3 Hz) at δH 5.14 ppm, thus supporting 
successful benzyl esterification. The 13C NMR spectrum of tert-butyl (S)-4-(3-(benzyloxy)-2-
((tert-butoxycarbonyl)amino)-3-oxopropyl)-1H-imidazole-1-carboxylate 5.7 recorded the 
correct numbers of carbon signals thus supporting the carbon skeleton identity of the target 
compound 5.7. Furthermore, the EI+ mass spectrum displayed the molecular ion peak at m/z 
445.1 [M]+ calculated for C23H31N3O6 445.2 [M]+. The fragments corresponding to the loss of 
one Boc and two Boc groups were also present in the spectrum at m/z 345.1 and 244.0 
respectively, thus providing further evidence of the structure of tert-butyl (S)-4-(3-
(benzyloxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-1H-imidazole-1-carboxylate 5.7.  
 
 








imidazole-1-carboxylate 5.7 in hand, the next challenge was to attempt a regioselective 
methylation at the hindered N-3 position of the imidazole heterocyclic ring. Several conditions 
were investigated, initially the reaction was carried out similarly to the conditions published 
by Mirzahosseini et al.12 Accordingly, 2.5 mol equivalents of iodomethane in methanol (at 0 
°C) was utilized, but did not reveal any new product, only the starting material was recovered. 
Therefore alternative conditions were explored as summarized in the Table 5.1. 
Parameters such as temperature, solvents, reaction time and mol equivalents of 
iodomethane were thoroughly investigated, unfortunately none proved to be successful.  
 
         Solvent         MeI (eq)          Temp (°C)           Time              Yield (%)a     Product(s) isolated 
 
           THF                        1.2-3                       rt                   Up to 2 days                 -                          No reaction 
            THF                           3                           60                    2 days                        85                       5.9:5.10 (1:1 ratiob)  
           DMF                       1.2-3                       rt                   Up to 2 days                 -                          No reaction 
           DMF                        1.2                         70                    2 days                         69                     5.9:5.10 (1.5:1 ratiob) 
     
a Isolated yield after SiO2 gel column purification. b ratio determined by NMR. 
Table 5.1. Methylation of tert-butyl (S)-4-(3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-1H-
imidazole-1-carboxylate 5.7 under various reaction conditions.   




The best conditions were found to be the use of 3 mol equivalents of iodomethane in THF 
solvent, refluxing at 60 °C for longer time up to 2 days thus affording a mixture of two isomers 
(5.9 & 5.10) inseparable by SiO2 gel chromatography, in a good yield of 85%. (Scheme 5.5)  
 
Scheme 5.5. Methylation of tert-butyl (S)-4-(3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-1H-
imidazole-1-carboxylate 5.7. Reagents and conditions. CH3I, THF, reflux at 60 °C, up to 2 days, 85%.  
 
The major challenge for this reaction is the parallel Boc deprotection on the imidazole 
heterocyclic ring. Mirzahosseini et al. also reported a similar parallel Boc deprotection to the 
methylation when treating Nα,NꞆ-bis(tert-butoxycarbonyl)-L-histidine with MeI in methanol 
even under milder conditions.12  
It was therefore suspected that the labile Boc group on the imidazole ring migrated before 
the methylation occurred, this probably explains the fact that this reaction yields a mixture of 
these two isomers. It is noteworthy that TLC analysis showed an additional very polar spot 




which was isolated and the NMR analysis revealed the product to be the dimethyl imidazolium 
salt, (S)-4-(3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-1,3-dimethyl-1H-
imidazol-3-ium 5.11, an unavoidable contamination as a large excess of iodomethane were 
utilized, the latter by-product was successfully removed during the purification process. 
Key diagnostic signals in the 1H NMR spectrum of the isolated products (5.9 & 5.10) were the 
appearance of two methyl signals resonating at δH 3.88 ppm and 3.85 ppm respectively, thus 
confirming the presence of the two regioisomers, benzyl Nα-(tert-butoxycarbonyl)-NꞆ-methyl-
L-histidinate 5.9 and benzyl Nα-(tert-butoxycarbonyl)-N∏-methyl-L-histidinate 5.10, in the 
ratio of 1:1 based upon integration of their respective methyl peaks. The 1H NMR spectrum 
also displayed two methylene proton signals, both resonating as doublet of doublets at δH 
3.43 ppm and 3.29 ppm respectively. A disappearance of the t-Boc signal resonating at δH 
1.61 ppm in 1H NMR spectrum of tert-butyl (S)-4-(3-(benzyloxy)-2-((tert-
butoxycarbonyl)amino)-3-oxopropyl)-1H-imidazole-1-carboxylate 5.7 confirmed the parallel 
Boc removal.  
 
5.4.2.3. Methylation of tert-butyl (S)-4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-
oxopropyl)-1H-imidazole-1-carboxylate 
 
Similar methylation conditions were performed on a different substrate, tert-butyl (S)-4-(2-
((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1H-imidazole-1-carboxylate 5.12 to 
determine the scope of this reaction.  





carboxylate 5.12 was treated with excess of iodomethane (2 mol equivalents) in THF solvent. 
TLC showed that the reaction proceeded very slowly at room temperature, even when the 
reaction was allowed to react for up to 2 days, only 21% of the product was recovered after 
silica gel chromatography since there were a lot unreacted starting material. However, the 
temperature was not raised hoping to avoid the formation of two regioisomers. Again, even 
at milder conditions, NMR analysis revealed the presence of the two regioisomers. These 
results suggest that the removal of the Boc group on the imidazole ring prevented the 
regioselective N-methylation of the imidazole heterocyclic ring under these reaction 
conditions. (Scheme 5.6) 
 
Scheme 5.6. Methylation of tert-butyl (S)-4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1H-
imidazole-1-carboxylate 5.12. Reagents and conditions. MeI (2 eq), THF, rt for 2 days, 21%. 
 
The 1H NMR spectrum of the isolated product provided strong evidence of the presence of 
two isomers (5.13 & 5.14). Key diagnostic signals were the methyl protons, of which two 
methyl group protons resonated at δH 4.00 ppm and 3.96 ppm, attributed to the N-methyl 
imidazole.  The other methyl proton resonating at δH 3.80 ppm assigned to the methyl ester 
group. In addition, the disappearance of singlet around δH 1.61 ppm confirmed the removal 
of Boc on the imidazole ring.  




Based upon the results, it has been concluded that the Boc group was not the best protecting 
group to achieve selective regioselective N-methylation of the imidazole as it leads to a 
mixture of regioisomers probably due to its labile nature under the reaction conditions 
especially using iodomethane as the alkylating reagent.  
Therefore an alternative methylating reagent as well as other bulky protecting group that are 
more stable under the reaction conditions were investigated.  
 
5.4.2.4. Methylation of Nα,NꞆ-dibenzyl-L-histidinate 
 
Due to the failure of regioselective methylation at the first attempt on histidines derivatives 
5.7 and 5.12, an alternative bulky protecting group were utilised. Thus, a benzyl group which 
is more stable under acidic and basic conditions was utilized as a substitute for the Boc 
protecting group.  
Histidine methyl ester hydrochloride 5.15 was benzylated at the N-α and N-1 imidazole 
positions in a good yield of 81%, by treatment of α-amino ester 5.15 with 2.2 molar 
equivalents of benzyl bromide under basic conditions (NaOH) in a mixture of H2O:THF (1:2). 
(Scheme 5.7) 
 
Scheme 5.7. Synthesis of methyl Nα,NꞆ-dibenzyl-L-histidinate 5.16. Reagents and conditions. (i) Benzyl bromide 
(2.2 eq), NaOH (2.2 eq)/H2O:THF (1:2), 24  hr at rt, 81%. 




The proton NMR specctrum of methyl Nα,NꞆ-dibenzyl-L-histidinate 5.16 revealed two signals 
resonating both as a multiplet, integrating  for 5 protons each, from δH 7.30 ppm to 7.27 ppm 
and from δH 7.15 ppm to 7.08 ppm, consistent with the presence of two phenyl groups. The 
proton NMR spectrum of 5.16 also displayed two methylene protons, one more deshielded, 
resonating as a quartet (J = 14.5 Hz) at δH 5.43 ppm assigned to the methylene attached to 
the N-1' of the imidazole, and the other methylene resonating as two sets of doublets at δH 
3.72 ppm (J = 13.7 Hz) and at δH 3.51 ppm (J = 13.7 Hz) assigned to the methylene on the N-α 
amino group. Thus supporting the successful double benzylation of histidine methyl ester 
hydrochloride 5.15. (Figure 5.5 )  
 
Figure 5.5.  1 H NMR spectrum of methyl Nα,NꞆ-dibenzyl-L-histidinate 5.16 in CDCl3  at 400 MHz. 
 
The 13C NMR spectrum of methyl Nα,NꞆ-dibenzyl-L-histidinate 5.16 recorded the right amount 
























































































































































128.7, 127.8, 119.8, 58.6, 54.9, 53.4, 51.1 and 33.5 ppm, thus confirming the carbon skeleton 
of Nα,NꞆ-dibenzyl-L-histidinate 5.16.  
Finally with methyl Nα,NꞆ-dibenzyl-L-histidinate 5.16 in hand, the regioselective methylation 
was attempted. Many conditions were investigated, using THF as solvent  and iodomethane 
as alkylating reagent at 60 °C. After 2 days neither TLC nor NMR analysis did not reveal any 
new product and only starting material was recovered. This suggested that methyl Nα,NꞆ-
dibenzyl-L-histidinate 5.16 is highly hindered therefore the methylation at N-3 position of the 
imidazole is a difficult task. (Scheme 5.8) 
 
Scheme 5.8.  Attempted N-3 regioselective methylation of methyl Nα,NꞆ-dibenzyl-L-histidinate 5.16.  
 
Van Den Berge et al. used methyl triflate, a more powerful methylating reagent than 
iodomethane to successfully alkylate at the hindered nitrogen of the imidazole heterocyclic 
ring.14 However, the authors were unsuccessful in the attempted N-methylation of the very 
hindered N-sulfonyl phenyl protected imidazole.  Alternative alkylating reagents such as ethyl 
triflate, ethyl bromoacetate, or benzyl bromide were also unsuccessful.14 Thus suggesting that 
the more hindered the imidazole ring is the more challenging the N-methylation.  
A more powerful methylating reagent, dimethyl sulfate, was subsequently considered. 
Finally, the regioselective N-methylation at the N-3 position of the imidazole was successfully 
achieved in a good yield of 72%. (S)-1-benzyl-4-(2-(benzylamino)-3-methoxy-3-oxopropyl)-3-




methyl-1H-imidazol-3-ium 5.17 was obtained by milder reacting methyl Nα,NꞆ-dibenzyl-L-
histidinate 5.16 with dimethyl sulfate as alkylating reagent in anhydrous DMF. (Scheme 5.9) 
 
Scheme 5.9.  Synthesis of (S)-1-benzyl-4-(2-(benzylamino)-3-methoxy-3-oxopropyl)-3-methyl-1H-imidazol-3-
ium 5.17. Reagents and conditions. (i) Me2SO4, DMF, 24-48 hr at rt, 72%. 
 
The evidence of successful regioselective methylation at N-3 position on the imidazole was 
provided by the proton NMR spectrum of (S)-1-benzyl-4-(2-(benzylamino)-3-methoxy-3-
oxopropyl)-3-methyl-1H-imidazol-3-ium 5.17 which revealed the appearance of a methyl 
proton resonating as a singlet at δH 3.54 ppm deshielded due to its presence on the imidazole 
ring (Figure 5.6).  
 





Figure 5.6. Expanded 1H NMR spectrum showing successful regioselective methylation of 5.16 to yield 5.17 in 
CDCl3  at 400 MHz. 
 
The 13C NMR spectrum of (S)-1-benzyl-4-(2-(benzylamino)-3-methoxy-3-oxopropyl)-3-methyl-
1H-imidazol-3-ium 5.17 recorded the correct amount of carbon signals, resonating at δC 
171.1, 138.3, 133.4, 132.2, 129.5, 129.0, 127.8, 120.0, 58.8, 54.9, 53.4, 51.9, 51.1 and 24.6 
ppm, thus supporting the carbon skeleton of 5.17 as shown in the Figure 5.7.  
 





Figure 5.7. 13C NMR spectrum of (S)-1-benzyl-4-(2-(benzylamino)-3-methoxy-3-oxopropyl)-3-methyl-1H-
imidazol-3-ium 5.17 in CDCl3  at 101 MHz. 
 
Furthermore, two dimensional NMR, HSQC, COSY (Figure 5.8) and HMBC (Figure 5.9) were 
utilized for a full structural assignment.  





Figure 5.8. COSY-NMR spectrum of (S)-1-benzyl-4-(2-(benzylamino)-3-methoxy-3-oxopropyl)-3-methyl-1H-
imidazol-3-ium 5.17 in CDCl3. 
 
2D-HMBC NMR spectrum in particular, clearly shows diagnostic 1H-13C correlations on the 
imidazole heterocyclic ring; a 3J through bond coupling between the methyl protons on the 
nitrogen at the N-3' position and the C4' carbon (blue) as well as another 3J through-bond 
coupling with the C2' carbon (red), hence unambiguously confirmed the position of the 
methyl at the hindered N-3 position of the heterocyclic imidazole ring. (Figure 5.9)  
All the remaining 1H-13C correlations were consistent with the structure of (S)-1-benzyl-4-(2-
(benzylamino)-3-methoxy-3-oxopropyl)-3-methyl-1H-imidazol-3-ium 5.17.  






Figure 5.9. A portion expanded HMBC-NMR spectrum of (S)-1-benzyl-4-(2-(benzylamino)-3-methoxy-3-
oxopropyl)-3-methyl-1H-imidazol-3-ium 5.17 in CDCl3. 
 
Finally, the EI+ mass spectrum displayed the molecular ion peak at m/z 364.2 [M]+ calculated 
for C22H26N3O2 364.2 [M]+ and the base peak at m/z 348.2 calculated for C21H22N3O2 348.2 [M-
CH3-H]+ corresponding to the loss one methyl and proton, thus providing further evidence of 
the structure of (S)-1-benzyl-4-(2-(benzylamino)-3-methoxy-3-oxopropyl)-3-methyl-1H-
imidazol-3-ium 5.17.  




Having successfully synthesized (S)-1-benzyl-4-(2-(benzylamino)-3-methoxy-3-oxopropyl)-3-
methyl-1H-imidazol-3-ium 5.17, the next challenge was to attempt the regioselective 
bromination at the 5-position of the imidazole.  
 
5.4.3. Bromination at the 5-position of the imidazole ring  
 
Bromination at the 5-position of the imidazole ring of (S)-1-benzyl-4-(2-(benzylamino)-3-
methoxy-3-oxopropyl)-3-methyl-1H-imidazol-3-ium 5.17, was envisaged as achievable by 
treatment with mild brominating reagent, NBS in acetonitrile solvent. A slight excess of NBS 
(1.1 mol equivalent) was added portion wise over 5-10 min period at 5°C to minimise any 
possible di-brominated and poly brominated side products. After 5 hr, TLC analysis of the 
reaction mixture revealed the formation of a product migrating as a single new spot. The NMR 
analysis of the reaction mixture revealed clearly the disappearance of the proton H-5' at δH 
6.42 ppm, thus providing further evidence of the successful bromination. Unfortunately, 
several attempts to isolate the brominated product 5.18 failed, as it decomposed upon either 
aqueous work up or SiO2 gel chromatography.  
Therefore, the crude brominated product 5.18 could be used as substrate for thionation 
reaction without further purification.  
It is noteworthy that mechanistically the bromination does not proceed through a lactone 
intermediate as the carboxylic acid is not free, hence the carbonyl group could not cyclise 
with the imidazole ring.16  




It is well known that halo aromatic compounds, in particular (5 or 2-bromo) imidazole 
derivatives do not smoothly undergo S-alkylation. The substitution of the bromo atom by 
sulfur derivative requires harsh conditions as highlighted by the work of Iddon and co-
workers.17 These authors successfully S-alkylated 2,4,5-tribromo-1-ethoxymethylimidazole 
with sodium methanethiolate in HMPA solvent at a temperature of 82 °C. However, this 
reaction seemed to be solvent-dependent, when HMPA was substituted by DMF the yield 
dropped drastically from 44% to 3%.17 
Noteworthy, Mirzahosseini et al. utilized a stable surfur source, (4-tolyl) methanethiol to 
substitute the bromine atom of an activated imidazole ring by sulfur via modified Ullman 
reaction.12 The authors claimed that the addition of CuI as a catalyst resulted in no reaction. 
Noticeably the reaction mixture turned deep purple, thus speculating the formation of a 
stable complex resulting from the chelation between the imidazole ring of histidine and 
transition metal (Cu).  
Whereas Ohba et al. treated the activated imidazole intermediate, 4-bromo-1-methyl-1H-
imidazole-5-carbaldehyde with either thiophenol, (4-methoxyphenyl) methanethiol or 1-
naphthalenethiol under basic conditions (NaH) in DMF solvent to successfully S-alkylate at the 
5-position of the imidazole heterocyclic ring.11 (Figure 5.2).  
Unfortunately, the removal of the para-methyl benzyl protecting group required the use of 
mercury (II) trifluoroacetate in TFA and toxic H2S gas.10-12 This led to unavoidable mercury 
contamination of the target compound, hence ovothiol is isolated as a trifluoroacetate salt. 
Moreover, these harsh conditions could probably lead to a racemization of the final product.  




Very recently, Daunay et al reported an oxidative introduction of sulfur regioselectively at the 
5-position of the imidazole heterocyclic ring using thioacetic acid as a sulfur source.18 The 
method involved bromination of the histidine derivative bearing a free carboxylic acid group 
using either bromine or NBS, prior to sulfurization. The deacetylation, step of the sequence 
was conducted by refluxing at 90°C in water in a presence of a large excess of 3-
mercaptopropionic acid (10 mol equivalents).18 This method appeared very attractive for the 
completion of the total synthesis of ovothiols.  
 
Scheme 5.10. Regioselective sulfurization at the 5-position of imidazole ring using thioacetic acid according to 
Daunay et al.18 
 
However, the S-alkylation of the synthesized brominated product, (S)-1-benzyl-4-(2-
(benzylamino)-3-methoxy-3-oxopropyl)-5-bromo-3-methyl-1H-imidazol-3-ium 5.18 using 
sulfur sources such as thioacetic acid, (4-methoxyphenyl) methanethiol or (4-tolyl) 
methanethiol was not attempted, bearing in mind that our goal was only to synthesize 
intermediates toward the synthesis of ovothiols while applying skills and knowledge gained 
during the synthesis of ergothioneine.  
 




5.4.4. Summary  
 
Advances toward the synthesis of ovothiol A was successfully conducted and several chemical 
synthetic challenges were thoroughly discussed. Successful regioselective methylation at the 
N-3 position of the imidazole heterocyclic ring was achieved using dimethyl sulfate as an 
alkylating reagent. The benzyl group was found to be the best protecting group for the N-1 
atom of the imidazole ring. Bromination at the 5-position of the imidazole ring was 
successfully achieved, even though the brominated product 5.18 was found to be unstable 
upon work up or SiO2 gel purification.  
 
It is believed that the thionation reaction requires a stable sulfur to be achieved successfully 
since the S-alkylation of the imidazole ring is not straightforward. However, the newly 
published work by Daunay et al could be used to investigate regioselective S-alkylation at the 
5-position of the imidazole ring. Hence, the regioselective S-alkylation subsequent to 
regioselective N-methylation and bromination strategy developed in this work could lead to 
the synthesis of ovothiols, in fewer steps, without the need of tedious purification process, 
more intriguingly utilizing L-histidine, the ovothiol’s biosynthetic precursor as a simple 
starting material (Scheme 5.11 ). 





Scheme 5.11.  Proposed ovothiol A synthesis route. Reagents and conditions. (i) Benzyl bromide (2.2 eq), NaOH 
(2.2 eq)/H2O:THF (1:2), 24 hr at rt, 81%; (ii) Me2SO4, DMF, 24-48 hrs at rt, 72%; (iii) NBS, CH3CN, 0 °C to rt (iv) 
thionation and benzyl deprotection (v) air (O2), For analytical purpose ovothiol A has to be intentionally oxidized 
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The natural thiohistidines ergothioneine and ovothiols are powerful antioxidants and the 
interest in them have been increasing over the last few decades. Studies conducted 
independently by two research groups, Steyn lab1,2 and Sao emani and co-workers,3 
suggested that enzymes implicated in the biosynthesis of ergothioneine could act as potential 
anti-tuberculosis drugs target.  
 
The increasing benefit of ergothioneine in human as well as its possible link to bacteriological 
disease such as tuberculosis is of interest. However, its availability is somewhat limited, 
isolation from natural sources is a troublesome task and the available total synthesis was 
hampered by many drawbacks.4,5 This thesis described an improved synthesis of 
ergothioneine addressing many drawbacks of previous methods, hence achieving a good 
overall yield of 54-70%, while proceeding at milder conditions 25-40 °C (energy saving).6,7  
 
Early ergothioneine biosynthetic pathway elucidation studies utilized radiolabelled 
intermediates. However, due to the safety risk associated with these radiological techniques, 
the stable deuterated labelled intermediates were synthetized as alternative. These stable 
deuterated isotopic labelled intermediates are valuable internal standards in the quantitation 
of pathway metabolites during external stimuli, drug treatment or metabolomics studies.  
 




EgtE (PLP-dependent enzyme) catalysed the last step of the ergothioneine biosynthesis 
pathway that involves C-S lyase of 2-cysteinylhercynine sulfoxide to form ergothioneine.8 The 
inhibition of PLP-dependent enzymes has led to discovery of many drugs in the market, one 
successful example is difluoromethylornithine (DFMO), an efficient drug against Human 
African trypanosomiasis (HAT).9,10 This thesis describes the synthesis of the natural EgtE 
enzyme pathway substrate, 2-cysteinylhercynine sulfoxide and its related compounds were 
successfully synthesized, hence many experiments were conducted in a presence or absence 
of cell-free Mycobacterium smegmatis enzymatic preparations to better understand the C-S 
lyase mechanism. During the course of this study, an important observation was established 
that 2-cysteinylhercynine thioether and 2-cysteinylhercynine sulfoxide could undergo 
efficient C-S cleavage to produce ergothioneine. However, the thioether proved to be a better 
substrate for enzyme-free PLP mediated cleavage. Interestingly, 2-cysteinylhercynine sulfone 
did not produce any ergothioneine at all and was found to be inhibitor of ESH biosynthesis. 
2-Cysteinylhercynine sulfoxide in vitro inhibits the growth of Mycobacterium smegmatis, 
hence highlighting the importance of the sulfur oxidation state and the essentiality of 
ergothioneine for the survival of mycobacteria. With the availability of the crystal structure 
of almost all ergothioneine enzymes, in silico design and synthesis of ergothioneine inhibitors 
could provide a novel class of anti-tuberculosis drugs.11-14  
 
Mycobacterium tuberculosis prefers γ-glutamylcysteine over cysteine as their sulfur source to 
produce ergothioneine, due to the “cysteine problem”. Therefore, the first total synthesis of 
EgtC enzyme pathway substrate, γ-glutamylhercynylcysteine sulfoxide was successfully 




conducted. Three synthetic routes were thoroughly investigated and the EgtC enzyme 
substrate was successfully synthesised and characterised.  
 
Ovothiols also received a huge interest for the design of potential trypanosomal drugs. In 
particular, the 5-histidyl-cysteine sulfoxide synthetase (OvoA), the enzyme which catalyzes 
the initial step of ovothiols biosynthesis have been proposed to be a potential drug target for 
infective disease. Moreover, several synthesized ovothiol analogues have shown therapeutic 
properties in human, such as 1-methyl-2-(3-trifluoromethylphenyl)-4 mercaptoimidazole 
which is demonstrated to be a potent agent in mammalian cerebral protection. 15  
Lastly, this thesis describes many challenges toward the synthesis of ovothiols starting with 
the commercially available L-histidine. Regioselective N-methylation as well as the selective 
bromination on the imidazole ring were successfully achieved thus paving the way for the 
improved total synthesis of ovothiols. Future studies could focus on developing a strategy for 
the sulfurization at 5-position required to obtain ovothiols using stable sulfur sources.  
 
The abundant stream of biology publications is indicative of the growing importance of 
ergothioneine worldwide. Overall, this thesis provides very important tools as well as valuable 
knowledge concerning natural thiohistidines synthesis. Hence, providing a platform for the 
future development of novel therapeutics useful as anti-tuberculosis, antitrypanosomal and 
anticancer drugs.  
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7.1. Synthesis and Characterisation of Compounds  
 
7.1.1. General Procedures 
 
All solvents were dried by appropriate techniques and freshly distilled before use. All 
commercially available reagents were purchased from Sigma-Aldrich, Merck or AK Scientific 
and were used without further purification.  
Unless otherwise stated, reactions were performed under an inert atmosphere of nitrogen in 
oven dried glassware and monitored by thin-layer chromatography (TLC) carried out on Merck 
silica gel 60-F254 sheets (0.2 mm layer) pre-coated plates and products visualized under UV 
light at 254 nm or by spraying the plate with an ethanolic solution of ninhydrin (2% v/v) 
followed by heating.  
Normal phase column chromatography was effected by using Merck Kieselgel silica gel 60 
(0.040-0.063 mm) and compounds eluted with the appropriate solvent mixtures. Reverse 
phase chromatography was effected by using Biotage KP-C-18-HS and compounds eluted with 
millipore water and AR methanol (gradient from water 100% to a mixture of water/MeOH 
85:15) unless otherwise stated. All compounds were dried under vacuum before yields were 
determined and spectroscopy analysis performed.  
Nuclear magnetic resonance spectra (1H and 13C) were recorded on a Varian Mercury 300 
MHz (75 MHz for 13C), Varian Unity 400 MHz (101 MHz for 13C), a Bruker unity 400 MHz (101 
MHz for 13C), or a Bruker unity 600 MHz (151 MHz for 13C) and were carried out in CDCl3, 




DMSO-d6 and D2O as the solvents unless otherwise stated. Chemical shifts are given in ppm 
relative to tetramethylsilane (TMS, δ = 0.00 ppm), which is used as internal standard. 
Assignments were confirmed by COSY, APT and HSQC analysis, when required. Coupling 
constants (J) are reported in Hertz (Hz). The spin multiplicities are indicated by the symbol s 
(singlet), d (doublet), dd (doublet of doublets), ddd (doublet of doublets of doublets), t 
(triplet), m (multiplet), q (quartet) and br (broad).  
 
Optical rotations were obtained using a Perkin Elmer 141 polarimeter at 20 °C. The 
concentration c refers to g/100mL. Melting points were determined using a Reichert-Jung 
Thermovar hot-plate microscope and are uncorrected. Infra-Red spectra were recorded on a 
Perkin-Elmer FT-IR spectrometer (in cm-1) from 4000 cm-1 to 450 cm-1. The numbering scheme 
given for each compound is for assignment purposes only and not necessarily consistent with 
the IUPAC naming convention. UV-Vis studies were conducted on UV-Vis spectrophotometer 
Agilent technology Cary 60 and the spectrums were processed using Scan Application version 
5.0.0.99 software and graphs plot using Excel 2013. 
 
Mass spectra were recorded on a JEOL GC MATE ΙΙ magnetic sector mass spectrometer (direct 
insertion probe-MS) and the base peaks are given, University of Cape Town.  
LCMS analyses were carried out with a UHPLC Agilent 1290 Infinity Series (Germany), accurate 
mass spectrometer Agilent 6530 Quadrupole Time Of Flight (QTOF) equipped with an Agilent 
jet stream ionization source (positive ionization mode) (ESI+) and column (Eclipse + C18 RRHD 
1.8 µm.2.1 X 50, Agilent, Germany). 




Enzymatic reactions were allowed to incubate in Nuaire incubator (DH Autoflow CO2 Air –
jarcketed Incubator), and centrifuged in Eppendorf© centrifuge (Model 5810R, Germany), 
Tygerberg Stellenbosch University, Cape Town, South Africa.  
 
7.1.2. Synthesis and characterization of Compounds 
 
N-benzyl L-histidine (2.28) 
 
In dichloromethane (10 mL) was suspended Nꞇ-benzyl-Nα-(tert-butoxycarbonyl)-L-histidine 
(2.27) (750 mg, 2.17 mmol) followed by the addition of trifluoroacetic acid (1 mL) with cooling 
in an ice bath. The resulting homogenous solution was allowed to stir at room temperature 
until complete deprotection as showed by thin layer chromatography. Solvent was removed 
and triturated with Et2O (15 mL) and dried to afford N-benzyl L-histidine TFA salt (2.28) as 
white crystals (700 mg, 90%). Mp: 230-233 °C, (Lit. 240 °C)10; 1H NMR (400 MHz, DMSO) δ 9.01 
(s, 1H, H-2'), 7.50 (s, 1H, H-5'), 7.39 (m, 5H, Phenyl), 5.37 (s, 2H, H-1''), 4.22 (t, J = 7.0 Hz, 1H, 
H-2), 3.22 (dd, J = 15.6, 7.0 Hz, 1H, H-3a), 3.14 (dd, J = 15.6, 7.0 Hz, 1H, H-3b); 13C NMR (101 
MHz, DMSO) δ 170.1 (C-1), 136.3 (C-2''), 135.8 (C-2'), 130.0 (C-4'), 129.4 (C-5'' C-6''), 129.0 (C-
7''), 128.6 (C-3''C-4''), 120.6 (C-5'), 51.7 (C-1''), 51.6 (C-2), 26.3 (C-3). 
 
 






In CH3CN (20 mL) was suspended N-benzyl L-histidine (2.28) (1.30 g, 5.30 mmol) followed by 
the addition of formaldehyde (1.2 mL, 15.5 mmol, 37%). To the resulting homogenous 
solution was added NaBH(OAc)3 (3.20 g, 15.5 mmol) and the solution was allowed to stir at 
room temperature for 24 hr. Undesirable salts were filtered thought celite and the solvent 
evaporated to dryness, reverse phase C18 column chromatography afforded Nꞇ-benzyl-Nα,Nα-
dimethyl-L-histidine (2.29) as a colourless solid (1.4 g, quantitative). Mp: 70-73 °C (dec); 1H 
NMR (300 MHz, D2O) δ 8.73 (s, 1H, H-2'), 7.51 – 7.37 (m, 5H, Ph), 7.34 (m, 1H, H-5'), 5.35 (s, 
2H, H-1''), 4.31 (dd, J = 9.5, 4.7 Hz, 1H, H-2), 3.48 (dd, J = 15.4, 4.7 Hz, 1H, H-3a), 3.39 (dd, J = 
15.4, 9.5 Hz, 1H, H-3b), 2.96 (s, 6H, H-1''' H-2'''); 13C NMR (101 MHz, D2O) δ 168.7 (C-1), 135.2 
(C-2'), 135.1 (C-2''), 133.6 (C-4'), 129.4 (C-3'' C-4''), 128.5 (C-5'' C-6''), 127.6 (C-7''), 121.0 (C-
5'), 66.0 (C-2), 65.9 (C-1''), 52.9 (C-1''' C-2'''), 21.9 (C-3); LRMS (EI+) m/z calculated for 
C15H19N3O2 273.1 [M]+ found 273.1 ([M]+, 7%), calculated for C14H19N3 229.2 [M-CO2]+ found 
229.1 ([M-CO2]+, 58%), calculated for C12H13N2 [M-H-CO2 -N(CH3)2]+ 185.1 found 185.1 ([M-H-








(S)-3-(1-benzyl-1H-imidazol-4-yl)-2-(trimethylammonio) propanoate (2.30)1 
 
In dry tetrahydrofuran (10 mL) was added Nꞇ-benzyl-Nα,Nα-dimethyl-L-histidine (2.29) (200 
mg, 0.732 mmol) and MeI (50 µL, 125 mg, 0.878 mmol). The resulting solution was allowed to 
stir at room temperature in the dark for 1-2 days. The solvent was removed and crystallization 
in the absolute ethanol afforded (S)-3-(1-benzyl-1H-imidazol-4-yl)-2-(trimethylammonio) 
propanoate (2.30) as yellow solid (197 mg, 93%). Mp: 90-93 °C; 1H NMR (300 MHz, D2O) δ 
8.32 (s, 1H, H-2'), 7.63 – 7.34 (m, 5H, Ph), 7.25 (s, 1H, H-5'), 5.34 (s, 2H, H-1''), 3.99 – 3.87  (m, 
1H, H-2), 3.50 – 3.20 (m, 2H, H-3), 3.33 (s, 9H, H-1'''H-2'''H-3'''); 13C NMR (101 MHz, D2O) δ 
170.4 (C-1), 137.1 (C-2'), 135.7 (C-2''), 132.0 (C-4'), 129.2 (C-3''C-4''), 128.7 (C-5''C-6''), 128.0 
(C-7''), 119.4 (C-5'), 78.0 (C-2), 52.3 (C-1''' C-2''' C-3'''), 51.4 (C-1''), 24.8 (C-3); LRMS (ESI+) m/z 
calculated for C16H22N3O2+ 288.2 [MH]+ found 288.2 ([MH]+, 65%), calculated for C15H22N3+ 
244.2 [M-CO2]+ found 244.2 ([M-CO2]+, 15%), calculated for C12H13N3 199.1 [M-CO2 –(CH3)3]+ 
found 199.2 ([[M-CO2 –(CH3)3]+ ; 12%).  
 
Hercynylcysteine thioether (or 2-cysteinylhercynine thioether) (One pot synthesis) (2.19)1 
 




In dimethylformamide (8 mL) was dissolved (S)-3-(1-benzyl-1H-imidazol-4-yl)-2-
(trimethylammonio) propanoate (2.30) (595 mg, 2.43 mmol) followed by the addition of N-
bromosuccinimide (1.80 g, 6.08 mmol). The resulting solution was allowed to stir at room 
temperature until complete disappearance of the starting material (thin layer 
chromatography monitoring), the solution became red-orange indicating the successful 
bromination.  
After successful bromination, L-cysteine HCl. H2O (1.07 g, 6.08 mmol) was added in one 
portion and the resulting solution was allowed to stir at room temperature for 24 hr. Reverse 
phase chromatography C18 afforded the product, 2-cysteinylhercynine thioether (2.19) was 
isolated in the form of a yellow hygroscopic solid as acetate salt (695 mg, 76%). [α]20D = -17° 
(c = 0.5, H2O); 1H NMR (400 MHz, D2O) δ 7.41 (m, 1H), 4.54 (dd, J = 7.7, 4.4 Hz, 1H, H-2''), 4.42 
(t, J = 5.0 Hz, 1H, H-2), 3.50 (dd, J = 15.2, 4.4 Hz, 1H, H-3a''), 3.36 (dd, J = 15.2, 7.7 Hz, 1H, H-
3b''), 3.19 (m, 2H, H-3), 2.80 (s, 9H, NMe3), 2.75 (s, 3H, acetate); 13C NMR (101 MHz, D2O) δ 
170.3 (C-1''), 170.0 (C-1), 129.4 (C-2'), 128.9 (C-4'), 120.9 (C-5'), 61.0 (C-2), 54.4 (C-2''), 51.7 
(C-1'''C-2'''C-3'''), 36.3 (C-3''), 23.9 (C-3); HRMS (ESI+): m/z 317.1284 [M]+. Calculated for 











S-(β-amino-β-carboxyethyl)ergothioneine sulfoxide or (2R)-2-ammonio-3-((4-((S)-2-
carboxylato-2-(trimethylammonio)ethyl)-1H-imidazol-2-yl)sulfinyl) propanoate or 2-
cysteinylhercynine sulfoxide (3.8) 2  
 
To a solution of H2O2 (30%, 224 mg, 6.58 mmol, 2.4 eq) were added hercynylcysteine 
thioether (2.19) (870 mg, 2.32 mmol) and para-toluene sulfonic acid (15 mg, 0.08 mmol). The 
resulting reaction mixture was allowed to stir at room temperature for 24 hr. At the end, the 
reaction mixture was lyophilised to dryness. C18 reverse phase chromatography afforded S-
(β-amino-β-carboxyethyl) ergothioneine sulfoxide acetate salt (3.8) as a yellow solid (640 mg, 
71%). [α]20D = -4° (c = 0.5, H2O); 1H NMR (300 MHz, D2O) δ 8.01 (s, 1H, H-5'), 4.49 (dd, J = 8.6, 
3.3 Hz, 1H, H-2''), 3.90 (dd, J = 16.1, 9.3 Hz, 1H, H-2), 3.65 (dd, J = 15.0, 3.3 Hz, 2H, H-1''), 3.52 
(dd, J = 9.3, 4.9 Hz, 1H, H-3a), 3.44 (dd, J = 9.3, 4.9 Hz, 1H, H-3b), 2.86 (s, 9H, NMe3), 2.79 (s, 
3H, acetate); 13C NMR (101 MHz, D2O) δ 171.8 (C-3''), 170.1 (C-1), 156.6 (C-2'), 129.5 (C-4'), 
125.5 (C-5'), 72.5 (C-2), 49.5 (NMe3), 49.1 (C-1''), 43.5 (C-2''), 20.8 (C-3); HRMS (ESI+): m/z 









S-(β-amino-β-carboxyethyl)ergothioneine sulfone or (R)-2-ammonio-3-((4-((S)-2-
carboxylato-2-(trimethylammonio)ethyl)-1H-imidazol-2-yl)sulfonyl) propanoate or 2-
cysteinylhercynine sulfone (3.16)1,3  
 
Hercynylcysteine thioether (2.19) (810 mg, 2.07 mmol) was added to a solution of H2O2 (30%, 
416 mg, 12.2 mmol, 4.8 eq) and boric acid (5 mg, 0.08 mmol). The reaction mixture was 
allowed to stir at room temperature for 24 hr. At the end of the reaction, the solvent was 
evaporated under high vacuum to afford the crude product, which was purified by C18 
reverse phase chromatography to afford S-(β-amino-β-carboxyethyl)ergothioneine sulfone 
acetate salt (3.16) as a yellow solid (545 mg, 65%). [α]20D = +4° (c = 0.5, H2O); 1H NMR (300 
MHz, D2O) δ 8.01 (s, 1H, H-5'), 4.52 (dd, J = 8.3, 3.1 Hz, 1H, H-2''), 3.89 (dd, J = 16.1, 9.3 Hz, 
1H, H-2), 3.68 (dd, J = 15.0, 2.8 Hz, 2H, H-1''), 3.59 – 3.43 (m, 2H. H-3), 2.85 (s, 9H, NMe3), 2.79 
(s, 3H, acetate); 13C NMR (101 MHz, D2O) δ 171.7 (C-3''), 170.0 (C-1), 159.8 (C-2'), 156.6 (C-4'), 
132.9 (C-5'), 64.3 (C-2), 56.7 (C-1''), 49.4 (NMe3), 49.1 (C-2''), 34.7 (C-3); HRMS (ESI+): m/z 
349.1177 [M]+. Calculated for C12H21N4O6S+, found 349.1182 [M]+. 
 
S-(2-nitrobenzyl) ethanethioate (2.38)4 
 




To THF (10 mL) were added potassium thioacetate (1.20 g, 9.81 mmol) and 2-
nitrobenzylbromide (400 mg, 1.85 mmol) at room temperature. The resulting reaction 
mixture was allowed to stir overnight at room temperature. The solvent was removed under 
vacuum and the residue was suspended in H2O (20 mL) and extracted with EtOAc (3 x 25 mL). 
Combined organic layers were dried over MgSO4 and the solvent evaporated under reduced 
pressure to afford S-(2-nitrobenzyl) ethanethioate (2.38) as a yellow liquid (378 mg, 97%). 1H 
NMR (300 MHz, CDCl3) δ 8.02 (d, J = 9.4 Hz, 1H, H-3), 7.62 (d, J = 7.7 Hz, 1H, H-6), 7.55 (t, J = 
6.8 Hz, 1H, H-4), 7.41 (t, J = 8.5 Hz, 1H, H-5), 4.41 (s, 2H, H-3'), 2.31 (s, 3H, H-2'). Proton NMR 




S-(2-nitrobenzyl) ethanethioate (2.38) (379 mg, 1.79 mmol) was dissolved in methanol (10 
mL) followed by the addition of concentrated HCl (32%) (1 mL) drop wise. The resulting 
reaction mixture was allowed to stir overnight at 60 °C. The solvent was removed and residue 
suspended in 2 N HCl (10 mL).  The aqueous layer was extracted with EtOAc (3 x 25 mL) and 
dried over Na2SO4 to afford (2-nitrophenyl)methanethiol (2.39) as a yellow solid (220 mg, 
73%). Proton NMR revealed a sufficiently pure product which was used without any further 
purification. 1H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 8.2 Hz, 1H, H-3), 7.58 (t, J = 7.5 Hz, 1H, H-
4), 7.48 (d, J = 5.8 Hz, 1H, H-6), 7.36 (t, J = 7.7 Hz, 1H, H-5), 4.02 (d, J = 8.4 Hz, 2H, H-1'), 2.13 




(t, J = 8.4 Hz, 1H, SH). 13C NMR (101 MHz, CDCl3) δ 133.7 (C-2), 133.4 (C-3), 133.1 (C-1), 132.8 
(C-5), 128.7 (C-4), 125.5 (C-6), 26.4 (C-1'). NMR data were in accordance with the literature.4 
 
Ergothioneine or (S)-3-(2-thioxo-2,3-dihydro-1H-imidazol-4-yl)-2-(trimethylammonio) 
propanoate (2.10). 
  
Method 1.  
 
The synthesis of ergothioneine was carried out as reported by Trampota et al.5  107 mg of L-
(+)-ergothioneine (2.10) was synthesized. Mp:276-279 °C literature 275-277 °C5; [α]20D = 
+138.21° (c = 1; H2O)5; Rf silica gel: 0.3 (methanol/water 9:1); 1H NMR (400 MHz, D2O) δ 7.05 
(s, 1H, H-5’), 3.76 (dd, J = 11.7, 4.0 Hz, 1H, H-2), 2.88 (m, 2H, H-3), 2.75 (s, 9H, NMe3); 13C NMR 
(101 MHz, D2O) δ 177.0 (C-1), 161.2 (C-2'), 128.9 (C-4'), 103.4 (C-5'), 60.6 (C-2), 55.6 (NMe3), 
24.9 (C-3); νmax (KBr)/cm-1 3138s (NH) 1746s (RCOOH), 1995m (N=C-S), 1403s (C=C aromatic 
ring); HRMS (ESI+): m/z 230.0963 [M]+ calculated for C9H16N3O2S+, found 230.0958 [M]+.  
 
Method 2. C-S bond cleavage of 2-cysteinylhercynine thioether (or hercynylcysteine 
thioether) (2.19) afforded ergothioneine 
 
In H2O (3 mL) were dissolved 2-cysteinylhercynine thioether (2.19) (48 mg, 0.15 mmol) and 
pyridoxal-5 phosphate (31 mg, 0.15 mmol). The reaction mixture was allowed to stir overnight 
at 40 °C (pH 4-5). The solvent was removed by lyophilisation; reverse phase C18 and Dowex-
(H+ form) column chromatography afforded (2.10) as a yellowish solid (26 mg, 76%) which 




was analysed by NMR. Data demonstrated the presence of ergothioneine and was consistent 
with that reported in the literature.5-7 
Method 3. Using thioacetic acid as a sulfur source 8 
In dimethylformamide (2 mL) was dissolved (S)-3-(1-benzyl-1H-imidazol-4-yl)-2-
(trimethylammonio) propanoate (2.30) (150 mg, 0.36 mmol) followed by the addition of N-
bromosuccinimide (141 mg, 0.792 mmol). The resulting solution was allowed to stir at room 
temperature until complete disappearance of the starting material (thin layer 
chromatography monitoring), the solution became red-orange indicating the successful 
bromination. After successful bromination, thioacetic acid (4-5 mol eq) was added in one 
portion and the resulting solution was allowed to stir at room temperature for 24 hr in the 
dark. DMF was removed under high vacuum and the crude residue was dissolved in MeOH (3 
mL) followed by the addition of NaOMe (0.2 M), the yellow orange solution immediately 
discoloured to become pale yellow. The reaction mixture was allowed to stir at room 
temperature for 2-3 hr, the pH was adjusted to 7-8 by Amberlyte-15 (H+ form) and the solvent 
removed to dryness. C18 reverse phase column chromatography was attempted to afford a 
product which had a small amount of desulfurized and acetylated products. The yield was 
calculated by integration of NMR signals (total yield of 64%).  
 
Na,Na-dimethyl-L-histidinate (3.2)  
 




To a solution of L-histidine (250 mg, 1.61 mmol) and formaldehyde (37%, 0,4 mL) in H2O (5 
mL) was added NaBH4 (128 mg, 3.38 mmol) portion wise with cooling in an ice water bath (0-
5 °C). The reaction mixture was allowed to stir in the ice water bath for 3 hr until reaction 
reached completion as revealed by thin layer chromatography. Solvent was removed to 
dryness and the residue was purified by C18 reverse phase chromatography to yield Na,Na-
dimethyl-L-histidinate (3.2) as a white solid (293 mg, quantitative). 1H NMR (300 MHz, D2O) δ 
7.70 (s, 1H, H-2'), 6.95 (s, 1H, H-5'), 3.46 (dd, J = 9.0, 5.8 Hz, 1H, H-2), 3.07 (dd, J = 14.7, 9.0 
Hz, 1H, H-3a), 2.97 (dd, J = 14.7, 5.8 Hz, 1H, H-3b), 2.51 (s, 6H, H-1'' H-2");13C NMR (101 MHz, 
D2O) δ 176.6 (C-1), 135.8 (C-2'), 133.4 (C-4'), 117.4 (C-5'), 70.9 (C-2), 41.4 (C-1" C-2"), 27.1 (C-
3); LRMS (EI+) m/z calculated for C8H14N3O2 184.1 found 184.0 ([MH]+, 7.3%), calculated for 
C7H12N3 139.0 found 139.0 ([M-CO2]+, 34. 8%).  
L-hercynine or (S)-1-carboxy-2-(1H-imidazol-4-yl)-N,N,N-trimethylethan-1-aminium (3.3)9,10 
 
Na,Na-dimethyl-L-histidinate (3.2) (649 mg, 3.56 mmol) was dissolved in methanol (20 mL), 
and the pH of the solution was adjusted to 8-9 with a concentrated solution of NH4OH (25%, 
80 µL), followed by the addition of iodomethane (700 mg, 4.93 mmol). The resultant solution 
was allowed to stir at room temperature for 24 hr. The solvent was evaporated to dryness to 
afford a crude product which was recrystallized in a mixture of warm methanol and diethyl 
ether to yield the iodide salt form of L-hercynine (3.2) as a white solid (489 mg, 42%). Mp: 




240-242°C (with decomposition); νmax KBr/cm-1 3435s (N-H) 1632m (RCOOH) 1496 w (C=C 
Aromatic) 1335w (C-N); [α]20D = +48.7° (c = 0.9, 5 N HCl); 1H NMR (400 MHz, D2O) δ 7.89 (s, 
1H, H-2'), 7.11 (s, 1H, H-5'), 3.98 (dd, J = 10.6, 4.8 Hz, 1H, H-2), 3.35 (s, 9H, H-1''H-2''H-3''), 
3.40 – 3.29 (m, 2H, H-3); 13C NMR (101 MHz, D2O) δ 170.9 (C-1), 136.1 (C-2'), 131.2 (C-5'), 
116.7 (C-4'), 78.4 (C-2), 52.2 (C-1''C-2''C-3''), 25.0 (C-3); LRMS (EI+) m/z calculated for 
C9H16N3O2+ 198.1 found 198.1 ([M+H]+; 31.4%); calculated for C9H15N3O2+ 197.1 found 197.1 
([M]+; 53.4%); calculated for C6H6N3O2 152.0 found 152.0 ([M-(CH3)3]+; 100%).  
 
L-Hercynine synthesis (3.3) (one pot)11  
 
L-histidine (250 mg, 1.60 mmol) was dissolved in NaOH (10%, 4 mL) followed by the addition 
of Me2SO4 (0.5 mL, 626 mg, 4.96 mmol). The reaction was allowed to stir for 30 min at 0 °C 
and for further 30 min at room temperature. The solution was neutralized with 0.5 N HCl, and 
lyophilised to dryness. The residue was triturated with Et2O and the residue purified by 
reverse phase C18 column chromatography to remove salts (by products) to yield L-hercynine 
(3.3) as white hygroscopic solid (290 mg). 
Deuterated hercynine or (S)-3-(1H-imidazol-4-yl)-2-(dimethyl(methyl-d3)ammonio) 
propanoate (3.4) 
 
To a solution of L-histidine (200 mg, 1.29 mmol) in CH3CN (10 mL) was added formaldehyde 
(37%, 157 mg, 145 µL, 1.93 mmol) in one portion. The solution was allowed to equilibrate to 




room temperature, thereafter sodium triacetoxyborohydride (615 mg, 2.90 mmol) and acetic 
acid glacial (73 µL) were added while the internal temperature was maintained at 0-5°C. The 
resulting solution was allowed to stir at room temperature for a 18-24 hr period. The reaction 
was quenched by the addition of HCl (5%, 5 mL) to pH ≤ 1 and then extracted with EtOAc (5 x 
20 mL). The organic layer was separated, washed with brine, dried (anhydrous MgSO4) and 
filtered. The filtrate was evaporated under vacuum to obtain crude Na,Na-dimethyl-L-
histidinate (3.2) which was used without further purification.  
Crude Na,Na-dimethyl-L-histidinate (3.2) (374 mg, 2.02 mmol) was dissolved in MeOH (5 mL), 
the solution adjusted to pH 9-10 with concentrated ammonia (25%), followed by the addition 
of iodomethane-d3 (489 mg, 3.03 mmol). The solution was allowed to stir at room 
temperature for 24 hr. The solvent was evaporated under high vacuum to dryness. Reverse 
phase chromatography (C18) and recrystallization in a mixture of warm EtOH/H2O afforded 
deuterated hercynine (3.4) as a yellow solid (249 mg, 61%). Mp: 142-145 °C (dec); 1H NMR 
(300 MHz, D2O) δ 7.84 (s, 1H, H-2'), 7.12 (s, 4H, H- H-5'), 4.01 (dd, J = 10.6, 4.7 Hz, 1H, H-2), 
3.38 (s, 6H, H-1'' H-2''), 3.39 – 3.36 (m, 2H, H-3); HRMS (ESI+): m/z 201.1431 [M]+. Calculated 
for C9H13D3N3O2+ found 201.1414 [M]+.  
Mecaptohistidine or (S)-2-amino-3-(2-mercapto-1H-imidazol-4-yl) propanoic acid (3.5) 
 
The synthesis of mercaptohistidine (3.5) was carried out as reported by Trampota et al.5 
Mercaptohistidine (3.5) was isolated as a white powder (2.01 g, 88%). Mp: 206-208°C (with 




decomposition) literature 204-206°C (with decomposition)5; νmax (KBr)/cm-1 3465s + 1634s + 
1129w (RNH2 Free) 2073s (N=C-S) 1383m (RCOO-); 1H NMR (400 MHz, D2O+DCl) δ 6.87 (s, 1H, 
H-5'), 4.31 (t, J = 6.6 Hz, 1H, H-2), 3.28 (dd, J = 16.1, 6.6 Hz, 1H, H-3a), 3.17 (dd, J = 16.1, 6.6 
Hz, 1H, H-3b), Carboxylic acid and amine protons signals were exchanged with D2O; 13C NMR 
(101 MHz, D2O) δ 170.5 (C-1), 156.6 (C-2’), 123.3 (C-4’), 116.1 (C-5’), 51.9 (C-2), 25.4 (C-3); 
LRMS (EI+) m/z calculated for C6H9N3O2S [M]+ 187.0 found 187.0 ([M] +; 92.7%). 
(S)-3-(2-(tert-butylthio)-1H-imidazol-4-yl)-2-(dimethylamino) propanoic acid (3.6)5 
 
Step 1.  
To a solution of mercaptohistidine (3.5) (2.27 g, 12.1 mmol) and t-butanol (2.34 g, 31.5 mmol) 
in distilled H2O (18 mL) was added concentrated hydrochloric acid (4 mL, 37%) at room 
temperature. The resulting reaction mixture was heated to 85-90 °C and kept at this 
temperature for a 3-4 hr period. Subsequently, the reaction mixture was concentrated by 
lyophilisation. The free amino acid was liberated by adjusting the pH of the solution to 5.0 
with aqueous sodium acetate, followed by lyophilisation to dryness, whereafter the amino 
acid was extracted with warm 2-propanol. After evaporation of the solvent, the product (S)-
2-amino-3-(2-(tert-butylthio)-1H-imidazol-4-yl) propanoic acid was obtained as yellow 
crystals (1.85 g, 62.7%). [α]20D = +14.1° (c = 0.7, H2O) lit.[α]25D = +13° (c = 1, H2O)5; νmax 
(KBr)/cm-1 3448s + 1561s + 1051w (RNH2 Free) 2237w (N=C-S) 1703m (RCOOH) 1337m (CH3) 
643 (S-R); 1H NMR (400 MHz, D2O) δ 7.60 (brs, 1H, H-5’), 4.18 (t, J = 3.0 Hz, 1H, H-2), 3.39 (dd, 




J = 11.0, 3.0 Hz, 1H, H-3a), 3.30 (dd, J = 11.0, 3.0 Hz, 1H, H-3b), 1.44 (s, 9H, t-butyl); LRMS (EI+) 
m/z calculated for C10H17N3O2S 243.1 [M]+ found 243.1 ([M]+; 4.2%), 199.1 ([M–CO2]+; 7.1 %), 




In a solution of THF (19 mL) was dissolved (S)-2-amino-3-(2-(tert-butylthio)-1H-imidazol-4-yl) 
propanoic acid (1.57 g, 6.45 mmol) followed by the addition of formalin (37%, 2.04 g, 25.1 
mmol) portion wise. The resulting mixture was allowed to equilibrate to room temperature 
and then sodium triacetoxyborohydride (3.76 g, 17.7 mmol) was added while the reaction 
temperature was maintained at 0-5°C. The resulting suspension was allowed to stir at 10 °C 
for 6-8 hr. The reaction mixture was cooled to -10 °C, and acidified with 2 N HCl (pH ≤1). The 
resulting solution was lyophilised and the residue was mixed with 13 mL methanol followed 
by filtration of the undesired inorganic salts. The filtrate was lyophilised to yield the 
dihydrochloride salt. The free amine was liberated by triturating with aqueous sodium acetate 
to pH 5.0, and extraction into 2-propanol, from where it was crystallized. The product (S)-3-
(2-(tert-butylthio)-1H-imidazol-4-yl)-2-(dimethylamino) propanoic acid (3.6) was obtained as 
colourless crystals (590 mg, 34%). 1H NMR (300 MHz, D2O) δ 6.30 (s, 1H, H-5'), 3.45 (d, J = 10.7 









Deuterated ergothioneine or (S)-2-(dimethyl(methyl-d3)ammonio)-3-(2-thioxo-2,3-dihydro-
1H-imidazol-4-yl) propanoate (3.7) 
 
(S)-3-(2-(tert-butylthio)-1H-imidazol-4-yl)-2-(dimethylamino) propanoic acid (3.6) (110 mg, 
0.405 mmol) was dissolved in MeOH (3 mL) and the pH was adjusted to 8.8-9.0 with 
ammonium hydroxide, followed by the addition of iodomethane-d3 (70 mg, 0.61 mmol) and 
the solution was allowed to stir at room temperature for 24 h. The mixture was concentrated 
under vacuum and the resulting white solid (ammonium chloride) was filtered and the cake 
was washed with methanol. The combined filtrates were evaporated to dryness to afford a 
crude, S-(tert-butyl) ergothioneine-d3. In the presence of 2-mercaptopropionic acid (1.70 g; 
16.1 mmol), crude S-(tert-butyl) ergothioneine-d3 was dissolved in 2 mL H2O followed by the 
addition of HCl (1 mL, 32%). The resulting mixture was refluxed for 21 hr. After cooling the 
reaction mixture was extracted with EtOAc (3 x 15 mL) and then the aqueous layer was 
adjusted to pH 7 with a solution of ammonia (25% v/v) followed by lyophilisation. The residue 
was again extracted with EtOAc (3 x 20 mL) followed by partitioning in a mixture of distilled 
water: EtOAc 50:50 (v/v). The aqueous layer was retained and the organic phase discarded. 
The aqueous phase was lyophilised to dryness. Purification by reverse phase chromatography 
(C18) and recrystallization afforded (S)-2-(dimethyl(methyl-d3)ammonio)-3-(2-thioxo-2,3-
dihydro-1H-imidazol-4-yl) propanoate (3.7) as a yellow solid (93 mg, quantitative). Mp:158-
160 °C (dec); 1H NMR (400 MHz, D2O) δ 6.95 (s, 1H, H-5'), 4.34 – 4.13 (m, 1H, H-2), 3.41 (dd, J 




= 11.3, 8.5 Hz, 2H, H-3), 3.39 (s, 6H, H-1'' H-2''); 13C NMR (101 MHz, D2O) δ 180.3 (C-1), 134.9 
(C-2'), 119.1 (C-4'), 115.8 (C-5'), 75.5 (C-2), 52.5 (C-1'' C-2'' C-3''), 22.7 (C-3); HRMS (ESI+): m/z 
233.1152 [M]+. Calculated for C9H13D3N3O2S+, found 233.1160 [M]+.  
 
Benzyl O-(tert-butyldimethylsilyl)-L-serinate (4.8) 
 
To a suspension of L-serine benzyl ester hydrochloride (4.7) (1.00 g, 4.31 mmol) and TBDMSCl 
(0.68 g, 4.53 mmol) in CH3CN (130 mL), was added DBU (1.31 g, 1.30 mL, 8.63 mmol) with 
cooling at 0 °C. The resulting homogenous solution was allowed to stir overnight at room 
temperature. The solvent was evaporated in under vacuum, the residue was suspended in 
H2O (15 mL) and the aqueous phase extracted with EtOAc (3 × 20 mL). The combined organic 
layers were dried over MgSO4 and evaporated to dryness to afford benzyl O-(tert-
butyldimethylsilyl)-L-serinate (4.8) as a yellowish oil (1.34 g, 99.9%). The NMR analysis 
showed a pure compound which was used in the next step without any further purification. 
For analytical purposes, a sample was purified by flash chromatography (hexane/EtOAc 5:1 
to 1:5); 1H NMR (400 MHz, CDCl3) δ 7.43-7.26 (m, 5H, Ph), 5.19 (d, J = 1.7 Hz, 2H, H-1'), 3.98 
(dd, J = 9.7, 4.2 Hz, 1H, H-3a), 3.84 (dd, J = 9.7, 3.8 Hz, 1H, H-3b), 3.57 (t, J = 3.8 Hz, 1H, H-2), 
1.76 (br.s, 2H, NH), 0.88 (s, 9H, H-4''H-5''H-6''), 0.06 (s, 3H, H-2''), 0.03 (s, 3H, H-1''); 13C NMR 
(101 MHz, CDCl3) δ 174.0 (C-1), 135.8 (C-2' ), 128.6 (C-3'C-7'), 128.3 (C-4'C-5'C-6'), 66.7 (C-1'), 
65.4 (C-2), 56.7 (C-3), 25.8 (C-4''C-5''C-6''), 18.2 (C-3''), -5.6 (C-1''), -5.5 (C-2''); LRMS (EI+) didn’t 




display the molecular ion but fragment at m/z calculated for C8H20NOSi [M–COOBn] (174.1) 
found 174.0 ([M–COOBn]+ ; 37.5%).  
 
(S)-5-(benzyloxy)-4-((tert-butoxycarbonyl)amino)-5-oxopentanoic acid (4.10) 
 
L-Glutamic benzyl ester (4.9) (150 mg, 0.632 mmol) was dissolved in a mixture of H2O:dioxane 
(2:1, 12 mL) followed by the addition of Et3N (88 µL, 64 mg, 0.63 mmol). The resulting 
homogeneous solution was cooled to 0 °C and (Boc)2O (152 mg, 0.696 mmol) was added 
portion wise. The reaction mixture was allowed to stir overnight at room temperature. The 
solvent was removed under vacuum, and the residue partitioned between EtOAc:H2O (1:1, 
50 mL). The aqueous phase was extracted with EtOAc (4 x 15 mL), the combined organic layers 
washed with brine (20 mL), dried over Na2SO4 and the solvent was evaporated to afford crude 
(S)-5-(benzyloxy)-4-(tert-butoxycarbonylamino)-5-oxopentanoic (4.10) as a yellowish oil (213 
mg, quantitative). For analytical purposes, a small amount was purified by flash SiO2 column 
chromatography (CH2Cl2 100; CH2Cl2:MeOH 80:20). 1H NMR (300 MHz, CDCl3) δ 7.44 – 7.31 
(m, 5H, Ph), 5.20 (d, J = 2.1 Hz, 2H, H-1''), 4.64 (dd, J = 9.4, 2.9 Hz, 1H, H-4), 2.72 – 2.42 (m, 2H, 
H-2), 2.30 (ddd, J = 19.6, 13.2, 9.4 Hz, 1H, H-3a), 2.01 (ddt, J = 13.2, 9.4, 3.3 Hz, 1H, H-3b), 1.42 
(s, 9H, Boc); 13C NMR (75 MHz, CDCl3) δ 173.2 (C-1), 171.2 (C-5), 149.3 (C-1'), 135.1 (C-2''), 
128.7 (C-3'' C-7''), 128.6 (C-5''), 128.5 (C-4'' C-6''), 83.6 (C-2'), 67.1 (C-1''), 59.0 (C-4), 31.1 (C-




2), 27.8 (C-3'C-4'C-5'), 21.3 (C-3); LRMS (EI+) m/z calculated for C17H23NNaO6 360.1 found 





(S)-5-(Benzyloxy)-4-(tert-butoxycarbonylamino)-5-oxopentanoic acid (4.10) (169 mg, 0.500 
mmol) was dissolved in a dry DCM (6 mL) followed by the addition of EDCI.HCl (105 mg, 0.55 
mmol), HOBt (74 mg, 0.55 mmol) and DIPEA (65 mg, 88 µL, 0.55 mmol) while the internal 
temperature was maintained to 0 °C using an ice water bath. After 10 min, benzyl O-(tert-
butyldimethylsilyl)-L-serinate (4.8) (186 mg, 0.60 mmol) was added with cooling at 0 °C. The 
resulting reaction mixture was allowed to stir at room temperature for 24 hr and monitored 
by TLC. The solvent was removed to dryness and the residue was partitioned into H2O:EtOAc 
(1:2, 50 mL). The aqueous layer was extracted with EtOAc (4 x 15 mL), the combined organic 
layers were washed with brine (20 mL), dried over Na2SO4 and evaporated to dryness to afford 
a crude product as a yellow oil. Flash SiO2 column chromatography (CH2Cl2 100, CH2Cl2:MeOH, 
80:20) afforded benzyl N5-((S)-1-(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-1-oxopropan-2-
yl)-N2-(tert-butoxycarbonyl)-L-glutaminate as a yellowish oil (270 mg; 86%). 1H NMR (400 
MHz, CDCl3) δ 7.31 – 7.27 (m, 10H), 5.27 – 5.06 (m, 4H), 4.34 – 4.21 (m, 1H), 4.11 (dd, J = 10.1, 




2.6 Hz, 1H), 3.96 (dd, J = 10.1, 2.6 Hz, 1H), 3.87 – 3.79 (m, 1H), 2.61 – 2.37 (m, 1H), 2.16 (ddd, 
J = 19.8, 12.8, 7.3 Hz, 1H), 2.03 – 1.81 (m, 2H), 1.43 (s, 9H), 0.85 (s, 9H), 0.09 – -0.04 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 173.1 (C-5), 171.4 (C-1), 171.1 (C-1'''), 156.5 (C-1''), 135.6 (C-2'), 
135.3 (C-2IV), 128.6 (4C, meta), 128.4 (4C, ortho), 128.3 (C-5'), 128.2 (C-5IV), 67.3 (C-1'), 67.2 
(C-1IV), 64.2 (C-2''), 63.3 (C-2'''), 56.2 (C-2), 54.42 (C-4), 30.4 (C-3), 28.3 (3C-Boc), 25.6 (3C, C-
4V, 5V & 6V), 18.2 (C-3V), -5.7 (C-1V), -5.5 (C-2V); LRMS (EI+) m/z calculated for C33H48N2NaO8Si 





In dry THF (5 mL) was dissolved benzyl N5-((S)-1-(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-
1-oxopropan-2-yl)-N2-(tert-butoxycarbonyl)-L-glutaminate (4.11) (200 mg, 0.320 mmol) 
followed by the addition TBAF (1 M in THF, 0.35 mmol) drop wise. The resulting reaction 
mixture was allowed to stir at room temperature for 5 - 10 hr (TLC monitoring). Solvent was 
removed to dryness, the residue was dissolved in EtOAc (25 mL) and washed with water (10 
mL), brine (10 mL) and dried over Na2SO4 to afford crude product which was purified 
successively by SiO2 (gradient CH2Cl2 100% to CH2Cl2/MeOH 80:20)  and Amberlyte 15 ion 
exchange (H+-form) (to trap unreacted TBAF) chromatography to yield pure product (4.11) as 




a yellow oil (98 mg, 59%); 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.30 (m, 10H), 5.24 – 5.04 (m, 
4H, H-1' H-1IV), 4.43 – 4.18 (m, 2H, H-3"'), 3.61 (t, J = 4.9 Hz, 1H, H-2), 3.44 (t, J = 6.6 Hz, 1H, 
H-2"'), 2.58 – 2.36 (m, 2H, H-3), 2.30 – 2.14 (m, 1H, H-4a), 2.07 – 1.87 (m, 1H, H-4b), 1.44 (s, 
9H, Boc); 13C NMR (101 MHz, CDCl3) δ 169.8 (C-5), 153.6 (C-1), 153.5 (C-1"'), 153.0 (C-1"), 
135.7 (2C, C-2' C-2IV), 128.6 (2C, C-4' C-6'), 128.5 (2C, C-4IV C-6IV), 128.3 (2C, C-3' C-7'), 128.2 
(2C, C-3IV C-7IV), 125.5 (2C, C-5' C-5IV), 82.2 (C-2"), 71.2 (C-1'), 68.7 (C-1IV), 66.4 (C-3"'), 59.4 (C-
2"'), 53.2 (C-2), 31.7 (C-4), 27.8 (3C, C-3" C-4" C-5"), 19.2 (C-3); LRMS (EI+) didn’t display the 
molecular ion but fragment at  m/z calculated for C15H16N2O6 [M – Bn – Boc –2H]+ (320.1) 





2, 4, 6-Trichloro-[1, 3, 5] triazine (56 mg, 0.11 mmol) was added portion wise in DMF (1 mL) 
while the internal temperature was maintained at 25 °C. After the formation of a white solid, 
the reaction was monitored (TLC) until complete disappearance of 2, 4, 6-trichloro-[1, 3, 5] 
triazine. Two hours later, benzyl N5-((S)-1-(benzyloxy)-3-hydroxy-1-oxopropan-2-yl)-N2-(tert-
butoxycarbonyl)-L-glutaminate (4.12) (56 mg, 0.11 mmol) in CH2Cl2 (5 mL) was added in one 
portion. The resulting mixture was allowed to stir at room temperature for 21 hr. The reaction 




mixture was quenched by the addition of water (10 mL). The aqueous layer was extracted 
with EtOAc (3 x 15 mL) and the combined organic layers were washed successively with 
saturated aqueous sodium carbonate (10 mL) and brine (10 mL), dried over Na2SO4, filtered 
and concentrated under vacuum to yield benzyl N5-((S)-1-(benzyloxy)-3-chloro-1-oxopropan-
2-yl)-N2-(tert-butoxycarbonyl)-L-glutaminate (4.13) as a yellow oil (49 mg, 83%). 1H NMR (400 
MHz, CDCl3) δ 7.26 (s, 10H, Ph), 5.21 – 5.09 (m, 4H, H-1' H-1IV), 4.31 (dd, J = 7.4, 3.6 Hz, 1H, H-
3a"'), 4.29 – 4.26 (m, 1H, H-3b"'), 3.67 – 3.59 (m, 1H, H-2), 3.46 (ddd, J = 6.6, 5.7, 2.4 Hz, 1H, 
H-2"'), 2.58 – 2.24 (m, 2H, H-3), 2.21 – 1.87 (m, 2H, H-4), 1.46 (s, 9H, Boc). LRMS (EI+) m/z 
calculated for C27H3335ClN2O7 532.2 found 532.1 ([35M] +, 14.5%), calculated for C27H3337ClN2O7 
534.2 found 534.0 ([37M]+, 4.8%); calculated for C22H2435ClN2O5 431.1 found 431.1 ([35M-Boc]+, 




In MeOH (3 mL) were added benzyl N5-((S)-1-(benzyloxy)-3-hydroxy-1-oxopropan-2-yl)-N2-
(tert-butoxycarbonyl)-L-glutaminate (4.12) (47 mg, 0.09 mmol) and Pd/C 10% (240 mg), 
followed by the addition of TFA (1 mL) with cooling in ice bath. The resulting reaction mixture 
was hydrogenated at room temperature for 24 hr. The catalyst was removed by filtration 
through celite and C18 reverse phase chromatography afforded N5-((S)-1-carboxy-2-
hydroxyethyl)-L-glutamine (4.14) as a yellow oil (20 mg, 95%). 1H NMR (400 MHz, D2O) δ 4.27 




(ddd, J = 26.8, 15.2, 8.3 Hz, 1H, H-2), 4.03 (dd, J = 23.4, 8.7 Hz, 1H, H-1'), 3.94 – 3.62 (m, 2H, 




To a suspension of serine benzyl ester hydrochloride (200 mg, 0.863 mmol) and Et3N (126 mg, 
1.25 mmol) in THF (5 mL) cooled at 0°C, was added a solution of (Boc)2O (151 mg, 0.691 mmol) 
in THF (5 mL) drop wise over a period of 30 min. The mixture was allowed to warm to room 
temperature while stirring for 5 h, thereafter, the reaction temperature was raised to 50°C 
for further 2 h. The solvent was removed under vacuum, and the residue partitioned between 
Et2O:H2O (1:1, 50 mL). The aqueous layer was extracted with Et2O (4 x 20 mL), the combined 
organic layers were successively washed with 5% NaHCO3 (20 mL) and brine (20 mL). Dried 
over MgSO4 and the solvent was evaporated to afford benzyl (tert-butoxycarbonyl)-L-serinate 
as a hygroscopic yellowish oil (260 mg, quantitative). The NMR showed pure product which 
was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 7.38-7.31 
(m, 5H, Ph), 5,50 (br.s, 1H, NH), 5.21 (d, J = 2.3 Hz, 2H, H-1'), 4.41 (br.s, 1H, H-2), 3.97 (dd, J = 
11.1, 3.9 Hz, 2H, H-3a), 3.89 (dd, J = 11.1, 3.9 Hz, 2H, H-3b), 2.44 (br.s, 1H, OH), 1.44 (s, 9H, t-
butyl); 13C NMR (101 MHz, CDCl3) δ 170.7 (C-1), 155.8 (C-1''), 135.3 (C-2'), 128.6 (C-3'C-7'), 
128.2 (C-4'C-6'), 126.3 (C-5'), 67.5 (C-1'), 63.5 (C-2), 55.9 (C-2''), 28.3 (C-3''4''5''), 27.4 (C-3). 




The OH proton was assigned based on the D2O wash 1H NMR experiment. Data consistent 




2, 4, 6-Trichloro-[1, 3, 5] triazine (179 mg; 0.971 mmol) was added portion wise in DMF (1 mL)  
while the internal temperature was maintained at 25 °C. After the formation of a white solid, 
the reaction was monitored (TLC) until complete disappearance of the starting material, 
thereafter CH2Cl2 (15 mL) was added, followed by the addition of benzyl (tert-
butoxycarbonyl)-L-serinate. The resultant mixture was allowed to stir overnight at room 
temperature. The reaction mixture was diluted with water (15 mL), the organic layer was 
retained and the aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic 
layers were successively washed with saturated aqueous sodium carbonate (2 x 10 mL) and 
brine, dried (Na2SO4), filtered and concentrated under vacuum to yield benzyl (S)-2-((tert-
butoxycarbonyl)amino)-3-chloropropanoate as a yellow solid (211 mg, 76%). Due to the 
instability of the product upon silica, the obtained product was used without further 
purification. Mp: 52-55 °C; 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.29 (m, 5H), 5.40 (br.s, 1H, NH), 
5.21 (d, J = 2.7 Hz, 2H), 4.41 (br.s, 1H), 3.94 (m, 2H), 1.44 (s, 9H); LRMS (EI+) didn’t display the 




molecular ion but fragments at m/z calculated for C7H13ClNO2 178.1 found 178.0 ([35Cl–
COOBn]+ ; 11.2%), 180.0 ([37Cl–COOBn]+ ; 2.0%).  
 
S-benzyl-L-cysteine (4.26)14  
 
To a mixture of ethanol (70 mL) and 2N NaOH (30 mL, 2.40 g) were added L-cysteine 
hydrochloride (2.50 g, 14.2 mmol), and benzyl bromide (2.44 g, 1.7 mL, 14.2 mmol). The 
homogenous solution was allowed to stir at room temperature for 1-2 hr (TLC monitoring). 
The reaction was neutralised to pH 6-7 with careful addition of concentrated HCl. The 
precipitate was filtered and successively washed with water, ethanol, and Et2O to afford S-
benzyl-L-cysteine (4.26) as a white powder (2.4 g, 80%). Mp: 210-212 °C (Lit 215-216 °C)15 (Lit 
214 °C)16; 1H NMR (300 MHz, D2O) δ 7.24 – 7.06 (m, 5H, Ph), 3.94 (dd, J = 7.6, 4.6 Hz, 1H, H-
2), 3.59 (s, 2H, H-1'), 2.85 (dd, J = 15.0, 4.6 Hz, 1H, H-3a'), 2.74 (dd, J = 15.0, 7.6 Hz, 1H, H-
3b').15 13C NMR (101 MHz, D2O) δ 170.0 (C-1), 137.4 (C-2'), 128.9 (C-3'C-7'), 128.8 (C- 4'C-6'), 
127.5 (C-5'), 52.0 (C-2), 35.4 (C-1'), 30.4 (C-3); LRMS (EI+) m/z calculated for C10H13NO2S 211.1 









O, S- dibenzyl -N-(tert-butoxycarbonyl)-L-cysteinate (4.28) 
 
In a suspension of S-benzyl-L-cysteine (4.26) (315 mg, 1.50 mmol) in a mixture of H2O:THF 
(2:1, 15 mL) were added NaOH (60 mg, 1.50 mmol) and (Boc)2O (393 mg, 1.80 mmol) portion 
wise. The resulting homogenous solution was allowed to stir at room temperature overnight. 
Solvents were removed to dryness and the residue was triturated with Et2O. The residue was 
dissolved in DMF (6 mL), BnBr (257 mg, 180 µL, 1.50 mmol) was added in one portion and the 
resulting reaction mixture was allowed to stir at room temperature overnight. The reaction 
was quenched by the addition of H2O (50 mL) and the aqueous layer was extracted with EtOAc 
(4 x 25 mL), organic layers were retained, washed with brine (15 mL) and dried over MgSO4. 
SiO2 gel column chromatography afforded the product as colourless solid (4.28) (573 mg, 95% 
over 2 steps). Mp: 78-79 °C; 1H NMR (300 MHz, CDCl3) δ 7.46 – 7.33 (m, 5H, O-CH2-Ph), 7.33 
– 7.21 (m, 5H, S-CH2-Ph), 5.34 (br.s, 1H, NH), 5.19 (s, 2H, H-1'), 4.60 (dd, J = 13.9, 5.8 Hz, 1H, 
H-2), 3.70 (s, 2H, H-1''), 2.91 (dd, J = 13.9, 5.8 Hz, 1H, H-3a), 2.84 (dd, J = 13.9, 5.8 Hz, 1H, H-
3b), 1.48 (s, 9H, Boc); 13C NMR (75 MHz, CDCl3) δ 171.0 (C-1), 129.0 (C=O), 137.7 (C-2'), 135.1 
(C-2''), 129.0 (C-4'C-6'), 128.7 (C-3''C-7''), 128.6 (C-4''C-6''), 128.5 (C-5'), 128.3 (C-3'C-7'), 127.2 
(C-5''), 80.2 (C-(Boc)), 67.4 (C-1'), 53.2 (C-2), 36.6 (C-1''), 33.6 (C-2), 28.3 (3C (Boc)); LRMS (EI+) 
m/z calculated for C22H27NO4S [M]+ 401.2 found 401.1 ([M]+; 26 %); calculated for C17H18NO2S 




300.1 [M-Boc]+ found 300.1 ([M-Boc]+, 45%), calculated for C10H12NO2S 210.1 [M-Boc-Bn]+ 
found 210.0 ([M-Boc-Bn]+, 73%). 
Benzyl N,S-dibenzyl-L-cysteinate (4.27) 
 
In a solution of S-benzyl-L-cysteine (4.26) (250 mg, 1.18 mmol) in dimethylformamide (5 mL), 
was added Cs2CO3 (384 mg, 1.18 mmol) at room temperature. After 30 min, benzyl bromide 
(202 mg, 1.18 mmol) was added and the resultant solution was allowed to stir at room 
temperature for 24 hr. A mixture of (H2O:EtOAc, 1:1, 20 mL) was added and the organic layer 
retained. The aqueous layer was extracted with EtOAc (4 x 15 mL), the combined organic 
layers were dried over Na2SO4. Silica gel flash column chromatography (gradient petroleum 
ether 100% to petroleum ether/EtOAc 50:50) afforded benzyl N,S-dibenzyl-L-cysteinate (4.27) 
as a yellow oil (320 mg, 69%). 1H NMR (300 MHz, CDCl3) δ 7.54 – 7.16 (m, 15H, 3 x Ph), 5.20 
(s, 2H, H-1'), 3.86 (d, J = 13.1 Hz, 1H, H-1a'''), 3.69 (d, J = 13.1 Hz, 1H, H-1b'''), 3.69 (overlapped 
s, 2H, H-1''), 3.51 (t, J = 6.5 Hz, 1H, H-2), 2.79 (dd, J = 11.5, 6.5 Hz, 1H, H-3a), 2.73 (dd, J = 11.5, 
6.5 Hz, 1H, H-3b), 1.98 (br.s, 1H, NH); 13C NMR (75 MHz, CDCl3) δ 173.5 (C-1), 139.5 (C-2'), 
137.9 (C-2''), 135.7 (C-2'''), 129.0 (C-4' C-6'), 128.8 (C-3''C-7''), 128.7 (C-4''' C-6'''), 128.6 (C-3' 
C-7'), 128.5 (C-4''C-6''), 128.3 (C-3'''C-7'''), 128.1 (C-5'), 127.2 (C-5''), 127.1 (C-5'''),  66.8 (C-1'), 
60.1 (C-2), 51.9 (C-1'''), 36.6 (C-1''), 34.2 (C-3); LRMS (EI+) m/z calculated for C24H25NO2S [M]+ 




391.2 found 391.1 ([M]+; 75%); calculated for C17H18NO2S 300.1 [M-Bn]+ found 300.0 ([M-Bn]+, 
40%), calculated for C16H18NS 256.1 [M-CO2Bn]+ found 256.1 ([M-CO2Bn]+; 94%).  
O, S- dibenzyl L-cysteinate (4.23) 
 
In dichloromethane (5 mL) was dissolved O, S-dibenzyl-N-(tert-butoxycarbonyl)-L-cysteinate 
(4.28) (160 mg, 0.40 mmol) followed by the addition of trifluoroacetic acid (1 mL) with cooling 
in an ice water bath. The resulting solution was allowed to stir at room temperature until 
complete disappearance of starting material as indicated by TLC. The solvent was removed, 
H2O was added, the pH was adjusted to 8 with NaHCO3 and the aqueous layer was extracted 
with EtOAc (3 x 10 mL). Organic layers were retained, washed with brine (15 mL), dried over 
MgSO4 and filtered through a small layer of SiO2 gel (5 g, 1 cm x 2.5 cm), solvent evaporated 
under vacuum to afford O, S-dibenzyl-L-cysteinate (4.23) as a yellow orange solid (110 mg, 
91%). Mp:65-67 °C; 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.30 (m, 5H, O-CH2-Ph), 7.28 – 7.21 (m, 
5H, S-CH2-Ph), 5.14 (s, 2H, H-1'), 3.70 (s, 2H, H-1''), 3.62 (dd, J = 7.5, 4.7 Hz, 1H, H-2), 2.83 (dd, 
J = 13.5, 4.7 Hz, 1H, H-3a), 2.66 (dd, J = 13.5, 7.5 Hz, 1H, H-3b), 1.69 (br.s, 2H, NH);  13C NMR 
(101 MHz, CDCl3) δ 173.9 (C-1), 137.9 (C-2'), 135.5 (C-2''), 128.9 (C-4' C-6'), 128.6 (C-3'' C-7''), 
128.5 (C-4'' C-6''), 128.4 (C-5'), 128.3 (C-3' C-7'), 127.2 (C-5''), 67.0 (C-1'), 54.2 (C-2), 36.5 (C-
1''), 36.4 (C-3); LRMS (EI+) m/z calculated for C17H19NO2S [M]+ 301.1 found 301.1 ([M]+; 72%); 
calculated for C10H12NO2S 210.1 [M-Bn]+ found 210.0 ([M-Bn]+, 79%), calculated for C10H13NS 
179.1 [M-CO2Bn]+ found 179.1 ([M-CO2Bn]+, 39%).  







In dry dichloromethane (5 mL) were added (S)-5-(benzyloxy)-4-((tert-butoxycarbonyl)amino)-
5-oxopentanoic acid (4.10) (101 mg, 0.30 mmol), DIC (38 mg, 50 µL, 0.30 mmol), HOBt (41 
mg, 0.30 mmol) and DIPEA (39 mg, 0.30 mmol) at room temperature. Ten min later, O,S-
dibenzyl-L-cysteinate (4.23) (75 mg, 0.25 mmol) was added and the resulting reaction mixture 
was allowed to stir at room temperature for 24 hr. The solvent was evaporated to dryness, 
residue purified by SiO2 column chromatography (hexane/EtOAc 80:20) to give the coupling 
product (4.24) as colourless solid (144 mg, 92%). Mp: 92-95 °C; [α]20D = + 40.0° (c = 10, CHCl3), 
1H NMR (300 MHz, CDCl3) δ 7.50 – 7.32 (m, 10H, 2 X O-CH2-Ph), 7.32 – 7.20 (m, 5H, S-CH2-Ph), 
6.47 (br.s, 1H, NH), 5.29 (br.s, 1H, NH), 5.19 (s, 4H, H-1'' H-1iv), 4.90 – 4.75 (m, 1H, H-1'), 4.52 
– 4.29 (m, 1H, H-4), 3.69 (d, J = 13.5 Hz, 1H, H-1a'''), 3.63 (d, J = 13.5 Hz, 1H, H-1b'''), 2.92 (dd, 
J = 13.9, 6.2 Hz, 1H, H-2'a), 2.84 (dd, J = 13.9, 6.2 Hz, 1H, H-2'b), 2.34 – 2.11 (m, 3H, H-3 H-2a), 
2.11 – 1.82 (m, 1H, H-2b), 1.45 (s, 9H, Boc); 13C NMR (101 MHz, CDCl3) δ 172.1 (C-1), 171.6 
(C=O), 170.6 (C=O), 155.7 (C=O (Boc)), 137.7 (C-2iv), 135.3 (C-2''), 135.1 (C-2'''), 128.9 (C-4iv C-
6iv), 128.6 (C-4''C-6''), 128.5 (C-3''' C-6'''), 128.4 (C-5''' C-7'''), 128.3 (C-5iv), 128.2 (C-5''), 128.1 
(C-3iv C-7iv), 128.1 (C-3'' C-7''),  127.2 (C-5'''), 80.1 (C(Boc)), 67.5 (C-1iv), 67.2 (C-1''), 53.0 (C-1'), 
51.5 (C-4), 36.4 (C-1'''), 33.5 (C-2'), 32.2 (C-2), 28.3 (3C (Boc)), 27.8 (C-3); LRMS (EI+) didn’t 




display the molecular ion but the fragmentations at m/z calculated for C22H25N2O5S 429.1 
found 429.1 ([M-Boc-Bn]+; 15%); calculated for C14H19N2O3S 295.1 [M-Boc-CO2Bn]+ found 
295.1 ([M-Boc-CO2Bn]+; 7%). 
 
N5-((R)-1-carboxy-2-mercaptoethyl)-L-glutamine (γ-glutamylcysteine) (4.18) 
 
To methanol (5 mL) were added benzyl N5-((R)-1-(benzyloxy)-3-(benzylthio)-1-oxopropan-2-
yl)-N2-(tert-butoxycarbonyl)-L-glutaminate (4.24) (115 mg, 0.19 mmol), Pd/C (10%, 600 mg) 
and TFA (1 mL). The resulting reaction mixture was allowed to hydrogenate at room 
temperature for 24 hr. The catalyst was removed by filtration through celite and washed with 
water. The combined filtrates were evaporated to dryness. Reverse phase C18 column 
chromatography afforded γ-glutamylcysteine (4.18) as a white solid (41 mg, 85%). 1H NMR 
(300 MHz, D2O) δ 4.58 – 4.36 (m, 1H, H-1'), 4.29 – 4.08 (m, 1H, H-4), 3.87 (d, J = 19.0 Hz, 2H, 
H-2'), 2.82 – 2.47 (m, 2H, H-2), 2.38- 2.20 (m, 2H, H-3), proton NMR spectrum similar with the 
one reported in the literature 23; 13C NMR (101 MHz, DMSO) δ 173.2 (C=O), 170.5 (C=O), 156.9 
(C-1), 51.2 (C-1'), 47.8 (C-4), 29.3 (C-2), 25.3 (C-3), 23.3 (C-2'). LRMS (ESI+) m/z calculated for 
C8H15N2O5S 251.1 found 251.2 ([MH]+; 10%); calculated for C7H17N2O+ 145.1 [M-CO2-SH-H2O]+ 
found 145.2 ([M-CO2]+; 100%).  
 
 







In DMF (1 mL) were added (S)-3-(1-benzyl-1H-imidazol-4-yl)-2-(trimethylammonio) 
propanoate (2.30) (21 mg, 0.05 mmol) and N-bromosuccinimide (18 mg, 0.10 mmol) at room 
temperature. The resultant reaction mixture was allowed to stir at room temperature until 
complete disappearance of the starting material (TLC monitoring). γ-glutamylcysteine (20 mg, 
0.08 mmol, 1.6 eq) was added in one portion and the resulting reaction mixture was allowed 
to stir at room temperature for 1-3 hr. Solvent was removed to dryness. Reverse phase C18 
column chromatography afforded the product (4.2) as a colourless solid (2 mg, 7%). 1H NMR 
(300 MHz, D2O) δ 8.52 (s, 1H, H-5'''), 4.58 – 4.40 (m, 2H, H-2 H-1'), 4.31 – 4.17 (m, 1H, H-2''), 
3.97 – 3.83 (m, 2H, H-2'), 3.78 (s, 9H, NMe3), 3.61 (dd, J = 12.2, 6.5 Hz, 1H, H-3a"), 3.50 (dd, J 












To a mixture of CH3CN:H2O (1:1, 4 mL) were added hercynylcysteine thioether (2.19) (254 mg, 
0.80 mmol) and NaOH (35 mg, 0.88 mmol). The resulting reaction mixture was allowed to stir 
at room temperature overnight. The solvent was removed to dryness, the residue was 
dissolved in DMF followed by the addition of benzyl bromide (287 mg, 200 µL, 1.68 mmol) 
and the resulting solution was allowed to stir at room temperature for 24 hr. The solvent was 
removed to dryness and SiO2 gel column chromatography afforded the product (4.41) as a 
yellow solid (155 mg, 33%). 1H NMR (300 MHz, CDCl3) δ 8.89 (br.s, 1H, NH), 7.49 (s, 1H, H-5'), 
7.42 – 7.27 (m, 10H, 2 x Ph), 5.36 – 5.03 (m, 4H, CH2–Ph), 4.69 – 4.51 (m, 1H, H-2"), 4.01 – 
3.84 (m, 1H, H-2), 3.61 (dd, J = 11.2, 3.0 Hz, 1H, H-1a"), 3.39 (dd, J = 11.2, 7.7 Hz, 1H, H-1b"), 
3.12 (dd, J = 11.7, 6.7 Hz, 2H, H-3), 2.73 (s, 9H, NMe3), 1.41 (s, 9H, Boc); 13C NMR (101 MHz, 
CDCsl3) δ 177.9 (2C, C-1 C-3"), 170.6 (C=O), 135.1 (C-2'), 133.3 (C-4'), 129.4 (C-5'), 128.9 (2C, 
C-2"' C-2iv), 128.6 (4C, C-4"' C-6"' C-4iv C-6iv), 128.5 (2C, C-5"' C-5iv), 128.4 (4C, C-3"' C-7"' C-3iv 
C-7iv), 68.3 (C-2), 67.9 (C, Boc), 67.5 (2C, C-1"' C-1iv), 53.1 (C-2"), 41.2 (C-3), 34.8 (C-1"), 29.6 
(3C, NMe3), 28.3 (3C, Boc). 
 








To a solution of (S)-1-(benzyloxy)-3-(2-(((R)-3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-3 
oxopropyl)thio)-1H-imidazol-4-yl)-N,N,N-trimethyl-1-oxopropan-2-aminium (4.41) (37 mg, 
0.06 mmol) in dichloromethane (2 mL), was added TFA (0.5 mL) with cooling in an ice bath 
and the resulting reaction mixture was allowed to stir at room temperature overnight until 
TLC confirmed complete Boc removal.  
The solvent was removed to dryness and the residue was redissolved in DCM (3 mL), DIPEA 
(9 mg, 10 µL, 0.07 mmol), HOBt (10 mg, 0.07 mmol), (S)-5-(benzyloxy)-4-((tert-
butoxycarbonyl)amino)-5-oxopentanoic acid (4.10) (24 mg, 0.07 mmol) and DIC (9 mg, 0.01 
mmol) were added with cooling in ice bath. The resulting solution was allowed to stir at room 
temperature for 24 hr. The solvent was removed to dryness, water (10 mL) was added, 
extracted with EtOAc (4 x 10 mL), organic layers were retained and dried over MgSO4. SiO2 
gel column chromatography (gradient hexane/EtOAc) afforded the desired product (4.42) as 




a yellow oil (46 mg, 88%). 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.25 (m, 16H, 3 x Ph, Overlapped 
s, H-5'), 5.26 – 5.08 (m, 6H, 3 x CH2-Ph), 4.73 – 4.56 (m, 1H, H-2), 3.99 (ddd, J = 19.7, 13.3, 6.6 
Hz, 1H, H-4'''), 3.91 – 3.76 (m, 1H, H-2''), 3.66 (s, 9H, NMe3), 2.67 – 2.44 (m, 2H, H-1''), 2.43 – 
2.27 (m, 2H, H-3), 2.19 (dd, J = 13.9, 6.8 Hz, 2H, H-2'''), 2.08 – 1.89 (m, 2H, H-3'''), 1.42 (s, 9H, 
Boc); 13C NMR (101 MHz, CDCl3) δ 173.1 (2C, C-3'' C-5'''), 172.0 (C-1'''), 171.2 (C-1), 155.3 
(C=O), 149.3 (C-2'), 135.3 (3C-ipso Ph), 135.1 (C-4'), 128.7 (6C-meta Ph), 128.6 (3C-para Ph), 
128.3 (6C-ortho Ph), 114.7 (C-5'), 83.6 (C-Boc), 67.2 (3C, CH2-Ph), 59.0 (C-2), 51.7 (3C, NMe3), 






To a solution of (S)-1-(benzyloxy)-3-(2-(((R)-3-(benzyloxy)-2-((S)-5-(benzyloxy)-4-((tert-
butoxycarbonyl)amino)-5-oxopentanamido)-3-oxopropyl)thio)-1H-imidazol-4-yl)-N,N,N-
trimethyl-1-oxopropan-2-aminium (4.42) (74 mg, 0.091 mmol) in DCM (1 mL) was added 




mCPBA (70%, 24 mg, 0.10 mmol) in ice bath (0 °C). The resulting solution was allowed to stir 
at room temperature for 6 hr (TLC monitoring). Solvent was removed and SiO2 column 
chromatography afforded the desired sulfoxide (4.42) as a yellow solid (55 mg, 72%); 1H NMR 
(400 MHz, CDCl3) δ 7.41 (s, 1H, H-5'), 7.40 – 7.25 (m, 15H, 3 x Ph), 5.31 – 5.07 (m, 6H, 3 x CH2-
Ph), 4.67 – 4.57 (m, 2H, H-2 H-4'''), 4.31 – 4.25 (m, 2H, H-1" major diastereoisomer), 4.24 – 
4.20 (m, 2H, H-1" minor diastereoisomer), 4.08 – 3.89 (m, 1H, H-2"), 3.66 (s, 9H, NMe3), 2.61 
– 2.47 (m, 2H, H-3), 2.41 – 2.24 (m, 2H, H-2'''), 2.07 – 1.91 (m, 2H, H-3'''), 1.42 (s, 9H, Boc); 13C 
NMR (101 MHz, CDCl3) δ 173.3 (C-1'''), 171.2 (C-1), 169.0 (2C, C-3'' C-5'''), 149.3 (C=O), 135.1 
(C-2'), 134.7 (3C-ipso Ph), 131.3 (C-4'), 129.8 (6C-meta Ph), 128.6 (3C-para Ph), 128.5 (6C-
ortho Ph), 128.3 (C-5'), 83.7 (C-Boc), 67.4 (3C, CH2-Ph), 59.0 (3C, NMe3), 51.8 (C-2), 47.9 (C-1'' 
major diastereoisomer), 45.8 (C-1'' minor diastereoisomer), (42.9 (C-4'''), 42.4 (C-2''), 31.1 (C-
3), 28.3 (C-2"'), 27.8 (3C, Boc), 21.5 (C-3'''). 
 
(2S)-3-(2-(((R)-2-((S)-4-amino-4-carboxybutanamido)-2-carboxyethyl)sulfinyl)-2,3-dihydro-
1H-imidazol-4-yl)-2-(trimethylammonio) propanoate (4.1) 
 
To a solution of (2S)-1-(benzyloxy)-3-(2-(((R)-3-(benzyloxy)-2-((S)-5-(benzyloxy)-4-((tert-
butoxycarbonyl) amino)-5-oxopentanamido)-3-oxopropyl) sulfinyl)-1H-imidazol-4-yl)-N,N,N-




trimethyl-1-oxopropan-2-aminium (4.42) (30 mg, 0.036 mmol) in methanol (1 mL), were 
added Pd/C (10%, 100 mg) and TFA (0.2 mL) with cooling in an ice bath (0 °C). The resulting 
reaction mixture was allowed to hydrogenate at room temperature for 2 days until complete 
deprotection as monitored by paper chromatography. Pd/C was removed by filtration 
through celite, solvent evaporated under vacuum and reverse phase C18 column 
chromatography afforded the desired product (4.1) as white solid (11 mg, 65%). 1H NMR (400 
MHz, D2O) δ 7.65 (s, 1H, H-5'), 4.48 (m, 2H, H-2" H-4'''), 4.28 (dt, J = 13.2, 6.7 Hz, 2H, H-1" 
major diastereoisomer), 4.24 – 4.18 (m, 2H, H-1'' minor diastereoisomer), 4.01 (m, 1H, H-2), 
3.94 (s, 9H, NMe3), 3.63 (dd, J = 11.6, 4.1 Hz, 1H, H-3a), 3.53 (dd, J = 11.6, 8.6 Hz, 1H, H-3b), 
2.83 – 2.58 (m, 2H, H-2'''), 2.41 – 2.21 (m, 2H, H-3'''); 13C NMR (101 MHz, D2O) δ 182.0 (2C, C-
5''' C-3"), 177.1 (C-1'''), 174.9 (C-1), 133.9 (C-2'), 129.7 (C-4'), 128.8 (C-5'), 85.6 (C-2), 56.1 (C-
2''), 53.7 (C-4'''), 52.1 (NMe3), 44.0 (C-1" major diastereoisomer), 43.9 (C-1" minor 
diastereoisomer), 36.7 (C-2'''), 29.4 (C-3'''), 27.7 (C-3); LRMS (EI+) didn’t display the molecular 
ion but characteristic fragmentations at m/z calculated for C15H23N5O4S+ 369.1 [M-2 CO2-3H]+ 
found 369.3 [M-2 CO2-3H]+, calculated for C12H17N4O4S 313.1 [M-2 CO2-N(CH3)3]+ found 313.2 









To a suspension of L-histidine (1.50 g, 9.70 mmol) in a mixture of H2O:THF (2:1, 15 mL) were 
added NaHCO3 (1.79 g, 21.3 mmol) and di-tert-butyl dicarbonate (4.23 g, 19.4 mmol). The 
resulting solution was allowed to stir at room temperature for 24 hr. At the end of the reaction 
(TLC monitoring), THF was removed in the rotary evaporator and the remaining water layer 
was extracted with EtOAc (2 x 15 mL). The pH of the water layer was adjusted to 5-6 with 
citric acid and extracted again with EtOAc (3 x 20 mL). The combined organic layers were 
washed with brine, dried over MgSO4 and filtered over a small layer of SiO2 gel to afford Nα,Nꞇ-
bis(tert-butoxycarbonyl)-L-histidine (5.6) as a colourless solid (2.14 g, 63%). Mp: 76-79 °C (Lit 
73-75 °C) 17; [α]20D = +94° (c = 1, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 8.12 (s, 1H, H-2'), 7.17 (s, 
1H, H-5'), 5.46 (br.s, 1H, NH), 4.48 (m, 1H, H-2), 3.27 (dd, J = 14.6, 3.3 Hz, 1H, H-3a), 3.19 (dd, 
J = 14.6, 5.0 Hz, 1H, H-3b), 1.61 (s, 9H, ImBoc), 1.46 (s, 9H, Boc); 13C NMR (101 MHz, CDCl3) δ 
173.1 (C-1), 155.2 (C=O (ImBoc)), 146.2 (C=O (Boc)), 137.0 (C-2'), 136.5 (C-4'), 115.6 (C-5'), 86.4 





In dimethylformamide (5 mL) were added Nα,Nꞇ-bis(tert-butoxycarbonyl)-L-histidine (5.6) 
(750 mg, 2.11 mmol) and Cs2CO3 (1.03 g, 3.17 mmol) and the resulting solution was allowed 




to stir at room temperature. After 30 min, BnBr (552 mg, 0.4 mL, 3.23 mmol) was added in 
one portion and the reaction mixture was allowed to stir at room temperature for 22 hr (TLC 
monitoring). Water (50 mL) was added and the aqueous solution was extracted by EtOAc (4 x 
25 mL). Combined organic layers were washed with brine (20 mL) and dried over MgSO4. Flash 
SiO2 column chromatography (hexane: EtOAc, 25:75) afforded tert-butyl (S)-4-(3-(benzyloxy)-
2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-1H-imidazole-1-carboxylate (5.7) as a white 
solid (850 mg, 91%). Mp: 90-93 °C; [α]20D = -5.3° (c = 1, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 
7.94 (s, 1H, H-2'), 7.38 – 7.27 (m, 5H, Ph), 7.01 (s, 1H, H-5'), 5.81 (br.s, 1H, NH), 5.14 (q, J = 
12.3 Hz, 2H, H-1''), 4.69 – 4.55 (m, 1H, H-2), 3.11 – 2.92 (m, 2H, H-3), 1.60 (s, 9H, ImBoc), 1.43 
(s, 9H, Boc); 13C NMR (101 MHz, CDCl3) δ 171.7 (C-1), 155.5 (C=O (ImBoc)), 146.8 (C=O (Boc)), 
138.5 (C-2''), 136.7 (C-2'), 135.6 (C-4'), 128.5 (C-4''C-6''), 128.3 (C-3''C-7''C-5''), 114.6 (C-5'), 
85.5 (C (ImBoc)), 79.7 (C (Boc)), 66.6 (C-1''), 53.3 (C-2), 30.2 (C-3), 28.3 (3C-(Boc)), 27.9 (3C-
(ImBoc)); LRMS (EI+) m/z calculated for C23H31N3O6 445.2 [M]+ found 445.1 ([M]+, 40%), 
calculated for C19H23N3O6 389.2 [M-t-butyl]+ found 389.0 ([M-t-butyl]+, 100%), calculated for 
C18H23N3O4 345.2 [M-Boc]+ found 345.1 ([M-Boc]+, 34%), calculated for C13H14N3O2 244.1 [M-













Benzyl Nα-(tert-butoxycarbonyl)-Nꞇ-methyl-L-histidinate (5.9) and benzyl Nα-(tert-
butoxycarbonyl)-N∏-methyl-L-histidinate (5.10) 
      
To a solution of tert-butyl (S)-4-(3-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)-
1H-imidazole-1-carboxylate (5.7) (135 mg, 0.30 mmol) in THF (5 mL) was added iodomethane 
(128 mg, 60 µL, 0.90 mmol) and the resulting reaction mixture was allowed to reflux for two 
days at 60 °C. After cooling at room temperature, the solvent was removed and the crude 
residue was purified by SiO2 gel column chromatography to afford a mixture of products (5.9 
and 5.10) as brown solid (92 mg, 85%). 1H NMR (300 MHz, CDCl3) δ 7.50 – 7.30 (m, 6H, Ph, H-
2'), 7.08 (s, 1H, H-5'), 5.32 (d, J = 11.9 Hz, 1H, H-1a''), 5.18 (d, J = 11.9 Hz, 1H, H-1b''), 4.57 (dd, 
J = 12.7, 6.7 Hz, 1H, H-2), 3.88 (s, 3H, H-1' isomer 5.9), 3.85 (s, 3H, H-3' isomer 5.10), 3.77 – 
3.68 (m, 1H, H-3a isomer 5.9), 3.53 (dd, J = 12.7, 4.7 Hz, 1H, H-3b isomer 5.9), 3.43 (dd, J = 












To a mixture of THF:H2O (1:1, 20 mL) were added histidine methyl ester dihydrochloride (1.5 
g, 6.20 mmol), NaHCO3 (1.3 g, 15.5 mmol) and (Boc)2O (2.84 g, 13.02 mmol) at room 
temperature. The resulting homogenous reaction mixture was allowed to stir at room 
temperature for 19 hr (TLC monitoring). Solvent was removed to dryness and a mixture of 
H2O:EtOAc (1:1, 50 mL) was added to the residue. Organic layer was retained and the aqueous 
phase was extracted with EtOAc (3 x 25 mL). Combined organic layers were washed with brine 
(10 mL), dried over MgSO4 and flash SiO2 chromatography afforded tert-butyl (S)-4-(2-((tert-
butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1H-imidazole-1-carboxylate (5.12) as a 
colourless solid (2.20 g, 96%). 1H NMR (300 MHz, CDCl3) δ 8.00 (s, 1H, H-2'), 7.12 (s, 1H, H-5'), 
5.67 (br.s, 1H, NH), 4.62 – 4.38 (m, 1H, H-2), 3.68 (s, 3H, OCH3), 3.03 (dd, J = 17.1, 6.9 Hz, 2H, 
H-3), 1.56 (s, 9H, Boc Im), 1.38 (s, 9H, Boc); 13C NMR (75 MHz, CDCl3) δ 172.2 (C-1), 155.4 (C=O 
(Boc)), 146.8 (C=O (Boc Im)), 138.2 (C-4'), 136.6 (C-2'), 114.6 (C-5'), 85.6 (C (Boc Im)), 79.9 (C 








Methyl Nα-(tert-butoxycarbonyl)-N∏-methyl-L-histidinate (5.13) and Nα-(tert-
butoxycarbonyl)-Nꞇ-methyl-L-histidinate (5.14) 
 
To a solution of tert-butyl (S)-4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1H-
imidazole-1-carboxylate (5.12) (1.19 g, 3.22 mmol) in THF (5 mL) was added iodomethane 
(914 mg, 400 µL, 6.44 mmol) and the resulting reaction mixture was allowed to stir at room 
temperature for two days. Solvent was removed and the residue purified by SiO2 column 
chromatography to afford a mixture of product (5.13 and 5.14) as yellow solid (200 mg, 21%). 
1H NMR (300 MHz, CDCl3) δ 9.84 (s, 1H, H-2'), 7.17 (s, 1H, H-5'), 5.59 (br.s, 1H, NH), 4.56 (m, 
1H, H-2), 4.00 (s, 3H, H-1' isomer 5.14), 3.96 (s, 3H, H-3' isomer 5.13), 3.80 (s, 3H, H-1''), 3.28 
(dd, J = 15.8, 5.0 Hz, 1H, H-3a), 3.17 (dd, J = 15.8, 7.7 Hz, 1H, H-3b), 1.41 (s, 9H, Boc). 
 
Methyl Nα,Nꞇ-dibenzyl-L-histidinate (5.16) 
 




To a mixture of THF:H2O (1:2, 6 mL) were added histidine methyl ester dihydrochloride (700 
mg, 2.90 mmol), NaOH (255 mg, 6.38 mmol) and benzyl bromide (1.09 g, 0.8 mL, 6.38 mmol) 
rapidly. The resulting solution was allowed to stir at room temperature for 24 hr. The solvent 
was removed to dryness and to the residue was added H2O (10 mL). The aqueous layer was 
extracted with EtOAc (4 x 20 mL), organic layers were washed with brine (10 mL), dried over 
MgSO4, and the residue was triturated several times with Et2O to afford pure methyl Nα,Nꞇ-
dibenzyl-L-histidinate (5.16) as a colourless solid (800 mg, 81%), without the need of any SiO2 
column chromatography. 1H NMR (400 MHz, CDCl3) δ 10.38 (s, 1H, NH), 7.30 – 7.27 (m, 5H, 
Ph imidazole), 7.29 (overlapped, s, 1H, H-2'),  7.15 – 7.08 (m, 5H, Ph), 6.42 (s, 1H, H-5'), 5.43 (q, J 
= 14.5 Hz, 2H, H-1'''), 3.79 (s, 3H, H-4), 3.72 (d, J = 13.7 Hz, 1H, H-1a''), 3.54 (dd, J = 6.2, 8.7 Hz, 
1H, H-2), 3.51 (d, J = 13.7 Hz, 1H, H-1b''), 2.67 (dd, J = 16.3, 6.2 Hz, 1H, H-3a), 2.60 (dd, J = 
16.3, 8.7 Hz, 1H, H-3b), 13C NMR (101 MHz, CDCl3) δ 170.9 (C-1), 137.7 (C-2'), 133.1 (C-4'), 
132.0 (C-2''' C-2''), 129.4 (C-7''' C-7'' C-3''' C-3''), 128.7 (C-6''' C-6'' C-4''' C-4''), 127.8 (C-5''' C-









In dry DMF (2 mL) were added methyl Nα,Nꞇ-dibenzyl-L-histidinate (5.16) (280 mg, 0.80 mmol) 
and Me2SO4 (151 mg, 110 µL, 1.2 mmol). The resulting reaction mixture was allowed to stir at 
room temperature for 1-2 days. The reaction was quenched by the addition of HCl (5%, 10 
mL) and extracted with EtOAc (3 x 20 mL). Combined organic layers were washed successively 
by H2O, HCl 5% and brine, dried over MgSO4 and purified by SiO2 gel column chromatography 
(EtOAc 100% to EtOAc/MeOH 80:20) to afford (S)-1-benzyl-4-(2-(benzylamino)-3-methoxy-3-
oxopropyl)-3-methyl-1H-imidazol-3-ium (5.17) as a yellow oil (211 mg, 72%). 1H NMR (300 
MHz, CDCl3) δ 9.81 (s, 1H, NH), 7.15 – 7.05 (m, 5H, PhImidazole), overlapped 7.11 (s, 1H, H-2'), 
6.97 – 6.86 (m, 5H, Ph), 6.35 (s, 1H, H-5'), 5.20 (d, J = 2.6 Hz, 2H, H-1'''), 3.61 (s, 3H, H-4), 3.54 
(s, 3H, H-3'), 3.36 (dd, J = 6.2, 8.7 Hz, 1H, H-2), 3.32 (dd, J = 14.3, 6.2 Hz, 2H, 1''), 2.65 – 2.57 
(m, 2H, H-3); 13C NMR (101 MHz, CDCl3) δ 171.1 (C-1), 138.3 (C-2'), 133.4 (C-4'), 132.2 (C-2''' 
C-2''), 129.5 (C-7''' C-7'' C-3''' C-3''), 129.0 (C-6''' C-6'' C-4''' C-4''), 127.8 (C-5''' C-5''), 120.0 (C-
5'), 58.8 (C-2), 54.9 (C-1'''), 53.4 (C-1''), 51.9 (C-3'), 51.1 (C-4), 24.6 (C-3); LRMS (EI+) m/z 
calculated for C22H26N3O2 364.2 found 364.2 ([M]+ ; 1%), calculated for C21H22N3O2 348.2 found 




In acetone (6 mL) were added methyl (tert-butoxycarbonyl)-L-histidinate (165, 0.613 mL), 
Cs2CO3 (402 mg, 1.23 mmol) and bromide benzyl (105 mg, 70 µL, 0.613 mmol) at room 




temperature. The resulting reaction mixture was allowed to stir overnight at room 
temperature. Undesired inorganic salts were removed by filtration, the solvent removed to 
dryness, the residue obtained was purified by SiO2 gel column chromatography to afford 
methyl Nꞇ-benzyl-Nα-(tert-butoxycarbonyl)-L-histidinate as a yellow sticky oil (218 mg, 99%). 
1H NMR (300 MHz, CDCl3) δ (major rotamer) 7.43 (s, 1H, H-2'), 7.33 – 7.29 (m, 5H, Ph), 7.12 
(d, J = 7.7 Hz, 1H, H-5'), 5.91 (br.s, 1H, NH), 5.46 (s, 2H, -CH2-Ph), 4.45 – 4.30 (m, 1H, H-2), 3.60 
(s, 3H, OCH3), 3.05 (dd, J = 6.5, 3.7 Hz, 2H, H-3), 1.32 (s, 9H, Boc); 13C NMR (101 MHz, CDCl3) δ 
(major rotamer) 170.8 (C-1), 155.3 (C=O), 133,1 (C(Ph)), 132.7 (C-4'), 131.8 (C-2'), 129.5 (2 x 
CH(Ph meta)), 129.0 (2 x CH(Ph orto)), 128.2 (CH (Ph para)), 120.6 (C-5'), 80.6 (C(Boc)), 53.5 
(OCH3), 52.2 (C-2), 51.3 (-CH2-Ph), 29.9 (C-3), 28.4 (3C, Boc). 
 
 
7.2. Total Protein extraction and Purification from Mycobacterium 
smegmatis.1 
7.2.1. Mc2155 (M. smegmatis) growth conditions. 
 
M. smegmatis cultures (800 mL) were grown to exponential phase, and dried to obtain 10 g 
of dry cells. The obtained pellets of M. smegmatis cells were thereafter stored at -80°C until 
it was required. 
7.2.2. Total protein extraction. 
 
M.smeg cells was sonicated for 35 min at 4°C (25 pulses), followed by the addition of 
potassium phosphate buffer (60 mL; pH 7). The solution was allowed to stir at 4°C for 10 min 
and thereafter centrifuged at 3000 rpm for 20 min. The supernatant was collected, measured 




and the appropriate amount of ammonium sulfate was gradually added while stirring at 4 °C 
overnight to obtain 60-70% saturation.20 After precipitation of total protein the suspension 
was centrifuged at 4°C at 3000 rpm for 20 min and stored at -20°C. A tablet of complete ultra-
tablets, EDTA-free, glass vials (Roche ©) containing a cocktail of protease inhibitors was added 
to preserve the enzymatic activities of the crude enzyme preparation after cell lysis. 
 
7.2.3. Total protein purification. 
 
The total protein ammonium complex salt precipitates were resuspended in a buffer mixture 
(20 mL, pH 7) containing pyridoxal phosphate (10 mL, 20µM), potassium phosphate buffer (8 
mL, 50 mM; pH 7) and (2 mL, 1mM EDTA).  
 
7.2.4. Protein calibration curve 
 
In order to determine the total protein concentration, the protein Dc assay and the Bradford 
assays were used. The calculated M. smegmatis total protein concentration was determined 
by Bradford assay and was found to be 10.33 µg/µL. 
 
7.3. HPLC –ESI/MS (QTOF) analysis. 
 
Analyses were carried out with a UHPLC Agilent 1290 Infinity Series (Germany), accurate mass 
spectrometer Agilent 6530 Quadrupole Time Of Flight (QTOF) equipped with an Agilent jet 
stream ionization source (positive ionization mode) (ESI+) and column (Polaris 3 C18 Ether 100 
X 2 mm, particle size 3 µm, Agilent, Germany). 




15 µL of concentrate samples were injected into the LCMS. Analyte separation was attempted 
in 0.1% formic acid in milli-Q water (solvent A) and mixture of 90% acetonitrile, 0.1% formic 
acid, 10% milli-Q water (solvent B) as mobile phase in an isocratic flow rate of 0.3 mL/min. 
The system was controlled with the software packages Mass Hunter workstation software 
(Qualitative and Quantitative version B.05.00; Build 5.0.519.0, Agilent 2011, Germany). 
 
7.4. In vitro reconstituted biosynthesis of ergothioneine in 
Mycobacterium smegmatis.1,21 
The experiments were performed in triplicate, repeated several times (more than three 
times) and these results were reproducible.   
7.4.1. Enzymatic reactions using M. smegmatis cell-free lysate enzyme 
preparation  
 
100 µL reactions containing 20 mM Tris HCl pH= 7.4, 20 mM NaCl, 0.2 mM FeSO4.7 H2O, 0.5 
mM mercaptoethanol, 83 µL of crude enzymes and 50 mM of the substrates. The crude 
enzyme reactions were incubated for 1 day at 37 °C. The reaction was stopped by heating the 
mixture at 90 °C for 2 min followed by lyophilisation and subsequent reconstitution in LC 








7.4.2. Non-enzymatic cleavage of the C-S bond catalysed by PLP 
  
100 µL reactions containing 20 mM Tris HCl pH= 7.4, and 50 mM of the substrates, and 50 
mM of PLP. The non-enzymatic reactions were incubated for 1 day at 37 °C, followed by 
lyophilisation and subsequent reconstitution in LC buffer before analysis by LC/MS.  
 
7.5. Mycobacterium smegmatis Ergothioneine enzymes inhibition by 
S-(β-amino-β-carboxyethyl)ergothioneine sulfone (3.16).  
 
Reactions (100 µL) containing 20 mM Tris HCl pH= 7.4, 20 mM NaCl, 0.2 mM FeSO4.7 H2O, 0.5 
mM mercaptoethanol, 66 µL of crude enzymes and 50 mM of substrates and S-(β-amino-β-
carboxyethyl)ergothioneine sulfone 3.16. The reaction was stopped by heating the mixture at 
90 °C for 2 min followed by lyophilisation. The crude enzyme reactions were incubated for 1 
day at 37 °C. The reaction was stopped by heating the mixture at 90 °C for 2 min followed by 
lyophilisation and subsequent reconstitution in LC buffer before analysis by LC/MS.  
7.6. Determination of the Minimum Inhibitory Concentration (MIC) 
(Broth micro-dilution method)22  
 
A two-fold serial dilution of the drug was performed across a V-bottom 96 well plate (Lasec) 
in a volume of 50 µL. An equal volume of exponential mycobacterial culture diluted to 104 
CFU/mL was aliquoted in every well except the first row of wells, which serve as the negative 
control. After incubation for 3-4 days, growth was assessed visually by looking for a white 




pellet at the bottom of the well, and 10 µL of 0.02% Resazurin or Alamar blue staining (Sigma 
Aldrich) was added in every well, as it becomes pink in a reduced environment (caused by 
oxygen depletion). The MIC is reported as the range between the concentration of the well 
where 99% of the growth is inhibited and the well just before it (where growth was detected). 
Results are representatives of at least three biological replicates.  
 
7.7. UV-vis spectroscopy monitoring of the oxidation of thiols in 
presence of NBS/DMF 
 
7.7.1. Preparation of solutions  
 
A stock solution of phosphate-buffered saline (PBS) 0.01 M, pH 7.4 was freshly prepared and 
stored at 4 °C until use. Thiol solutions of either cysteine (1 mM) or γ-glutamylcysteine (1 mM) 
were prepared by dilution in PBS buffer and immediately analyzed by UV-vis 
spectrophotometer.  
To DMF (1 mL) was added NBS (36 mg, 0.2 mmol) in one portion and the resulting solution 
was allowed to stir at room temperature. An aliquoted 30 µL of the resulting solution was 
diluted with PBS buffer to reach the final volume of 3 mL solution of NBS/DMF (100x dilution) 








7.7.2. Detection of free thiols  
 
To a solution of NBS/DMF (1 mL) prepared as described above, was added the thiol, either 
cysteine (10 mg, 0.09 mmol) or γ-glutamylcysteine (25 mg, 0.09 mmol) depending on the case.  
One drop of 1 mM DTNB was added to 30 µL of aliquoted reaction mixture and the resulting 
solution was diluted with PBS buffer to reach the final volume of 3 mL which was analyzed by 
UV-vis spectrophotometer at the specific time.  
 
7.7.3. Reduction of disulfides by DTT subsequently followed by free thiols 
detection.  
 
To 1 mL of a solution of NBS/DMF/cysteine or NBS/DMF/γ-glutamylcysteine prepared as 
described above, was added 1 mM DTT and the resulting reaction mixture was allowed to stir 
at room temperature. 5 min or one hr later, one drop of 1 mM DTNB was added and the 
resulting reaction mixture was diluted with PBS buffer to reach a final volume of 3 mL which 
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